LOOD LOTS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Blood Clots: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83794-5 1. Blood Clots-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on blood clots. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON BLOOD CLOTS ........................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Blood Clots .................................................................................... 7 E-Journals: PubMed Central ....................................................................................................... 18 The National Library of Medicine: PubMed ................................................................................ 19 CHAPTER 2. NUTRITION AND BLOOD CLOTS ................................................................................. 35 Overview...................................................................................................................................... 35 Finding Nutrition Studies on Blood Clots................................................................................... 35 Federal Resources on Nutrition ................................................................................................... 37 Additional Web Resources ........................................................................................................... 37 CHAPTER 3. ALTERNATIVE MEDICINE AND BLOOD CLOTS ........................................................... 41 Overview...................................................................................................................................... 41 National Center for Complementary and Alternative Medicine.................................................. 41 Additional Web Resources ........................................................................................................... 48 General References ....................................................................................................................... 57 CHAPTER 4. CLINICAL TRIALS AND BLOOD CLOTS........................................................................ 59 Overview...................................................................................................................................... 59 Recent Trials on Blood Clots........................................................................................................ 59 Keeping Current on Clinical Trials ............................................................................................. 64 CHAPTER 5. PATENTS ON BLOOD CLOTS ........................................................................................ 67 Overview...................................................................................................................................... 67 Patents on Blood Clots ................................................................................................................. 67 Patent Applications on Blood Clots ............................................................................................. 88 Keeping Current ........................................................................................................................ 115 CHAPTER 6. BOOKS ON BLOOD CLOTS ......................................................................................... 117 Overview.................................................................................................................................... 117 Book Summaries: Federal Agencies............................................................................................ 117 Book Summaries: Online Booksellers......................................................................................... 118 The National Library of Medicine Book Index ........................................................................... 118 Chapters on Blood Clots............................................................................................................. 119 CHAPTER 7. MULTIMEDIA ON BLOOD CLOTS............................................................................... 121 Overview.................................................................................................................................... 121 Video Recordings ....................................................................................................................... 121 Bibliography: Multimedia on Blood Clots.................................................................................. 122 CHAPTER 8. PERIODICALS AND NEWS ON BLOOD CLOTS............................................................ 125 Overview.................................................................................................................................... 125 News Services and Press Releases.............................................................................................. 125 Newsletter Articles .................................................................................................................... 128 Academic Periodicals covering Blood Clots ............................................................................... 131 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 133 Overview.................................................................................................................................... 133 U.S. Pharmacopeia..................................................................................................................... 133 Commercial Databases ............................................................................................................... 135 Researching Orphan Drugs ....................................................................................................... 136 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 141 Overview.................................................................................................................................... 141 NIH Guidelines.......................................................................................................................... 141 NIH Databases........................................................................................................................... 143 Other Commercial Databases..................................................................................................... 145
viii Contents
APPENDIX B. PATIENT RESOURCES ............................................................................................... 147 Overview.................................................................................................................................... 147 Patient Guideline Sources.......................................................................................................... 147 Finding Associations.................................................................................................................. 158 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 161 Overview.................................................................................................................................... 161 Preparation................................................................................................................................. 161 Finding a Local Medical Library................................................................................................ 161 Medical Libraries in the U.S. and Canada ................................................................................. 161 ONLINE GLOSSARIES................................................................................................................ 167 Online Dictionary Directories ................................................................................................... 168 BLOOD CLOTS DICTIONARY.................................................................................................. 169 INDEX .............................................................................................................................................. 233
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with blood clots is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about blood clots, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to blood clots, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on blood clots. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to blood clots, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on blood clots. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON BLOOD CLOTS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on blood clots.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and blood clots, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “blood clots” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
E's on Down the Road Source: Walking. p. 36-38. November/December 2000. Summary: A National Institute of Medicine (NIM) expert panel raised the recommended daily intake (RDI) of vitamin E from 12 milligrams (mgs) to 15 mgs based on research citing its importance in disease prevention. The panel recommended that the daily intake come from foods rather than supplements. Foods rich in vitamin E include canola, olive, safflower, and corn oils as well as leafy green vegetables, wheat germ, nuts, olives, and seeds. The intake of 400 to 1,000 mgs recommended by some is far in excess of the amount that can be acquired through diet alone. Although evidence links diets rich in vitamin E to good health, the evidence is not so clear cut for supplements. Vitamin E found in foods consists of a complex group of chemicals called tocopherols. Some tocopherols work as antioxidants while others prevent blood clots from forming
4
Blood Clots
too readily. Supplements usually contain only a single form, alpha- tocopherol. The author suggests getting the first 15 mgs of vitamin E from food. If a person decides to add more through daily vitamin E supplements, there is little harm as long as the dosage is below 1,000 mgs. At high doses, vitamin E may cause stroke or bleeding problems in some people. The article provides a high-in-vitamin E recipe containing spinach and walnuts. The nutritional analysis of the recipe is also given. •
Managing Patients on Warfarin Therapy: A Case Report Source: SCD. Special Care in Dentistry. 21(3): 109-112. May-June 2001. Contact: Available from Special Care Dentistry. 211 East Chicago Avenue, Chicago, IL 60611. (312) 440-2660. Summary: Coagulotherapy is a common therapeutic regimen most frequently utilizing the drug called warfarin. This therapy may have important dental ramifications. As understanding of the mechanisms of action and drug interactions may help avoid problems. Questions commonly arise as to what dental procedures may be safely considered when a patient is on anticoagulant therapy. This article offers a case report that illustrates some of the dental and oral health concerns for managing patients on warfarin therapy. Coagutherapy level is measured in values of the International Normalized Ratio (INR). Any question about the appropriateness of dental procedures should be referred to the physician prescriber of the anticoagulant therapy. Generally, controlling bleeding is less of a problem than the management of thrombi (blood clots) and vascular occlusion (blockage) from decreased coagutherapy. The case presented includes the situation where INR reached a critical value as the result of drug interactions (antibiotics) and miscommunications. The authors remind readers that dental treatment for patients on anticoagulant therapy should be considered on an individual basis in consultation with the patient's physician to determine a level of anticoagulation that will provide minimum thrombosis (blood clot) risk and yet achieve workable hemostasis for the dental procedure. 3 tables. 27 references.
•
Floss or Die: Implications for Dental Professionals Source: Dentistry Today. 17(7): 76,78,80-82. July 1998. Contact: Available from Dentistry Today, Inc. 26 Park Street, Montclair, NJ 07042. (973) 783-3935. Summary: 'Floss or die' is a phrase coined by Dr. Raul Garcia, a research periodontist from Boston, Massachusetts, at a recent dental research conference. Since the original media attention, a number of newspapers and magazines have run related stories on the possible association of periodontal disease with a series of potentially life-threatening disorders. This article reviews current research in this area, summarizing the implications for practicing dental professionals. One study pointed to the possible causal relationship between certain plaque bacteria and aberrant blood platelet activity; such an interaction could result in an increased risk for blood clots, which are associated with myocardial infarction. A great deal of circumstantial evidence links untreated periodontal disease to endocarditis and lung infections in patients with chronic obstructive pulmonary disease. Furthermore, periodontal infection can affect the stability of type 1 diabetes and can weaken the host immune system. The authors report briefly on research that is looking for strategies to determine risk assessment for disease activity at susceptible sites in periodontal patients. Although there is much happening on the research front, the primary tool and most effective clinical treatment concept for periodontal disease management is still control of dental plaque. By suppressing plaque
Studies
5
formation, the risk of destructive periodontal infection, with its attendant loss of supporting structure, is lowered. In addition, according to current research, dentists may also be lowering the risk of several potentially fatal diseases. The remainder of the article briefly reviews the equipment and supplies available for this plaque-fighting effort, including the role of toothbrushing and flossing. Statistics estimate that only 2 to 10 percent of the population flosses regularly and effectively; this patient noncompliance is an overriding consideration in establishing therapy. 9 figures. 13 references. •
Hemorrhoids and More: Common Causes of Blood in the Stool Source: Digestive Health and Nutrition. 3(4): 24-26. July-August 2001. Contact: Available from American Gastroenterological Association. 7910 Woodmont Avenue, 7th Floor, Bethesda, MD 20814. (877) DHN-4YOU or (301) 654-2055, ext. 650. Email:
[email protected]. Summary: Most rectal bleeding is caused by hemorrhoids, which usually can be simply and effectively treated. This article reviews the many other conditions, including some serious disorders, that can cause blood in the stool. The author reminds readers that bleeding from any part of the nearly 40 foot long digestive tract can cause blood in the stool. Accurate and timely diagnostic tests are important to determine the cause of any bleeding. Bleeding higher up in the gut, from the esophagus or stomach, can result in stools with a black, tarry appearance. Bleeding from the lower end, such as the colon, or in large amounts, can appear as pure blood, blood clots, or as blood mixed with or streaking the stool. Another kind of blood, occult or hidden blood, may not be visible at all. A number of prescription and over the counter (OTC) medications can cause bleeding in the stomach and small intestine. The blood thinning drug warfarin also can induce bleeding in the intestine, as can some antibiotics. Other causes of bleeding can include ulcers, gastritis (inflammation of the stomach lining), ulcerative colitis, Crohn's disease, polyps (small growths inside the intestine), diverticular disease, abnormalities in the blood vessels (vascular anomalies), anal fissures (tears) and fistulas (abnormal openings between the anal canal and other organs, such as the bladder), and abscesses (pockets of infection. The author reiterates the importance of timely diagnosis, including a thorough patient history and evaluation of symptoms. Diagnostic tests can include blood tests, digital rectal examination, endoscopy, colonoscopy, sigmoidoscopy, fecal occult blood test, barium x rays, angiography (x rays of blood vessels), and nuclear scanning. Treatment depends on the source and extent of the bleeding.
•
Hormone Replacement: More Than Just Estrogen Source: Diabetes Self-Management. 15(2): 58, 60-62. March-April 1998. Contact: Available from R.A. Rapaport Publishing, Inc. 150 West 22nd Street, New York, NY 10011. (800) 234-0923. Summary: This article focuses on the use of hormone replacement therapy following menopause to reduce the risk of heart disease in women, particularly women with diabetes. It describes the normal body changes that occur during menopause. Early signs of menopause include irregular periods, hot flashes, and night sweats. Menopause can also weaken the muscles and tissues of the vagina and the base of the bladder. The article identifies the potential benefits of hormone replacement therapy, including reducing the risk of heart disease and preventing osteoporosis. It highlights potential concerns about hormone replacement therapy, including impairing blood glucose control, affecting blood pressure, and increasing the risk of developing blood clots and
6
Blood Clots
breast and endometrial cancer. The article discusses the available choices for hormone replacement and stresses the need for women with diabetes to talk with a doctor about hormone replacement therapy. It also includes a list of organizations and books that provide information about menopause and the pros and cons of hormone replacement therapy. •
Stroke! Source: Diabetes Forecast. 53(9): 58-62. September 2000. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article presents steps that people who have diabetes can take to significantly reduce their risk of stroke. Most strokes result from a blockage or rupture of a blood vessel in the brain. The blockages that cause stroke usually occur because blood clots have formed or fatty deposits have built up inside blood vessels. Strokes that occur when blood vessels burst open and bleed inside the head are less common than those caused by a blockage. Symptoms of stroke usually occur suddenly and may include weakness or numbness on one side of the body, loss of vision or dimness in one or both eyes, and difficulty talking or understanding speech. Some people experience mini strokes known as transient ischemic attacks. The symptoms for this type of stroke are the same as the symptoms of major stroke, but they last only a few minutes or hours. Although diabetes is considered a nonmodifiable risk factor for stroke, scientists are not sure why people who have diabetes are more likely to suffer a stroke. Prevention involves knowing one's individual risk factors and controlling or eliminating the modifiable ones. Modifiable risk factors include high blood pressure, high cholesterol, atrial fibrillation, cigarette smoking, heavy alcohol consumption, lack of physical activity, and obesity. The article presents suggestions for modifying these risk factors and provides a list of organizations that offer information about stroke.
•
Shiatsu Source: Positive Health. Number 24: 61-64. December-January 1998. Summary: This journal article presents a general overview of Shiatsu, which is a physical therapy applied at floor level with minimum physical effort by the therapist. Shiatsu uses Oriental Medicine as its theoretical framework and is a method of selfdevelopment that has the effect of focusing the mind and grounding the body and the mind. The history, environment, tools, and theoretical basis of Shiatsu are discussed. Three broad categories of Shiatsu technique are detailed: tonification, dispersal, and calming. According to the author, there are several essential techniques of Shiatsu: motivation; steadiness of breath; keeping a low center of gravity; relaxation and comfort; empty mind; support rather than force; positive connection; correctly angled pressure; technical ability, continuity, and fluency; and empathy. The article also lists contraindications to Shiatsu, including acute fevers; contagious diseases; internal bleeding; blood clots; touch phobia; severe burns; bruises or swellings; fracture sites and areas of acute muscle or ligament injuries; cuts, local inflammation, and infection; twisted intestines; and varicose veins during pregnancy. This journal article contains 4 photographs and details on 2 resources.
Studies
7
Federally Funded Research on Blood Clots The U.S. Government supports a variety of research studies relating to blood clots. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to blood clots. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore blood clots. The following is typical of the type of information found when searching the CRISP database for blood clots: •
Project Title: AGING VENOUS THROMBI WITH ULTRASOUND ELASTICITY IMAGING Principal Investigator & Institution: Rubin, Jonathan M.; Professor and Director/ Ultrasound; Radiology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 30-JUN-2006 Summary: Deep venous thrombosis (DVT) remains a significant clinical problem today with over 250,000 patients per year affected. Unfortunately, the gold standard diagnostic technique, duplex venous ultrasound, can only diagnose but not characterize these clots. This inability to determine clot maturity has major implications regarding which anticoagulation therapy, with its associated morbidity and mortality, one would use in treatment. The sine qua non of clot maturity is increasing hardness of thrombi, and in this regard, there exists an ultrasound technique, known as reconstructive ultrasound elasticity imaging, that is a very sensitive and well-defined way to estimate tissue hardness. In addition, elasticity imaging has the very attractive property that it would require no change in the standard diagnostic ultrasound technique, i.e. pushing on the leg veins and simultaneously imaging. We are proposing to use elasticity imaging to determine the maturity/age of DVTs. We will attack this problem in three ways: 1) We will create theoretical models of clot in veins for optimizing speckle tracking algorithms, for modeling the vessel boundary response to deformations when clots of varying hardness lie within a vein, and for estimating the non-linearities in Young's modulus, the measure of hardness, as a function of strain. 2) We will study the ability of elasticity imaging to distinguish differences in clot maturity in a well-developed model of thrombosis in ligated rat inferior vena cavas. This model will be used to determine if elasticity imaging can detect the day-to-day changes in thrombus hardness over a nineday maturation period, where clots will change from acute, softer clots to subacute to chronic, hard thrombi. Further, we will correlate these hardness estimates with the clot fibrin concentration, the primary cause of hardening, over time. 3) We will validate elasticity imaging in two patient populations, one with known acute DVT in which the
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
8
Blood Clots
precise onset of thrombosis is known, and a second population with known longstanding, chronic DVT. We will accurately determine the ability of elasticity imaging to distinguish between the thrombi in these two groups. We believe that elasticity imaging is a natural solution to the clot characterization problem, and in this proposal, we will fully test the ability of the ultrasound elasticity imaging to address this important clinical issue. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ARE SUBARACHNOID BLOOD CLOTS VISIBLE ON FLAIR MRI?: STROKE Principal Investigator & Institution: Busch, Elmar; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOBEHAVIORAL PREDICTORS OF CORONARY ANGIOPLASTY OUTCOMEN Principal Investigator & Institution: Kop, Willem J.; Assistant Professor; Henry M. Jackson Fdn for the Adv Mil/Med Rockville, Md 20852 Timing: Fiscal Year 2001; Project Start 01-FEB-1999; Project End 31-JAN-2003 Summary: Percutaneous coronary revascularization procedures are increasingly used in the treatment of coronary artery disease, with approximately 300,000 interventions performed each year. Despite new developments in cardiology such as infra-coronary stents and anticoagulant pharmacological treatments a major problem remains the frequent occurrence of coronary restenosis and new cardiac events within six months after the intervention. These adverse outcomes occur in one out of four patients and have substantial impact on the costs of medical care and patients' quality of life. Research indicates that hemostatic factors (e.g., fibrinogen, von Willebrand factor, and plasminogen activator inhibitor) promote the formation of blood clots and that these factors predict coronary restenosis. Moreover, prior longitudinal studies have also demonstrated that the psychosocial traits of hostility and depression affect clinical progression of coronary disease. These psychosocial factors significantly predict adverse long-term outcome after revascularization and both hostility and depression are known to affect blood clotting factors. In addition, acute mental and physical stress are reported to affect blood clotting factors (coagulation and fibrinolysis) and responses to stress are reported to be more pronounced in hostile individuals. However, previous research on predictors of adverse clinical outcome after percutaneous coronary revascularization has not examined stress-induced changes in hemostatic factors and the consequences of these responses for progression of coronary artery disease. Therefore, the present study will investigate whether psychosocial factors and responses to acute mental stress affect measures of the blood clotting process that are involved in progression of coronary disease, thereby increasing the risk of an adverse prognosis following percutaneous coronary revascularization. This study may improve the identification of patients at risk for recurrent cardiac events and provide further understanding of the pathophysiological mechanisms involved in the progression of coronary artery disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
9
Project Title: CEREBRAL MICROVASCULAR ENDOTHELIN PRODUCTION Principal Investigator & Institution: Yakubu, Momoh A.; Ctr/Cardiovascular Diseases; Texas Southern University 3201 Wheeler Ave Houston, Tx 77004 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2004 Summary: (provided by the applicant): Cerebral hemorrhage is the main cause of abnormal cerebral arteriolar constriction resulting in cerebral ischemia that leads to paralysis, mental and physical disabilities, and deaths. Despite progress in the diagnosis of subarachnoid hemorrhage (SAH), SAH-induced cerebral vasospasm remains one of treatable causes of morbidity and mortality in patients. The mechanism(s) by which cerebral arterial narrowing occurs following hemorrhage remain largely unknown, but modification of cerebral microvascular responses is prominent, and characterized by impaired vasodilator and increased vasoconstrictor mechanisms in cerebral arteries. Several factors may contribute to the observed alterations of pial arteriolar reactivity. Increased endothelin-1 (ET-1) production has been consistently observed and ET-1 has been implicated as a possible mediator of cerebral hemorrhage-induced vasospasm. However, the mechanism(s) by which increased ET-1 production occurs are not known. The proposed experiments are designed to test the hypothesis that by-products of hemolyzed blood clots {oxyhemoglobin (OxyHb), lysophosphatidic acid (LPA), or serotonin (5-HT)} stimulate ET-1 production via activation of protein kinase C (PKC). To test this hypothesis, two specific aims will be addressed using primary culture of cerebral microvascular endothelial cells. 1) To characterize the effects of OxyHb, LPA, or 5-HT on El-I production and 2) to determine the cellular mechanism(s) by which these vasospasmogenic agents released from blood clots stimulate El-I production. To accomplish these aims, primary cell culture, molecular biological, immunoblotting, and immunoprecipitation techniques will be employed to investigate the mechanism(s) involved in the regulation of ET-1 production by these blood by-products. The results from the proposed research will have important therapeutic implications for survivors of SAH, who experience complications that include paralysis, mental and physical derangement, loss of sight and hearing. Our understanding of the mechanisms underlying the consequences of SAH will make it possible for early and appropriate intervention to prevent or reduce these complications from hemorrhagic stroke. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--MOLECULAR GENETICS Principal Investigator & Institution: Shields, Peter G.; Professor & Chief; Georgetown University Washington, Dc 20057 Timing: Fiscal Year 2001 Summary: The Molecular Genetics Core Laboratory (MGCL) will provide an important resource to the TTURC based upon existing sample handling, biorepository and high throughput assay procedures. This core will be within Dr. Shields' Molecular Epidemiology Section the Laboratory of Human Carcinogenesis (LHC) within NCI. The MGCL is uniquely suited to provide the laboratory genetic support for existing hypotheses and to develop assays for new hypotheses. Our specific aims are: (1) to provide a certified Molecular Genetics Core Laboratory (MGCL) that ensures consistent and high quality sample handling, analysis and reporting for samples generated by the TTURC; (2) to provide sample receipt, sample processing and biorepository procedures for all TTURC samples; (3) to provide existing consistent methods for DNA extraction and genetic polymorphism analysis; and (4) to provide accurate reporting, quality control and quality assurance procedures. The MGCL will maintain CLIA certification
10
Blood Clots
for quality control and quality assurance, among existing procedures for accurate determination of assay results and reporting. Performing large-scale molecular epidemiology studies require experience and expertise. Our laboratory has done DNA extractions. from blood (white blood cells, blood clots and serum), buccal swabs, oral rinses, frozen human organ tissue (lung, liver, colon. breast), urine and paraffinembedded tissues. During the last five years, this constitutes DNA from more than 2,000 persons. Our success rates are greater than 98%. In calendar years 1996, 1997 and 1998, we performed 21 different genotyping assays for a total of 24,315 individual assays. There are different ways for laboratories to perform quality research. Ours is to maintain Clinical Laboratory Improvement Amendments (CLIA) certification. This is a government-mandated quality control and quality assurance monitoring program for clinical laboratories. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CRYSTAL STRUCTURE OF HUMAN FIBRINOGEN FRAGMENT D Principal Investigator & Institution: Doolittle, Russell F.; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001 Summary: Fibrinogen is the precursor of fibrin, the material of which blood clots are composed. It is a large molecular weight complicated protein composed of two pairs of three non-identical polypeptide chains. A genuine X-ray structure has never been obtained. Now we are determining the structures of the principal fragments of human fibrinogen, the largest of which is called fragment D. We have collected data on crystals of this fragment out to 3.8 E on an area detector, and data from several isomorphous derivatives have provided a preliminary if somewhat ambiguous electron density map. We hope that synchrotron data would allow better resolution. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IN VIVO EVALUATION OF STROKE ULTRASOUND CATHETER Principal Investigator & Institution: Hansmann, Douglas R.; Ekos Corporation 22122 20Th Ave Se, Ste 148 Bothell, Wa 98021 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2003 Summary: Stroke is a deadly and debilitating disease striking 700,000 Americans each year. Nearly 75% of these strokes are ischemic or caused by blood clots which stop blood flow to areas of the brain resulting in brain cell death. Once a patient seeks medical care, the largest challenge to preventing stroke-related disability is rapidly achieving lysis of the clot that is blocking blood flow. The faster the blood supply can be restored to the oxygen starved portions of the brain the less disability suffered by the patient. Locally directed ultrasound energy can enhance blood clot lysis resulting in a faster return of blood flow to the ischemic brain tissues. The goal of this project is to demonstrate that ultrasound energy radiating from the end of a catheter can enhance the lysis of blood clots in the neurovascular system for the treatment of stroke. The specific aims of this Phase I project are to: 1. Downsize the current EKOS ultrasound catheter to a 3.5 French product. 2. Demonstrate the ability of small ultrasound transducers to lyse plasma clots in vitro. 3. Demonstrate the ability of the downsized ultrasound catheters to lyse blood clots in vivo. PROPOSED COMMERCIAL APPLICATIONS: Our product will be an ultrasound microcatheter which will be used in the treatment of stroke. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
11
Project Title: INTEGRIN/CYTOSKELETON INTERACTIONS IN PLATELETS Principal Investigator & Institution: Burridge, Keith W T.; Professor; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2002 Summary: Platelets play a critical role in the development of blood clots. This is an important physiological event in normal hemostasis, but the pathological development of blood clots can lead to heart attacks and strokes. During the formation of a blood clot, platelets become activated and rapidly assemble their actin cytoskeletons. These become linked to the major transmembrane integrin alphaIIb/beta3, which mediates adhesion to fibrin on the outside of the platelet. The coupling of alphaIIb/beta3 to the cytoskeleton allows platelets to contract clots. The first aim of this grant is to determine how the cytoplasmic domains of alphaIIb/beta3 interact with specific cytoskeletal components. Several strategies will be used to identify cytoskeletal proteins that associate with alphaIIb/beta3 in vivo. The interactions of alphaIIb/beta3 mutated in the cytoplasmic domains will be investigated, as will the interactions of integrin chimeras, in which the cytoplasmic domains are ligated onto the transmembrane and extracellular domains of other proteins. A scheme is proposed to permit analysis of the cytoskeletal links to individual cytoplasmic domains of other proteins. A scheme is proposed to permit analysis of the cytoskeletal links to individual cytoplasmic domain chimeras as well to chimeras to have been induced to dimerize. The role of specific proteins, such as talin, vinculin and alpha-actinin, will be explored in cells from which vinculin has been deleted and in which talin or alpha-actinin have been functionally disrupted. Many agents which prevent platelet activation raise cyclic nucleotide levels and stimulate protein kinase A or G. A prominent substrate for these kinases in platelets in the vasodilator-stimulated phosphoprotein (VASP). We will explore the function of VASP and the consequence of its phosphorylation in relation both to actin polymerization and the activation of alphaIIb/beta3. In response to platelet activation and aggregation, several tyrosine kinases become activated. We will investigate the regulation of platelet tyrosine phosphorylation by tyrosine phosphatases (PTPs). Specifically, we will look for PTPs that associate with and regulate tyrosine kinases, and PTPs that associate with alphaIIb/beta3. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NMR STUDIES OF PLASMINOGEN AND RELATED GENOMIC DOMAINS Principal Investigator & Institution: Llinas, Miguel; Professor; Chemistry; CarnegieMellon University 5000 Forbes Ave Pittsburgh, Pa 15213 Timing: Fiscal Year 2001; Project Start 01-JUL-1982; Project End 31-MAR-2005 Summary: (Investigator's abstract) We propose to investigate via NMR spectroscopy the structure and function of genomic protein modules and multimodular arrays related to plasminogen (Pgn) and its activators urokinase (uPA) and tissue Pgnactivator (tPA). These proteins are found both in blood plasma and in the extracellular matrix (ECM) where they play crucial roles in the fibrinolytic dissolution of blood clots, cell proliferation and migration, embryogenesis, tissue remodeling metastasis, etc. Pgn, tPA and uPA contain kringle (K) domains that mediate their binding to specific substrates. The Pgn kringles interact with the inhibitor a2-antiplasmin C- and the Pgn N-terminal peptide domains. Interestingly, the Pgn KI, K2, K3, K5, their tandem arrays K123, K1234 (angiostatin), and K12345, as well as the uPA peptide KPSSPPEE 143 inhibit endothelial cell growth and migration, thus tissue and tumor vascularization. Antiangiogenic
12
Blood Clots
activities also are displayed by the blood plasma/ECM proteins kininogen D5 (a Zn2+binding domain) and thrombospondin 2nd type-1 domain. Implicated in tissue remodeling is the matrix metalloproteinase 2, which digests denatured collagen (gelatin) via adhesion through three fibronectin type II domains. Activation of Pgn by uPA, a key step in metastatic cell propagation, involves a membrane-anchored receptor (uPAR) which contains three snake neurotoxin-type modules. Related to uPA activity is the receptor associated protein (RAP), a chaperon that stabilizes newly synthesized low density lipoprotein receptor-related protein and the very low density lipoprotein receptor, presumably via its C-terminal domain (ctRAP). Pgn and tPA also are found in brain where their presence correlates with memory processes. In addition, in brain is neurotrypsin, a novel kringle containing proteinase. Of related neurological interest is the SEA module of agrin, a protein produced by motoneurons that induces the aggregation of nicotinic acetylcholine receptors. Functional in nerve tissue extension are various transmembrane protein tyrosine kinase receptors which contain kringle and frizzled (cysteine-rich) domains, likely to be involved in ligand binding. A main thrust of the project will be the development of CLOUDS, a relaxation matrix approach that avoids the assignment bottleneck and aims at high throughput structural analysis of protein NMR data. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLASMINOGEN ACTIVATION & SK: STRUCTURE-FUNCTION Principal Investigator & Institution: Reed, Guy L.; Associate Professor; Medicine; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-JUL-1998; Project End 30-JUN-2006 Summary: (provided by applicant): The plasminogen (Pg) system dissolves the thrombi (blood clots) that cause heart attacks and strokes. The Pg system is tightly regulated by protein-protein interactions with inhibitors, activators, substrates, etc. The cleavage of Pg to plasmin by streptokinase (SK), and other Pg activators, initiates fibrinolysis (clot dissolution) which saves the lives of heart attack patients. Recent studies have suggested that mechanistic insights into the regulation of the Pg system could further reduce the mortality from heart attacks, and improve the treatment of strokes, pulmonary embolism, etc. Because of its physiologic and therapeutic importance, our long term goal is to help elucidate the protein-protein interactions that regulate and modify the activity of the Pg system. The interactions between Pg and the indirect Pg activator SK are among the most biologically and medically important of these contacts. Studies performed in the first phase of this grant have helped to delineate the elegant interactions through which SK converts Pg (without cleavage) into the most catalytically efficient Pg activator, Insights have been made into defining the mechanisms through which: 1) SK forms a tight stable 'activator complex' with Pg (or plasmin), 2) SK nonproteolytically generates the latent active site in Pg creating a 'virgin enzyme' (Pg*), and 3) SK modifies the substrate specificity of Pg* or plasmin so that the complex can cleave Pg molecules. This continuation proposal is directed towards further dissecting the process of indirect Pg activation, in order to determine the novel mechanisms by which SK becomes a fibrin-dependent (or t-PA-like enzyme), to define whether fibrindependent SKs have the potential to be superior fibrinolytic agents, to understand the role of the Pg kringle domains in indirect Pg activation and, to define the intermolecular interactions that occur in the SK-Pg complex which are required for a SK-type of mechanism. In a broad scientific sense, insights into this unique process of indirect Pg activation should enlarge our understanding of how the catalytic activity and specificity
Studies
13
of Pg system is regulated, and could suggest rational ways to alter the indirect Pg activators so as to improve their therapeutic value for patients with thrombosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREVENTION OF BIOFILMS IN MEDICAL DEVICES Principal Investigator & Institution: Shenoy, Bhami C.; Altus Biologics, Inc. 625 Putnam Ave Cambridge, Ma 021394807 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JAN-2004 Summary: (provided by applicant): Design of new efficient drug delivery systems for proteins is one of the major themes of modern biotechnology and biopharmaceutical industry. We found that cross-linked enzyme crystals (CLECs) show remarkable stability at various pHs, on storage, against proteolysis and organic solvents. These properties make them ideal for treatment against biofilm formation on medical devices /implants such as urethral catheters, ureteric and prostatic stents, penile and testicular implants, artificial urinary sphincters, prostheses for hip and knee replacements, shunts for hydrocephalus, vascular grafts, heart valves, vascular access devices, voice prostheses, etc. In addition, the CLECS can be used for the prevention of blood clot formation, for example, in venous catheters. The CLEC agent will be used to coat the medical devices for the prevention of formation of bacterial biofilms on these devices as well as the prevention of blood clots. The biofilms form on the above medical devices by colonization of bacteria embedded in a matrix, which become resistant to commonly used antibiotics. In this Phase I study, we propose to develop two prototypes of CLECs of enzyme - Serratiopeptidase and Streptokinase for prevention of biofilms by Pseudomonas aeruginosa and Staphylococcus aureus microorganisms. The coating will prevent the adherence of these bacteria to medical devices. Currently, there are more than 850,000 case infections associated with aid devices annually in the United States. These may be associated with as many as 100,000 deaths per year. The CLECs of Serratiopeptidase and Streptokinase have enormous commercial potential over the currently available treatment for the prevention of contamination of medical devices by minimizing the need for replacement once they are implanted. The CLECs of Serratiopeptidase and Streptokinase will also be important in preventing biofilm-related infections which are resistant to commercially available antibiotics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRIMARY STRUCTURE OF PROTHROMBIN Principal Investigator & Institution: Mann, Kenneth G.; Professor and Chair; Biochemistry; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405 Timing: Fiscal Year 2001; Project Start 01-JAN-1994; Project End 31-DEC-2003 Summary: Factor V is a central participant in the blood clotting process. In its activated form (factor Va), when bound to a membrane, it serves as a factor Xa receptor and an effector of catalytic activity in the activation of prothrombin to thrombin. Studies of the prothrombinase complex and its components have provided not only significant information with respect to this complex, but also insights into the overall mechanism by which blood clots. The participation of factor V in the prothrombinase complex function is a consequence of both positive and negative regulatory processes which influence both the receptor and effector functions of the molecule. The activation of the procofactor, factor V, to the cofactor, factor Va, can be elicited by a number of proteolytic mechanisms, with the most important being thrombin. The negative
14
Blood Clots
regulation of factor Va occurs as a consequence of proteolytic cleavage by activated protein C (APC), an anticoagulant enzyme activated paradoxically by thrombin. In recent times, defects in the protein C system involving defects in protein C, protein S, thrombomodulin, and factor Va have been associated with significant thromboembolic events. During the past decade, the primary structure of factor V, its posttranslational modifications, its cleavage during activation and inactivation, and its biosynthesis and catabolism have been described. The present application seeks to extend our knowledge of the functions of factor V and factor Va using extensions of the approaches that have proved valuable in the past. These include: (a) the evaluation of the structure and function of the protein using the proteolytic fragments derived from natural factor V, factor Va and factor Vai, (b) the development an utilization of recombinant cofactor V and factor Va fragments to develop an understanding of the activity and the regulation of this important molecule, (c) the development of practical immunologic and genetic measurements of factor V fragments which may be used to evaluate hypercoagulable states and provide predictive information regarding the nature of genetic alterations which influence factor V structure and function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REACTION AND TRANSPORT DYNAMICS IN HUMAN BLOOD Principal Investigator & Institution: Diamond, Scott L.; Associate Professor; Chemical Engineering; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 15-JUL-1996; Project End 31-MAR-2005 Summary: (Verbatim from Applicant's Abstract): In the context of a given genotype and phenotype, the dynamics of blood clot assembly ultimately dictate: thrombosis; thrombolytic susceptibility of clots; stroke during cardiopulmonary bypass; restenosis after angioplasty; wound healing/inflammation; and pathogenesis of deep vein thrombosis or pulmonary embolism. During blood coagulation, activated platelets and neutrophils from homotypic and heterotypic aggregates through over ten receptormediated pathways while triggering thrombin formation and fibrin polymerization. Yet less is known quantitatively about the strengths and kinetics of platelet-platelet and platelet-neutrophil bonding that leads to aggregation or deposition under coagulating whole blood flow conditions or the biochemical reactivity of these aggregates. Furthermore, temporal resolution of events lasting only a few milliseconds is rarely achieved in most experiments. In vitro high speed imaging experiments will utilize human blood cells and proteins for kinetic studies of these interactions under controlled hemodynamic and coagulation conditions. Probability distributions and kinetic data from these experiments will be used to gain improved mechanistic understanding of human blood phenomena from receptor dynamics to vessel occlusion, in the hemodynamic setting. By defining the molecular dynamics of how blood clots are assembled under flow conditions as well as defining the flow regulation of various clotting scenarios, the risks of unregulated clotting, bleeding, and embolism will be more quantitatively understood for a given disease progression. Specific aims are: Aim 1 High speed imaging of platelet bonding dynamics that regulate thrombosis in clotting blood with emphasis on bond life dynamics. Aim 2 High speed imaging of neutrophil bonding dynamics that enhance cellular deposition with emphasis on selectin mediated pathways, erythrocyte interactions and membrane tethering. Aim 3 Quantifying mechanisms by which neutrophils act as procoagulant participants during clot assembly under defined flow conditions. Aim 4 Develop a set of generalized computational tools for the study of heterotypically aggregating-reacting blood. Overall, these studies seek
Studies
15
to provide fundamental insight into cell-cell interactions and coagulation biochemistry that occur under flow. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REPAIR & PREVENTION OF DNA DAMAGE & BREAST CANCER RISK Principal Investigator & Institution: Shore, Roy E.; Professor; Environmental Medicine; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2003; Project Start 02-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Dysfunction of pathways that maintain DNA genomic integrity may account for a significant fraction of breast cancer. A study of breast cancer susceptibility in relation to polymorphisms in genes that prevent or repair DNA damage is proposed. Specifically, it is hypothesized that women are at heightened risk for breast cancer when they have a gene allelic variant of functional significance in a pathway for carcinogen/pro-oxidant detoxification or DNA-repair. Having multiple gene variants in a pathway is expected to elevate breast cancer risk further. A cohort (New York University Women's Health Study) of 14,000 women who contributed blood 11-17 years ago has been followed up for breast cancer incidence; 622 incident, invasive breast cancers have been identified. A case-control study (1:2 matching) nested within the cohort will be conducted. DNA will be obtained from stored blood clots, buccal cells, or serum samples. Data on potential confounders were collected at entry and are updated on a regular basis. The DNA pathways selected for study pertain to DNADamage Prevention, Base Excison Repair (BER) and Nucleotide Excision Repair (NER). The repair pathways are complementary, in that BER fixes the ubiquitous damage that occurs in one or a few nucleotides while NER repairs larger lesions, such as bulky DNA adducts and DNA crosslinks. Both types of DNA damage, if unrepaired and occurring in a key gene, may cause a permanent mutation that promotes cancer development. The 13 genetic polymorphisms to be studied in the three pathways were selected on the basis of high allelic frequencies of the variants (10-50%) and evidence of their functional significance. Polymorphic variants in 3 genes that help prevent DNA damage (GSTP1, MnSOD, catalase) and 9 genes in the DNA nucleotide-excision repair pathway (XPC, XPD, XPF, XPG) or base-excision repair pathway (XRCC1, APE1, LIG3, POLD1, hOGG1) will be studied in relation to breast cancer risk. The polymorphisms either have not been studied previously in relation to breast cancer risk, or their contribution to risk is uncertain because of limitations in previous studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SITE DIRECTED THROMBOLYTIC AGENT Principal Investigator & Institution: Mcgowan, Eleanor B.; Aurazyme Pharmaceuticals, Inc. 2121 New Market Pky, Ste 124 Marietta, Ga 30067 Timing: Fiscal Year 2003; Project Start 24-FEB-2003; Project End 31-AUG-2004 Summary: (provided by applicant): Clot formation and dissolution are essential to human survival. Abnormal clot formation and occlusion of blood vessels of the heart, lung, brain, and peripheral circulation can result in death, incapacitation, and limb amputation. Rapid treatment with thrombolytic agents to dissolve clots and restore blood flow is a means to minimize morbidity and mortality in these patients. In the USA, more than 1 million patients are affected annually by blood clots in the heart, brain, lung or peripheral vessels, with more than 600,000 deaths occurring from myocardial infarction and ischemic stroke. This costs the US economy in excess of $40
16
Blood Clots
billion per year. This proposal is to assess the pre-clinical efficacy of a direct thrombolytic agent delivered locally in a rabbit model of abdominal aorta thrombosis. Active plasmin is generated from a stable depot form of plasmin, AZ-plasmin, by exposure to energy (light, sound waves). Plasmin is a proteolytic enzyme that digests fibrin and degrades clots, releasing trapped blood cells and re-establishing circulation. Local delivery of plasmin and its rapid inhibition by alpha2 antiplasmin distal to the clot site will limit bleeding side effects. Current thrombolytic therapies infuse protein activators (streptokinase, tissue plasminogen activator) to convert plasminogen to plasmin; plasminogen concentrations become limiting in areas of diminished blood flow. These therapies do not achieve their full potential due to significant side effects, including increased risk of hemorrhage and stroke. The proposed specific aims are (1) to optimize the preparation of AZ-plasmin from human plasmin and a proprietary inhibitor, AZ-nu, and determine the properties of AZ-plasmin and light-reactivated plasmin, using a synthetic substrate; (2) to characterize delivery and activation parameters for AZ-plasmin in plasma clots and blood clots in vitro, using catheters and fiber optic light or shock wave energy sources to activate AZ-plasmin to plasmin; and (3) to determine safety and efficacy of AZ-plasmin activated to plasmin for restoring blood flow in vivo in rabbits with abdominal aorta thrombosis, a model for peripheral arterial occlusion. These experiments will establish the utility of AZ-plasmin as a stable, effective source of the direct thrombolytic agent plasmin for treatment of occlusive thrombi, with the potential for a better safety profile and fewer side effects than current therapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SITOSTANOL & N-3 FATTY ACIDS ON STEROLS, FATTY ACIDS, LIPOPROTEINS, CHOLESTEROL Principal Investigator & Institution: Connor, William E.; Professor of Medicine; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2001 Summary: Participants in this research study will consist of 2 groups. One group will have a moderately high blood cholesterol level. The purpose of this study is to provide a nutritional, non-drug therapy to lower blood cholesterol levels and reduce the risk for heart disease. A substance in plants called sitostanol has been shown to block the absorption of dietary cholesterol that leads to a lower blood cholesterol level. Several companies have developed sitostanol-containing products. They have put sitostanol into margarine for use in this study. Another food that has been shown to decrease the risk of heart disease is fish oil. Fish oil contains omega-3 fatty acids. These fatty acids lower the blood triglyceride level, decrease the formation of blood clots that can block an artery and cause a heart attack and keep the heart beating in a normal rhythm. This study will show if sitostanol and fish oil are a good combination therapy to decrease the risk of heart disease. The second group of participants in this research study include those with an inherited disorder, sitosterolemia. The purpose of this study is to provide a nutritional, non-drug therapy to lower blood cholesterol and sitosterol levels and reduce the risk for heart disease. A substance in plants called sitostanol has been shown to block the absorption of dietary cholesterol that leads to a lower blood cholesterol level. This study will determine if sitostanol will also lower the blood sitosterol level. Several companies have developed sitostanol-containing products. They have put sitostanol into margarine for use in this study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
17
Project Title: STRUCTURAL DETERMINATION OF FACTOR IXA: BLOOD COAGULATION Principal Investigator & Institution: Lanzo, Cheryl; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001 Summary: Bleeding disorders can be characterized by excessive blood clotting known as thrombosis, or by the inability to form blood clots termed hemophilia. Blood clotting is a tightly regulated process involving exquisite control of the many proteins in the blood clotting cascade including factor IXa, factor VIIIa, factor Xa, and factor VIIa. We are working to understand the structural determinants of the regulation of factor IXa, a central protein in the clotting cascade. The activation of factor IXa results in clotting whereas the inhibition prevents clotting. Better understanding of the structure of factor IXa will lead to the design of small protein mimetics to treat blood clotting disorders. The catalytic activity of factor IXa is dependent on a cofactor called factor VIIIa. We are working on determining the structure of factor IXa with factor VIIIa in order to elucidate the structural determinants leading to the activation of factor IXa. Further, ecotin, a serine protease inhibitor, will be derivatized to specifically inhibit factor IXa. Inhibition of factor IXa is expected to protect against thrombosis without resulting bleeding complications which is expected from inhibiting factor Xa or factor VIIa. The crystallographic analysis of factor IXa-ecotin derivatives will facilitate our understanding of the region(s) of ecotin which are important for the inhibition of factor IXa. I am using the Computer Graphics Laboratory and MidasPlus to structurally model factor IXa with factor VIIIa and ecotin derivatives. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THROMBOMODULIN FUNCTION IN CELLULAR PHYSIOLOGY Principal Investigator & Institution: Weiler-Guettler, Hartmut; Blood Center of Southeastern Wisconsin Milwaukee, Wi 532012178 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-MAR-2004 Summary: Thrombomodulin (TM) has been defined in the context of the blood coagulation system as an endothelial thrombin receptor that suppresses the activation of the blood clotting mechanism. Formation of a thrombin- TM complex alters the substrate specificity of thrombin to generate the natural anticoagulant, activated protein C. In humans, genetic deficiencies leading to the reduced function of the TM-protein C pathway are commonly inherited risk factors for thrombotic disease. The complete ablation of TM function in mice via gene targeting results in early embryonic lethality, before the establishment of a functional cardiovascular system. Biochemical and genetic evidence indicates that the receptor's survival function in development does not involve the known anticoagulant mechanisms of protein C activation or thrombin binding, but a potentially novel activity that is absolutely required for a normal interaction between the developing fetus and the maternal environment. These findings suggest that TM has additional functions not related to blood coagulation that may fulfil important roles in yet other physiological processes, as suggested by the highly regulated expression pattern of the receptor in the developing lung, bone forming tissue, and in other nonendothelial cell types of adult mice. The objective of the proposed studies is to describe in precise molecular terms the mechanism underlying TM function in development and to delineate the physiological consequences of complete receptor deficiency in different stages of embryogenesis and in adult mice. Specifically, the survival of TM deficient mice will be examined in the complete absence of fibrin or fibrinolytic mechanisms to
18
Blood Clots
ascertain whether the death of TM null mice involves the formation or dissolution of blood clots. Critical structural domains of TM required for survival and interaction with intracellular pathways will be delineated by testing receptor mutants for their ability to support embryonic viability. Components interacting with these domains will eventually be identified with biochemical methods. The suspected role of TM in later stages of development will be determined by prolonging the survival of TM knock- out mice via a stage- and cell type-restricted restoration of TM expression in selected embryonic tissues. The cell type restricted ablation of the receptor gene will be employed to evaluate the proposed role of TM in lung morphogenesis and to examine in vivo the consequences of complete receptor deficiency in vascular endothelium and vascular smooth muscle cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THROMBOSIS TARGETED MRI CONTRAST AGENT Principal Investigator & Institution: Danilich, Michael J.; Luna Innovations, Inc. 2851 Commerce St Blacksburg, Va 24060 Timing: Fiscal Year 2003; Project Start 22-AUG-2003; Project End 29-FEB-2004 Summary: (provided by applicant): This proposal addresses the need for a minimally invasive diagnostic assay for the evaluation of pathological blood clots in patients suspected of developing intravascular blood clots that may manifest themselves as pulmonary embolism (PE), deep vein thrombosis (DVT) or thrombotic stroke. Indeed, thrombosis (the formation of blood clots) remains the leading cause of morbidity and mortality in the United States. Luna Innovations proposes to develop a trimetasphere based magnetic resonance imaging contrast agent for site directed thrombosis imaging. Luna Innovations will manufacture an appropriate trimetasphere nanomaterial (such as like Gd2ScN@C80) and functionalize it in preparation for conjugation to a monoclonal antibody with the highest specificity to a neo-epitope on the blood clot. Following this the trimetasphere-antibody complex will be evaluated in vitro experiments for the capability of the complex to target, image and destroy the blood clot. In phase I, Luna will demonstrate the ability of this complex to perform this task and optimize the complex for in vivo diagnostic imaging for phase II Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “blood clots” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for blood clots in the PubMed Central database: 3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
19
•
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. by Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J.; 2002 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150816
•
Tsetse thrombin inhibitor: Bloodmeal-induced expression of an anticoagulant in salivary glands and gut tissue of Glossina morsitans morsitans. by Cappello M, Li S, Chen X, Li CB, Harrison L, Narashimhan S, Beard CB, Aksoy S.; 1998 Nov 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24366
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with blood clots, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “blood clots” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for blood clots (hyperlinks lead to article summaries): •
A method for removing blood clots from the upper urinary tract. Author(s): Mungas J, Lebowitz JM, Sylora H. Source: The Journal of Urology. 1972 December; 108(6): 948-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5082753&dopt=Abstract
•
A simple method for isolation of DNA from blood clots suited for use in PCR. Author(s): Zeillinger R, Schneeberger C, Speiser P, Kury F. Source: Biotechniques. 1993 February; 14(2): 202-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8431280&dopt=Abstract
•
Acquisition of typing serum from post partum blood clots. Author(s): Gazit E, Efter T, Mizrachi Y, Mashiach I, Mashiach S, Serr D. Source: Tissue Antigens. 1977 January; 9(1): 66-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=850920&dopt=Abstract
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
20
Blood Clots
•
Acute thromboembolic events associated with intravenous immunoglobulin infusion in antibody-deficient patients. Author(s): Brown HC, Ballas ZK. Source: The Journal of Allergy and Clinical Immunology. 2003 October; 112(4): 797-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14564366&dopt=Abstract
•
Adenovirus in blood clots from cases of infectious hepatitis. Author(s): Hartwell WV, Love GJ, Eidenbock MP. Source: Science. 1966 June 3; 152(727): 1390. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5937134&dopt=Abstract
•
Alcohol levels in intracranial blood clots. Author(s): Freireich AW, Bidanset JH, Lukash L. Source: J Forensic Sci. 1975 January; 20(1): 83-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1117275&dopt=Abstract
•
An efficient extraction method from blood clots for studies requiring both host and viral DNA. Author(s): Basuni AA, Butterworth LA, Cooksley G, Locarnini S, Carman WF. Source: Journal of Viral Hepatitis. 2000 May; 7(3): 241-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10849268&dopt=Abstract
•
Antiphospholipid antibody. Babies, blood clots, biology. Author(s): Lockshin MD. Source: Jama : the Journal of the American Medical Association. 1997 May 21; 277(19): 1549-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9153370&dopt=Abstract
•
Anuria due to intrarenal blood clots in solitary kidney after change of ureteral stent: resolution with minimally invasive evacuation. Author(s): Roth S, Semjonow A, Waldner M, Hertle L. Source: The Journal of Urology. 1995 July; 154(1): 195-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7776422&dopt=Abstract
•
Ask the doctor. I have atherosclerosis in the arteries of my heart and neck, and my doctors want me to take aspirin. I also have arthritis and take Naprosyn for it every day. I have heard that Naprosyn can prevent blood clots, just like aspirin does. Can I just take Naprosyn, or do I still need to take aspirin, too, to protect my heart and brain from blood clots? Author(s): Lee TH. Source: Harvard Heart Letter : from Harvard Medical School. 2002 August; 12(12): 8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12217848&dopt=Abstract
Studies
21
•
Binding and lysing of blood clots using MRX-408. Author(s): Wu Y, Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G, Vielhauer MD. Source: Investigative Radiology. 1998 December; 33(12): 880-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9851822&dopt=Abstract
•
Binding of human tissue plasminogen activator (t-PA) to blood clots and clot-lytic activity of clot-bound t-PA. Author(s): Kimata H, Nakajima K, Yamamoto S, Hasegawa A. Source: J Pharmacobiodyn. 1990 December; 13(12): 745-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2129127&dopt=Abstract
•
Block of epidural needle by blood clots. Author(s): Hendley BJ. Source: Anaesthesia. 1991 November; 46(11): 996. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1750622&dopt=Abstract
•
Block of epidural needle by blood clots. Author(s): Lim ET, Teh TS, Li YH. Source: Anaesthesia. 1991 July; 46(7): 597-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1862920&dopt=Abstract
•
Blood clots in vessels surrounding symptomatic nerve roots in disc herniation patients: a pilot study. Author(s): Habtemariam A, Gronblad M, Virri J, Korkala O. Source: European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2002 October; 11(5): 447-51. Epub 2002 January 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12384752&dopt=Abstract
•
Blood clots mimicking peripheral intrabronchial tumors in patients with hemoptysis: CT and bronchoscopic findings. Author(s): Eisenhuber E, Brunner C, Bankier AA. Source: Journal of Computer Assisted Tomography. 2000 January-February; 24(1): 47-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10667657&dopt=Abstract
•
Blood clots: the nineteenth-century debate over the substance and means of transfusion in Britain. Author(s): Pelis K. Source: Annals of Science. 1997 July; 54(4): 331-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11619383&dopt=Abstract
22
Blood Clots
•
B-mode sonography of blood clots. Author(s): Coelho JC, Sigel B, Ryva JC, Machi J, Renigers SA. Source: Journal of Clinical Ultrasound : Jcu. 1982 September; 10(7): 323-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6815230&dopt=Abstract
•
Cardiology patient pages. Treatment of blood clots. Author(s): Goldhaber SZ, Grasso-Correnti N. Source: Circulation. 2002 November 12; 106(20): E138-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12427663&dopt=Abstract
•
Cellularity and fibrin mesh properties as a basis for ultrasonic tissue characterization of blood clots and thrombi. Author(s): Loiacono LA, Sigel B, Feleppa EJ, Swami VK, Parsons RE, Justin J, Yaremko MM, Rorke M, Kodama I, Golub RM, et al. Source: Ultrasound in Medicine & Biology. 1992; 18(4): 399-410. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1509615&dopt=Abstract
•
Cerebral blood flow velocities after subarachnoid haemorrhage in relation to the amount of blood clots in the initial computed tomography. Author(s): Boecher-Schwarz HG, Fries G, Mueller-Forell W, Kessel G, Perneczky A. Source: Acta Neurochirurgica. 1998; 140(6): 573-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9755324&dopt=Abstract
•
Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature. Author(s): Funabiki K, Masuoka H, Shimizu H, Emi Y, Mori T, Ito M, Nakano T. Source: Japanese Heart Journal. 2003 September; 44(5): 767-74. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14587658&dopt=Abstract
•
Coagulolysis: mechanism of formation and lysis of dilute whole blood clots and application of this assay into study of certain hypercoagulable states. Author(s): Taylor FB Jr, Nilsson UR, Creech RH, Carroll ET, Beisswenger JG. Source: Ser Haematol. 1973; 6(4): 528-48. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4277409&dopt=Abstract
•
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. Author(s): Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group. Source: The New England Journal of Medicine. 2003 October 30; 349(18): 1703-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14585938&dopt=Abstract
Studies
23
•
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Author(s): Sabovic M, Lijnen HR, Keber D, Collen D. Source: Thrombosis and Haemostasis. 1990 November 30; 64(3): 450-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2096491&dopt=Abstract
•
Correlation of scanning electron microscope and light microscope images of individual cells in human blood and blood clots. Author(s): McDonald LW, Hayes TL. Source: Experimental and Molecular Pathology. 1969 April; 10(2): 186-98. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5777796&dopt=Abstract
•
Dangerous seats? Crammed into airline economy class, you may be risking blood clots. Here's what you can do. Author(s): Smith IK. Source: Time. 2000 November 6; 156(19): 136. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11186856&dopt=Abstract
•
Detection of anti-nuclear antibodies from filter paper blood clots using indirect immunoenzyme technique: preliminary experience and results. Author(s): Chopra A, Anuradha V, Edmonds J. Source: J Assoc Physicians India. 2000 May; 48(5): 493-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11273141&dopt=Abstract
•
Dissolution of blood clots in the biliary ducts with a thrombolytic agent infused through nasobiliary catheter. Author(s): Moparty RK, Brown RD, Layden TJ, Chirravuri V, Wiley T, Venu RP. Source: Gastrointestinal Endoscopy. 2002 September; 56(3): 436-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196791&dopt=Abstract
•
DNA extraction from urea-preserved blood or blood clots for use in PCR. Author(s): Gelhaus A, Urban B, Pirmez C. Source: Trends in Genetics : Tig. 1995 February; 11(2): 41. Erratum In: Trends Genet 1995 April; 11(4): 129. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7716806&dopt=Abstract
•
Effect of protein concentration and blood clots on the “in vitro” anti-Pseudomonas aeruginosa activity of cefoperazone. Author(s): Frongillo RF, Moretti MV, Bittarelli C, Moretti A. Source: Boll Ist Sieroter Milan. 1983 November 30; 62(5): 417-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6422956&dopt=Abstract
24
Blood Clots
•
Effect of thiol derivatives on mixed mucus and blood clots in vitro. Author(s): Risack LE, Vandevelde ME, Gobert JG. Source: Resuscitation. 1978; 6(1): 9-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=97741&dopt=Abstract
•
Efficacy of alteplase thrombolysis for ED treatment of pulmonary embolism with shock. Author(s): Le Conte P, Huchet L, Trewick D, Longo C, Vial I, Batard E, Yatim D, Touze MD, Baron D. Source: The American Journal of Emergency Medicine. 2003 September; 21(5): 438-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14523886&dopt=Abstract
•
Elasticity and fracture strain of whole blood clots. Author(s): Riha P, Wang X, Liao R, Stoltz JF. Source: Clinical Hemorheology and Microcirculation. 1999; 21(1): 45-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10517487&dopt=Abstract
•
Elusive blood clots and fluctuating ventricular dilatation after neonatal intraventricular haemorrhage. Author(s): Fawer CL, Levene MI. Source: Archives of Disease in Childhood. 1982 February; 57(2): 158-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7065715&dopt=Abstract
•
Endobronchial streptokinase for bronchial obstruction by blood clots. Author(s): Cole RP, Grossman GJ. Source: The New England Journal of Medicine. 1983 April 14; 308(15): 905-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6835292&dopt=Abstract
•
Endobronchial streptokinase for relief of tracheobronchial obstruction by blood clots. Author(s): Maxwell SL, Stauffer JL. Source: Chest. 1992 June; 101(6): 1738-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1600809&dopt=Abstract
•
Endobronchial thrombolysis with streptokinase for airway obstruction due to blood clots. Author(s): Vajo Z, Parish JM. Source: Mayo Clinic Proceedings. 1996 June; 71(6): 595-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8642889&dopt=Abstract
Studies
25
•
Enhancement of red cell washout from blood clots by alteration of gel pore size and red cell flexibility. Author(s): Carr ME Jr, Hauge Y. Source: The American Journal of Physiology. 1990 November; 259(5 Pt 2): H1527-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1700633&dopt=Abstract
•
Evaluation of monoclonal antifibrin antibodies by their binding to human blood clots. Author(s): Liau CS, Haber E, Matsueda GR. Source: Thrombosis and Haemostasis. 1987 February 3; 57(1): 49-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3590080&dopt=Abstract
•
Factors influencing lysis of whole blood clots. Author(s): Taylor FB, Muller-Eberhard HJ. Source: Nature. 1967 December 9; 216(119): 1023-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4169258&dopt=Abstract
•
Femoral signal intensity: a new method for prediction of embolic risk. Author(s): Ercan E, Baris N, Tengiz I, Ercan HE, Onbasili OA, Duman C, Cinar CS. Source: Japanese Heart Journal. 2003 September; 44(5): 705-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14587652&dopt=Abstract
•
Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase. Author(s): Jacobsen CD, Fry GL, Wu KK, Southers NJ. Source: Thrombosis Research. 1975 April; 6(4): 327-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1079637&dopt=Abstract
•
Finger-like lysing patterns of blood clots. Author(s): Zidansek A, Blinc A, Lahajnar G, Keber D, Blinc R. Source: Biophysical Journal. 1995 September; 69(3): 803-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8519981&dopt=Abstract
•
Further studies on ultrasonic properties of blood clots. Author(s): Shung KK, Fei DY, Ballard JO 3rd. Source: Journal of Clinical Ultrasound : Jcu. 1986 May; 14(4): 269-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3084583&dopt=Abstract
•
Heparinized saline to aid aspiration of blood clots during laparoscopy. Author(s): Nduka CC, Darzi A. Source: The British Journal of Surgery. 1993 August; 80(8): 1082-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8402082&dopt=Abstract
26
Blood Clots
•
Importance of factor Xa in determining the procoagulant activity of whole-blood clots. Author(s): Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Source: The Journal of Clinical Investigation. 1993 May; 91(5): 1877-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8486759&dopt=Abstract
•
In vitro interaction between venous blood clots and radiopharmaceuticals. Author(s): Kempi V, Persson BR. Source: Nuklearmedizin. 1985 August; 24(4): 173-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4080561&dopt=Abstract
•
Influence of blood clots in the cumulus complex on oocyte fertilization and cleavage. Author(s): Daya S, Kohut J, Gunby J, Younglai E. Source: Human Reproduction (Oxford, England). 1990 August; 5(6): 744-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2254410&dopt=Abstract
•
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. Author(s): Duggan C, Marriott K, Edwards R, Cuzick J. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 October 1; 21(19): 3588-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512389&dopt=Abstract
•
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery. Author(s): WuDunn D. Source: American Journal of Ophthalmology. 1997 November; 124(5): 693-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9372728&dopt=Abstract
•
Low daily aspirin doses reduce risk of blood clots as effectively as higher doses. Author(s): Rollins G. Source: Rep Med Guidel Outcomes Res. 2001 February 22; 12(4): 5-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11767795&dopt=Abstract
•
Low dose, long-term warfarin safely prevents blood clots. Author(s): Levenson D. Source: Rep Med Guidel Outcomes Res. 2003 March 21; 14(6): 1-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12838964&dopt=Abstract
Studies
27
•
Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro. Author(s): Blinc A, Keber D, Lahajnar G, Stegnar M, Zidansek A, Demsar F. Source: Thrombosis and Haemostasis. 1992 December 7; 68(6): 667-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1287880&dopt=Abstract
•
Magnetic relaxation in blood and blood clots. Author(s): Bryant RG, Marill K, Blackmore C, Francis C. Source: Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 1990 January; 13(1): 133-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2319929&dopt=Abstract
•
Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro. Author(s): Blinc A, Keber D, Lahajnar G, Zupancic I, Zorec-Karlovsek M, Demsar F. Source: Haemostasis. 1992; 22(4): 195-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1468722&dopt=Abstract
•
Mechanism of accelerated lysis of blood clots from heparinised blood. Author(s): Morris CJ, Williamson N, Wolf P. Source: Haemostasis. 1981; 10(5): 245-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7274777&dopt=Abstract
•
Molecular masking and unmasking of the paramagnetic effect of iron on the proton spin-lattice (T1) relaxation time in blood and blood clots. Author(s): Finnie M, Fullerton GD, Cameron IL. Source: Magnetic Resonance Imaging. 1986; 4(4): 305-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3669945&dopt=Abstract
•
Near-fatal air embolism: fibrin sheath as the portal of air entry. Author(s): Roberts S, Johnson M, Davies S. Source: Southern Medical Journal. 2003 October; 96(10): 1036-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14570352&dopt=Abstract
•
New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Author(s): Bajaj SP, Joist JH. Source: Seminars in Thrombosis and Hemostasis. 1999; 25(4): 407-18. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10548073&dopt=Abstract
28
Blood Clots
•
Obliteration of the left atrial appendage for prevention of thromboembolism. Author(s): Halperin JL, Gomberg-Maitland M. Source: Journal of the American College of Cardiology. 2003 October 1; 42(7): 1259-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14522492&dopt=Abstract
•
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation. Author(s): Lockhart MS, Lee ET, Taylor FB Jr. Source: Thrombosis Research. 1982 December 1; 28(5): 625-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6820194&dopt=Abstract
•
Opacification of formed blood clots by water-soluble radiopaque contrast media. Author(s): Reich SB, Dorsay RH. Source: Radiology. 1972 August; 104(2): 291-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5044983&dopt=Abstract
•
Penicillin--the duration of its activity in blood clots. Author(s): Juniper RP. Source: Br J Oral Surg. 1972 March; 9(3): 222-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4505409&dopt=Abstract
•
Plasminogen activation and lysis of blood clots induced by cells in vitro. Author(s): Knox P, Crooks S. Source: Journal of Cellular Physiology. 1988 June; 135(3): 467-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2456288&dopt=Abstract
•
Positional shift of intraventricular blood clots demonstrated by computed tomography. Author(s): Vermess M, Di Chiro G, Newby NR, Herdt JR. Source: Radiology. 1976 February; 118(2): 341-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=766057&dopt=Abstract
•
Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. Author(s): Samama MM, Rached RA, Horellou MH, Aquilanti S, Mathieux VG, PluBureau G, Elalamy I, Conard J. Source: British Journal of Haematology. 2003 October; 123(2): 327-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14531916&dopt=Abstract
Studies
29
•
Preventing air embolism when removing CVCs: an evidence-based approach to changing practice. Author(s): Peter DA, Saxman C. Source: Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses. 2003 August; 12(4): 223-8; Quiz 229. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14515601&dopt=Abstract
•
Preventing blood clots with drugs. Author(s): Miller CA. Source: Geriatric Nursing (New York, N.Y.). 1999 March-April; 20(2): 108-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10382429&dopt=Abstract
•
Prospective and retrospective studies of zinc concentrations in serum, blood clots, hair and urine in young patients with insulin-dependent diabetes mellitus. Author(s): Hagglof B, Hallmans G, Holmgren G, Ludvigsson J, Falkmer S. Source: Acta Endocrinol (Copenh). 1983 January; 102(1): 88-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6337453&dopt=Abstract
•
Proton NMR study of the state of water in fibrin gels, plasma, and blood clots. Author(s): Blinc A, Lahajnar G, Blinc R, Zidansek A, Sepe A. Source: Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 1990 April; 14(1): 105-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2161980&dopt=Abstract
•
Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. Author(s): Taylor FB Jr, Muller-Eberhard HJ. Source: The Journal of Clinical Investigation. 1970 November; 49(11): 2068-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4248913&dopt=Abstract
•
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Author(s): Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Source: Nature Medicine. 1995 September; 1(9): 932-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7585220&dopt=Abstract
•
Removal of subarachnoid blood clots after subarachnoid hemorrhage. Author(s): Wakabayashi T, Fujita S. Source: Surgical Neurology. 1984 June; 21(6): 553-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6719326&dopt=Abstract
30
Blood Clots
•
Results of removal of blood clots after massive anterior chamber haemorrhage with secondary glaucoma following ocular contusion through a large 90 degrees limbal incision. Author(s): Mortada A. Source: Bull Ophthalmol Soc Egypt. 1974; 67: 57-61. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4466555&dopt=Abstract
•
Retrograde trypsin instillation into the renal pelvis for the dissolution of obstructive blood clots. Author(s): Grabe M, Forsberg B. Source: European Urology. 1986; 12(1): 69-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3948901&dopt=Abstract
•
Right-sided chest-lead abnormalities on EKG in acute pulmonary embolism. Author(s): Cheng TO. Source: Journal of the National Medical Association. 2003 September; 95(9): 862. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14527054&dopt=Abstract
•
Risk assessment for venous thromboembolism in acute medical illness. Author(s): Hampton KK, Walker I. Source: Hosp Med. 2003 September; 64(9): 508-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14521063&dopt=Abstract
•
Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Author(s): Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Source: Circulation. 1995 August 15; 92(4): 962-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7641380&dopt=Abstract
•
Roles of subarachnoid blood clots and norepinephrine in cerebral vasospasm. Author(s): Shigeno T, Saito I, Sano K, Takakura K, Brock M. Source: Acta Neurochirurgica. 1982; 63(1-4): 277-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7102419&dopt=Abstract
•
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. Author(s): Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III Investigators. Source: The New England Journal of Medicine. 2003 October 30; 349(18): 1713-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14585939&dopt=Abstract
Studies
31
•
Streptokinase for endobronchial blood clots. Author(s): Bansal A. Source: Chest. 1999 August; 116(2): 587. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10453905&dopt=Abstract
•
Studies on thrombolysis with streptokinase. II. The influence of changes due to age in thrombi and whole blood clots. Author(s): Gottlob R, Blumel G, Piza F, Brucke R, Bohmig HJ. Source: Thromb Diath Haemorrh. 1968 July 31; 19(3): 516-25. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5751633&dopt=Abstract
•
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. Author(s): Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Source: The New England Journal of Medicine. 2003 October 30; 349(18): 1695-702. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14585937&dopt=Abstract
•
Suction curettage for removal of retained intrathoracic blood clots and pleural lesions. Author(s): Redan JA, Palmer MT, Tylutki FJ. Source: Jsls. 1999 April-June; 3(2): 117-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10444010&dopt=Abstract
•
The effect of heparin on the viscoelasticity of whole blood clots. Author(s): Overholser KA, Itin JP, Brown DR, Harris TR. Source: Biorheology. 1975 August; 12(5): 309-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1203534&dopt=Abstract
•
The incidence of thromboembolism in the surgical intensive care unit. Author(s): Major KM, Wilson M, Nishi GK, Farber A, Chopra R, Chung A, McVay C, Spivak J, Shabot MM. Source: The American Surgeon. 2003 October; 69(10): 857-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14570363&dopt=Abstract
•
The influence of various plasma components on the lysis of dilute human blood clots. Author(s): Gallimore MJ, Shaw JT. Source: Thromb Diath Haemorrh. 1969 November 15; 22(2): 223-33. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5380946&dopt=Abstract
32
Blood Clots
•
The relationship between cerebral blood flow velocities and the amount of blood clots in computed tomography after subarachnoid haemorrhage. Author(s): Jarus-Dziedzic K, Zub W, Wronski J, Juniewicz H, Kasper E. Source: Acta Neurochirurgica. 2000; 142(3): 309-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10819262&dopt=Abstract
•
The role of histopathologic examination of intracranial blood clots removed for hemorrhage of unknown etiology: a clinical pathologic analysis of 31 cases. Author(s): Abrahams NA, Prayson RA. Source: Annals of Diagnostic Pathology. 2000 December; 4(6): 361-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11149966&dopt=Abstract
•
There is synergism between high-intensity, low-frequency ultrasound and streptokinase but not with eptifibatide, heparin, and aspirin. Differential effects on fresh and aged blood clots. An in vitro study. Author(s): Wyshelesky A, Iakobishvili Z, Matz I, Golovchiner G, Vaturi M, Siegel RJ, Birnbaum Y. Source: Thrombosis Research. 2001 August 15; 103(4): 337-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11562343&dopt=Abstract
•
Transvaginal sonography in the treatment of acute urinary retention due to intravesical blood clots. Author(s): Yang JM, Huang WC. Source: Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine. 2003 August; 22(8): 851-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12901416&dopt=Abstract
•
Ultrasonic tissue characterization of blood clots. Author(s): Sigel B, Feleppa EJ, Swami V, Justin J, Consigny M, Machi J, Kikuchi T, Lizzi FL, Kurohiji T, Hui J. Source: The Surgical Clinics of North America. 1990 February; 70(1): 13-29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2406962&dopt=Abstract
•
Ultrasound of the traumatized spleen: left butterfly sign in lesions masked by echogenic blood clots. Author(s): Weill F, Rohmer P, Didier D, Coche G. Source: Gastrointest Radiol. 1988; 13(2): 169-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3282965&dopt=Abstract
•
Unusual echocardiographic presentations of pulmonary embolism in transit. Author(s): Leitman M, Sidenko S, Peleg E, Wolf R, Sucher E, Rosenblath S, Vered Z. Source: Isr Med Assoc J. 2003 September; 5(9): 675-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509165&dopt=Abstract
Studies
33
•
Use of blood clots as enzyme source in gel electrophoresis. Author(s): Koen AL. Source: Biochemical Genetics. 1971 October; 5(5): 449-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=5520792&dopt=Abstract
•
Use of natriuretic peptides in guiding treatment decisions for acute pulmonary embolism. Author(s): Smithline H. Source: Circulation. 2003 September 30; 108(13): E93; Author Reply E93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14517155&dopt=Abstract
•
Use of streptokinase for lysing blood clots in the pelvis of a renal allograft. Author(s): Fares JA, Nahas WC, Campagnari JC, Ianhez LE, Sabbaga E, Arap S. Source: Transplantation. 1989 November; 48(5): 879-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2815262&dopt=Abstract
•
Utility of brain natriuretic peptide to predict right ventricular dysfunction and clinical outcome in patients with acute pulmonary embolism. Author(s): Kruger S, Merx MW, Graf J. Source: Circulation. 2003 September 30; 108(13): E94-5; Author Reply E94-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14517156&dopt=Abstract
•
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Author(s): Verso M, Agnelli G. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 October 1; 21(19): 3665-75. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512399&dopt=Abstract
35
CHAPTER 2. NUTRITION AND BLOOD CLOTS Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and blood clots.
Finding Nutrition Studies on Blood Clots The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “blood clots” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
36
Blood Clots
The following information is typical of that found when using the “Full IBIDS Database” to search for “blood clots” (or a synonym): •
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. Author(s): Institute of Internal and Vascular Medicine, University of Perugia, 06126 Perugia, Italy.
[email protected] Source: Gresele, P Momi, S Berrettini, M Nenci, G G Schwarz, H P Semeraro, N Colucci, M J-Clin-Invest. 1998 February 1; 101(3): 667-76 0021-9738
•
Cardiology patient pages. Treatment of blood clots. Author(s): Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA.
[email protected] Source: Goldhaber, S Z Grasso Correnti, N Circulation. 2002 November 12; 106(20): e13840 1524-4539
•
Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Author(s): Laboratoire d'Hemostase, Hopital de Rangueil, Toulouse, France. Source: Bendayan, P Boccalon, H Dupouy, D Boneu, B Thromb-Haemost. 1994 May; 71(5): 576-80 0340-6245
•
Effect of thrombin-induced hemostasis on the efficacy of an absorbable adhesion barrier. Author(s): Department of Obstetrics and Gynecology, Yale University Medical Center, New Haven, Connecticut. Source: Wiseman, D M Gottlick, L E Diamond, M P J-Reprod-Med. 1992 September; 37(9): 766-70 0024-7758
•
Enhancement of red cell washout from blood clots by alteration of gel pore size and red cell flexibility. Author(s): Department of Pathology, Medical College of Virginia, Richmond. Source: Carr, M E Hauge, Y Am-J-Physiol. 1990 November; 259(5 Pt 2): H1527-32 00029513
•
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Author(s): Department of Radiology, Oncology and Clinical Immunology, Division of Clinical Immunology, the Rudbeck Laboratory, University Hospital, Uppsala, Sweden. Source: Ozmen, Lisa Ekdahl, Kristina Nilsson Elgue, Graciela Larsson, Rolf Korsgren, Olle Nilsson, Bo Diabetes. 2002 June; 51(6): 1779-84 0012-1797
•
Mechanisms for the anticoagulant effects of synthetic antithrombins. Author(s): Canadian Red Cross Society, Blood Transfusion Service, Hamilton, Ontario. Source: Ofosu, F A Adv-Exp-Med-Biol. 1993; 340213-26 0065-2598
•
Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Author(s): Laboratoire de Thrombose Experimentale, Institut des Cordeliers, Universite Pierre et Marie Curie, Paris VI, France. Source: Meddahi, S Bara, L Fessi, H Samama, M M Blood-Coagul-Fibrinolysis. 2000 January; 11(1): 51-9 0957-5235
Nutrition
37
•
Summaries for patients. Ximelagatran versus warfarin to prevent blood clots after knee replacement surgery. Source: Anonymous Ann-Intern-Med. 2002 October 15; 137(8): I38 1539-3704
•
Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Author(s): Department of Biomedical Sciences, University of Bari, Italy.
[email protected] Source: Colucci, M D'Aprile, A M Italia, A Gresele, P Morser, J Semeraro, N ThrombHaemost. 2001 Apr; 85(4): 661-6 0340-6245
•
Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism. Author(s): Istituto di Patologia Generale, Universita di Bari, Italy. Source: Colucci, M Triggiani, R Cavallo, L G Semeraro, N Blood. 1989 November 1; 74(6): 1976-82 0006-4971
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
38
Blood Clots
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to blood clots; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Vitamin E Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,906,00.html Vitamin K Source: Healthnotes, Inc.; www.healthnotes.com Vitamin K Alternative names: Menadione, Menaphthone, Menaquinone, Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com Vitamin K Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin K Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10068,00.html
•
Minerals Calcium Source: Healthnotes, Inc.; www.healthnotes.com Calcium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,884,00.html Magnesium Source: Prima Communications, Inc.www.personalhealthzone.com
Nutrition
39
Magnesium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,890,00.html Vanadium Alternative names: Vanadate Source: Integrative Medicine Communications; www.drkoop.com •
Food and Diet Brazil Nuts Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,115,00.html Chondroitin Sulfate Source: Healthnotes, Inc.; www.healthnotes.com Garlic Alternative names: Allium sativum Source: Integrative Medicine Communications; www.drkoop.com Garlic Source: Prima Communications, Inc.www.personalhealthzone.com Garlic Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,21,00.html Mushrooms Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10046,00.html Omega-3 Fatty Acids Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,992,00.html Soybeans Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,105,00.html
41
CHAPTER 3. ALTERNATIVE MEDICINE AND BLOOD CLOTS Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to blood clots. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to blood clots and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “blood clots” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to blood clots: •
A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Author(s): Ohkura N, Enjyoji K, Kamikubo Y, Kato H. Source: Blood. 1997 September 1; 90(5): 1883-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9292521&dopt=Abstract
•
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Author(s): Hershberger E, Rybak MJ. Source: Antimicrobial Agents and Chemotherapy. 2000 March; 44(3): 598-601. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10681324&dopt=Abstract
42
Blood Clots
•
Anticoagulant albumin fragments that bind to fibrinogen/fibrin: possible implications. Author(s): Galanakis DK. Source: Seminars in Thrombosis and Hemostasis. 1992 January; 18(1): 44-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1574716&dopt=Abstract
•
Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Author(s): McGrath BJ, Kang SL, Kaatz GW, Rybak MJ. Source: Antimicrobial Agents and Chemotherapy. 1994 September; 38(9): 2034-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7811015&dopt=Abstract
•
Cerastotin, a serine protease from Cerastes cerastes venom, with platelet-aggregating and agglutinating properties. Author(s): Marrakchi N, Barbouche R, Guermazi S, Karoui H, Bon C, El Ayeb M. Source: European Journal of Biochemistry / Febs. 1997 July 1; 247(1): 121-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9249017&dopt=Abstract
•
Changes in regional ventilation after autologous blood clot pulmonary embolism. Author(s): Vidal Melo MF, Harris RS, Layfield D, Musch G, Venegas JG. Source: Anesthesiology. 2002 September; 97(3): 671-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12218535&dopt=Abstract
•
Characterization of a membrane protease from rat submaxillary-gland mitochondria that possess thrombin-like activity. Author(s): Bharadwaj M, Bharadwaj D, Hati RN. Source: The Biochemical Journal. 1996 January 1; 313 ( Pt 1): 193-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8546683&dopt=Abstract
•
Characterization of a thrombin-like enzyme from the venom of Trimeresurus jerdonii. Author(s): Lu QM, Jin Y, Li DS, Wang WY, Xiong YL. Source: Toxicon : Official Journal of the International Society on Toxinology. 2000 September; 38(9): 1225-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10736476&dopt=Abstract
•
China: a new medicine born of tradition. Author(s): Wen W. Source: Unesco Cour. 1979 July; 7: 25-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12309932&dopt=Abstract
Alternative Medicine 43
•
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Author(s): Broze GJ Jr, Higuchi DA. Source: Blood. 1996 November 15; 88(10): 3815-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8916945&dopt=Abstract
•
Colcemid but not taxol modulates the migratory behavior of human T lymphocytes within 3-D collagen lattices. Author(s): Nikolai G, Niggemann B, Werner M, Zanker KS. Source: Immunobiology. 1999 September; 201(1): 107-19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10532284&dopt=Abstract
•
Cold induced retraction of reptilase clots. Author(s): Kubisz P. Source: Scand J Haematol. 1974; 13(3): 175-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4218358&dopt=Abstract
•
EDTA-induced changes in platelet structure and function: clot retraction. Author(s): White JG. Source: Platelets. 2000 February; 11(1): 49-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10938882&dopt=Abstract
•
Effect of clot removal and surgical manipulation on regional cerebral blood flow and delayed vasospasm in early aneurysm surgery for subarachnoid hemorrhage. Author(s): Hosoda K, Fujita S, Kawaguchi T, Shose Y, Hamano S, Iwakura M. Source: Surgical Neurology. 1999 January; 51(1): 81-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9952128&dopt=Abstract
•
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma. Author(s): Carroll RC, Lockhart MS, Taylor FB Jr. Source: The Journal of Laboratory and Clinical Medicine. 1984 May; 103(5): 695-703. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6232329&dopt=Abstract
•
Effect of tPA on regional lung perfusion in unilobar canine pulmonary thromboembolism. Author(s): Ikeda T, Nakatani S, Takata H, Nosaka M, Yoshikawa A, Tanaka H, Yukawa S. Source: American Journal of Respiratory and Critical Care Medicine. 1997 November; 156(5): 1483-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9372664&dopt=Abstract
44
Blood Clots
•
Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. Author(s): de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. Source: Bju International. 1999 November; 84(7): 845-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10532984&dopt=Abstract
•
Effects of colchicine and vinblastine on platelet contractility and release. Author(s): Kuntamukkula MS, Moake JL, McIntire LV, Cimo PL. Source: Thrombosis Research. 1982 June 1; 26(5): 329-39. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7164026&dopt=Abstract
•
Effects of fish-oil constituents and plasma lipids on fibrinolysis in vitro. Author(s): al-Awadhi AM, Dunn CD. Source: British Journal of Biomedical Science. 2000; 57(4): 273-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11204855&dopt=Abstract
•
Effects of serum versus plasma on agglutination of antibody-coated indicator cells by human rheumatoid factors. Author(s): Faulk WP, Torry DS, McIntyre JA. Source: Clinical Immunology and Immunopathology. 1988 February; 46(2): 169-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3338191&dopt=Abstract
•
Examination of irreversible platelet-fibrinogen interactions. Author(s): Peerschke EI, Wainer JA. Source: The American Journal of Physiology. 1985 May; 248(5 Pt 1): C466-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3158213&dopt=Abstract
•
Expelling clots. Author(s): McLean MT. Source: Midwifery Today Childbirth Educ. 1995 Summer; (34): 38. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7787906&dopt=Abstract
•
Fibrin-blood platelet interaction in a contracting clot. Author(s): Cohen I, Gabbay J, Glaser T, Oplatka A. Source: British Journal of Haematology. 1975 September; 31(1): 45-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=813758&dopt=Abstract
•
Fibrinolysis and coagulation. I. Effect of calcium on lysis of euglobulin clots. Author(s): Helle I.
Alternative Medicine 45
Source: Scand J Haematol. 1967; 4(1): 21-32. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4961989&dopt=Abstract •
Flow cytometric immunophenotyping of leukemia cells in clotted blood and bone marrow. Author(s): De Vis J, Renmans W, Segers E, Jochmans K, De Waele M. Source: Journal of Immunological Methods. 1991 March 21; 137(2): 193-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2013696&dopt=Abstract
•
Histo-chemical studies on the anti-ulcer effect of bamboo grass in rats. Author(s): Otani K, Yanaura S, Yuda Y, Kawaoto H, Kajita T, Hirano F, Osawa F, Inouye S. Source: Int J Tissue React. 1990; 12(6): 319-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2151721&dopt=Abstract
•
Influence of NA2-EDTA and some compounds used for dissolution of fibrin clots on the physiochemical properties of fibrinogen and fibrin. Author(s): Godal HC, Brosstad F, Kierulf P. Source: Bibl Haematol. 1977; 44: 151-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=104706&dopt=Abstract
•
Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma' peptide. Author(s): Moaddel M, Farrell DH, Daugherty MA, Fried MG. Source: Biochemistry. 2000 June 6; 39(22): 6698-705. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10828988&dopt=Abstract
•
Massive subchorionic hematoma (Breus' mole) complicated by intrauterine growth retardation. Author(s): Nishida N, Suzuki S, Hamamura Y, Igarashi K, Hayashi Z, Sawa R, Yoneyama Y, Asakura H, Kawabata K, Shima Y, Shin S, Araki T. Source: Journal of Nippon Medical School = Nihon Ika Daigaku Zasshi. 2001 February; 68(1): 54-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11180702&dopt=Abstract
•
Mechanism of plasma clotting by Erysipelothrix rhusiopathiae. Author(s): Takahashi T, Takahashi I, Tamura Y, Sawada T, Yoshida T, Suzuki S, Muramatsu M. Source: Journal of Clinical Microbiology. 1990 October; 28(10): 2161-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2229337&dopt=Abstract
46
Blood Clots
•
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation. Author(s): Lockhart MS, Lee ET, Taylor FB Jr. Source: Thrombosis Research. 1982 December 1; 28(5): 625-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6820194&dopt=Abstract
•
Ocular massage in a case of central retinal artery occlusion the successful treatment of a hitherto undescribed type of embolism. Author(s): Schmidt D. Source: European Journal of Medical Research. 2000 April 19; 5(4): 157-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10799350&dopt=Abstract
•
Orthodontics and dentistry for the hemophilic patient. Author(s): Grossman RC. Source: Am J Orthod. 1975 October; 68(4): 391-403. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1101695&dopt=Abstract
•
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Author(s): Palmer SM, Rybak MJ. Source: Antimicrobial Agents and Chemotherapy. 1996 March; 40(3): 701-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8851596&dopt=Abstract
•
Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer. Author(s): Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2000 November; 6(11): 4201-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11106232&dopt=Abstract
•
Platelet microtubules in clot structure formation and contractile force generation: investigation of a controversy. Author(s): Jen CJ, McIntire LV. Source: Thrombosis and Haemostasis. 1986 August 20; 56(1): 23-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2877507&dopt=Abstract
•
Proteoglycan degradation in hemarthrosis. Intraarticular, autologous blood injection in rat knees. Author(s): Niibayashi H, Shimizu K, Suzuki K, Yamamoto S, Yasuda T, Yamamuro T. Source: Acta Orthopaedica Scandinavica. 1995 February; 66(1): 73-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7863774&dopt=Abstract
Alternative Medicine 47
•
Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (Agkistrodon contortrix contortrix). Author(s): Guan AL, Retzios AD, Henderson GN, Markland FS Jr. Source: Archives of Biochemistry and Biophysics. 1991 September; 289(2): 197-207. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1898066&dopt=Abstract
•
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Author(s): Lee TH, Montalvo L, Chrebtow V, Busch MP. Source: Transfusion. 2001 February; 41(2): 276-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11239235&dopt=Abstract
•
Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called “acute phase” by SDS electrophoresis of fibrin obtained from EDTA-plasma. Author(s): Holm B, Godal HC. Source: Thrombosis Research. 1984 August 1; 35(3): 279-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6431629&dopt=Abstract
•
Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging. Author(s): Busch E, Kruger K, Allegrini PR, Kerskens CM, Gyngell ML, Hoehn-Berlage M, Hossmann KA. Source: Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 1998 April; 18(4): 407-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9538906&dopt=Abstract
•
Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus. Author(s): Tsianos EB, Stathakis NE. Source: Thrombosis and Haemostasis. 1980 December 19; 44(3): 130-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6162208&dopt=Abstract
•
Stabilization of platelet-fibrinogen interactions: modulation by divalent cations. Author(s): Peerschke EI. Source: The Journal of Laboratory and Clinical Medicine. 1993 January; 121(1): 135-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8426076&dopt=Abstract
•
The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes. Author(s): Martin W. Source: Medical Hypotheses. 1984 November; 15(3): 305-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6521675&dopt=Abstract
48
Blood Clots
•
The structural properties and contractile force of a clot. Author(s): Jen CJ, McIntire LV. Source: Cell Motil. 1982; 2(5): 445-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6891618&dopt=Abstract
•
U-46619, a stable analogue of prostaglandin H2, induces retraction of human plateletrich plasma clots. Author(s): Bertele V, Di Minno G, de Gaetano G. Source: Thrombosis Research. 1980 May 1-15; 18(3-4): 543-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6774436&dopt=Abstract
•
Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. Author(s): Wagner KR, Xi G, Hua Y, Zuccarello M, de Courten-Myers GM, Broderick JP, Brott TG. Source: Journal of Neurosurgery. 1999 March; 90(3): 491-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10067918&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
Alternative Medicine 49
The following is a specific Web list relating to blood clots; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Alzheimer's Disease Source: Integrative Medicine Communications; www.drkoop.com Arteriosclerosis Source: Integrative Medicine Communications; www.drkoop.com Atherosclerosis Source: Integrative Medicine Communications; www.drkoop.com Atherosclerosis and Heart Disease Prevention Source: Prima Communications, Inc.www.personalhealthzone.com Blood Clots Source: Integrative Medicine Communications; www.drkoop.com Bone Loss Source: Integrative Medicine Communications; www.drkoop.com Breast Cancer Source: Integrative Medicine Communications; www.drkoop.com Cancer Prevention (reducing the Risk) Source: Prima Communications, Inc.www.personalhealthzone.com Cataracts (prevention) Source: Prima Communications, Inc.www.personalhealthzone.com Cirrhosis Source: Integrative Medicine Communications; www.drkoop.com Coronary Artery Disease Source: Integrative Medicine Communications; www.drkoop.com Diabetes Mellitus Source: Integrative Medicine Communications; www.drkoop.com Edema Source: Integrative Medicine Communications; www.drkoop.com Heart Attack Source: Healthnotes, Inc.; www.healthnotes.com Hemophilia Source: Integrative Medicine Communications; www.drkoop.com
50
Blood Clots
Hemorrhoids Source: Healthnotes, Inc.; www.healthnotes.com High Cholesterol Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Prima Communications, Inc.www.personalhealthzone.com High Homocysteine Source: Healthnotes, Inc.; www.healthnotes.com High Triglycerides Source: Healthnotes, Inc.; www.healthnotes.com Hypercholesterolemia Source: Integrative Medicine Communications; www.drkoop.com Hypoparathyroidism Source: Integrative Medicine Communications; www.drkoop.com Inflammatory Bowel Disease Source: Integrative Medicine Communications; www.drkoop.com Liver Disease Source: Integrative Medicine Communications; www.drkoop.com Menopause Source: Integrative Medicine Communications; www.drkoop.com Miscarriage Source: Integrative Medicine Communications; www.drkoop.com Nail Disorders Source: Integrative Medicine Communications; www.drkoop.com Nausea Source: Prima Communications, Inc.www.personalhealthzone.com Osteoporosis Source: Integrative Medicine Communications; www.drkoop.com Phenylketonuria Source: Healthnotes, Inc.; www.healthnotes.com Prostate Cancer Source: Healthnotes, Inc.; www.healthnotes.com Prostate Cancer Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 51
Pulmonary Hypertension Source: Integrative Medicine Communications; www.drkoop.com Shock Source: Integrative Medicine Communications; www.drkoop.com Spontaneous Abortion Source: Integrative Medicine Communications; www.drkoop.com Stroke Source: Healthnotes, Inc.; www.healthnotes.com Stroke Source: Integrative Medicine Communications; www.drkoop.com Tias Source: Integrative Medicine Communications; www.drkoop.com Transient Ischemic Attacks Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Integrative Medicine Communications; www.drkoop.com Varicose Veins Source: Integrative Medicine Communications; www.drkoop.com Varicose Veins Source: Prima Communications, Inc.www.personalhealthzone.com Water Retention Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Chelation Therapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,679,00.html Reflexology Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,730,00.html Shiatsu Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,733,00.html Trager Approach Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com
52
Blood Clots
Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,741,00.html •
Herbs and Supplements Alfalfa Alternative names: Medicago sativa Source: Healthnotes, Inc.; www.healthnotes.com Allium Sativum Source: Integrative Medicine Communications; www.drkoop.com Alpha-linolenic Acid Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,1025,00.html Aminoglycoside Antibiotics Source: Healthnotes, Inc.; www.healthnotes.com Amoxicillin Source: Healthnotes, Inc.; www.healthnotes.com Ampicillin Source: Healthnotes, Inc.; www.healthnotes.com Anthocyanins Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,1026,00.html Antibiotic Combination: Sulfa Drugs Source: Integrative Medicine Communications; www.drkoop.com Antibiotics Source: Healthnotes, Inc.; www.healthnotes.com Antibiotics (general) Source: Prima Communications, Inc.www.personalhealthzone.com Antioxidants Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10004,00.html Aortic Glycosaminoglycans Source: Prima Communications, Inc.www.personalhealthzone.com Azithromycin Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 53
Bilberry Alternative names: Vaccinium myrtillus, European Blueberry, Huckleberry Source: Integrative Medicine Communications; www.drkoop.com Bilberry Source: Prima Communications, Inc.www.personalhealthzone.com Cephalosporins Source: Healthnotes, Inc.; www.healthnotes.com Cephalosporins Source: Integrative Medicine Communications; www.drkoop.com Chlorhexidine Source: Healthnotes, Inc.; www.healthnotes.com Ciprofloxacin Source: Healthnotes, Inc.; www.healthnotes.com Clarithromycin Source: Healthnotes, Inc.; www.healthnotes.com Clindamycin Oral Source: Healthnotes, Inc.; www.healthnotes.com Clindamycin Topical Source: Healthnotes, Inc.; www.healthnotes.com Coenzyme Q Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,768,00.html Dapsone Source: Healthnotes, Inc.; www.healthnotes.com Dicloxacillin Source: Healthnotes, Inc.; www.healthnotes.com Dipyridamole Source: Healthnotes, Inc.; www.healthnotes.com Docosahexaenoic Acid Source: Healthnotes, Inc.; www.healthnotes.com Doxycycline Source: Healthnotes, Inc.; www.healthnotes.com Erythromycin Source: Healthnotes, Inc.; www.healthnotes.com
54
Blood Clots
European Blueberry Source: Integrative Medicine Communications; www.drkoop.com Feverfew Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,780,00.html Flavonoids Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,782,00.html General Anesthetics Source: Healthnotes, Inc.; www.healthnotes.com Gentamicin Source: Healthnotes, Inc.; www.healthnotes.com Ginger Alternative names: Zingiber officinale Source: Integrative Medicine Communications; www.drkoop.com Ginkgo Source: Prima Communications, Inc.www.personalhealthzone.com Ginkgo Biloba Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,788,00.html Glutathione Source: Healthnotes, Inc.; www.healthnotes.com Glycyrrhiza1 Alternative names: Licorice; Glycyrrhiza glabra L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Grape Seed Extract Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,793,00.html Green Tea Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10032,00.html Heparin Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 55
Huckleberry Source: Integrative Medicine Communications; www.drkoop.com Lapacho Source: Integrative Medicine Communications; www.drkoop.com Levofloxacin Source: Healthnotes, Inc.; www.healthnotes.com Loracarbef Source: Healthnotes, Inc.; www.healthnotes.com Macrolides Source: Healthnotes, Inc.; www.healthnotes.com Macrolides Source: Integrative Medicine Communications; www.drkoop.com Menadione Source: Integrative Medicine Communications; www.drkoop.com Menaphthone Source: Integrative Medicine Communications; www.drkoop.com Menaquinone Source: Integrative Medicine Communications; www.drkoop.com Minocycline Source: Healthnotes, Inc.; www.healthnotes.com Neomycin Source: Healthnotes, Inc.; www.healthnotes.com Nitrofurantoin Source: Healthnotes, Inc.; www.healthnotes.com Nitrous Oxide Source: Healthnotes, Inc.; www.healthnotes.com Panax Alternative names: Ginseng; Panax ginseng Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Pau D'arco Alternative names: Tabebuia avellanedae, Lapacho Source: Integrative Medicine Communications; www.drkoop.com Penicillin Derivatives Source: Integrative Medicine Communications; www.drkoop.com Penicillin V Source: Healthnotes, Inc.; www.healthnotes.com
56
Blood Clots
Penicillins Source: Healthnotes, Inc.; www.healthnotes.com Phosphatidylserine Source: Prima Communications, Inc.www.personalhealthzone.com Phylloquinone Source: Integrative Medicine Communications; www.drkoop.com Quinolones Source: Healthnotes, Inc.; www.healthnotes.com Quinolones Source: Integrative Medicine Communications; www.drkoop.com Ribes Alternative names: Black Currant; Ribes nigrum L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Ruta Alternative names: Rue; Ruta graveolens L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Sulfamethoxazole Source: Healthnotes, Inc.; www.healthnotes.com Sulfasalazine Source: Healthnotes, Inc.; www.healthnotes.com Sulfonamides Source: Healthnotes, Inc.; www.healthnotes.com Tabebuia Avellanedae Source: Integrative Medicine Communications; www.drkoop.com Tanacetum Alternative names: Feverfew; Tanacetum parthenium (L.) Schultz-Bip. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Tetracycline Source: Healthnotes, Inc.; www.healthnotes.com Tetracycline Derivatives Source: Integrative Medicine Communications; www.drkoop.com Tetracyclines Source: Healthnotes, Inc.; www.healthnotes.com Tobramycin Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 57
Trimethoprim Source: Healthnotes, Inc.; www.healthnotes.com Trimethoprim/sulfamethoxazole Source: Healthnotes, Inc.; www.healthnotes.com Vaccinium Myrtillus Source: Integrative Medicine Communications; www.drkoop.com Vanadate Alternative names: Vanadium Source: Integrative Medicine Communications; www.drkoop.com Vanadyl Alternative names: Vanadium Source: Integrative Medicine Communications; www.drkoop.com Warfarin Source: Healthnotes, Inc.; www.healthnotes.com Zanthoxylum Alternative names: Prickly Ash; Zanthoxylum sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zingiber Alternative names: Ginger; Zingiber officinale Roscoe Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zingiber Officinale Source: Integrative Medicine Communications; www.drkoop.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
59
CHAPTER 4. CLINICAL TRIALS AND BLOOD CLOTS Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning blood clots.
Recent Trials on Blood Clots The following is a list of recent trials dedicated to blood clots.8 Further information on a trial is available at the Web site indicated. •
A safety and efficacy trial evaluating the use of SanOrg34006 compared to placebo in patients who have completed 6 months of treatment for symptomatic pulmonary embolism or deep vein thrombosis Condition(s): Pulmonary Embolism; Deep Vein Thrombosis Study Status: This study is currently recruiting patients. Sponsor(s): Organon Purpose - Excerpt: Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant (blood-thinning) drugs are normally given immediately after the clot is discovered and are continued for a period of 3 or 6 months during which time the risk for recurrence is highest. Research has shown that when oral anticoagulants are used appropriately during this period, patients are less at risk for a recurrent blood clot and this risk reduction outweighs the potential for bleeding to occur. In this study, patients who had a blood clot in the lung or in a leg vein and completed 6 months of treatment with daily oral vitamin K antagonists (acenocoumarol or warfarin) or onceweekly injections of SanOrg34006 (a new anticoagulant drug) will receive an additional 6 months of once-weekly SanOrg34006 injections or injections of a solution containing no drug (placebo). This trial will evaluate whether patients treated for an additional 6 months with SanOrg34006 have fewer recurrences of blood clots when compared to patients treated with placebo. Assignment to either SanOrg34006 or placebo will be
8
These are listed at www.ClinicalTrials.gov.
60
Blood Clots
purely by chance. Neither the patients nor their doctors will know which treatment is being given. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00071279 •
A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of pulmonary embolism Condition(s): Pulmonary Embolism Study Status: This study is currently recruiting patients. Sponsor(s): Organon Purpose - Excerpt: Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SanOrg34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Assignment to either SanOrg34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00062803
•
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Condition(s): adenocarcinoma of the pancreas; Pancreatic Cancer; Quality of Life; Thromboembolism Study Status: This study is currently recruiting patients. Sponsor(s): University of Rochester; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00031837
Clinical Trials 61
•
Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins Condition(s): Thrombosis Study Status: This study is currently recruiting patients. Sponsor(s): Warren G Magnuson Clinical Center (CC) Purpose - Excerpt: This study will test the effectiveness of low-dose recombinant tissue plasminogen activator (rtPA, or alteplase) in dissolving blood clots in major arm or neck veins. rtPA is given to patients with heart attacks to dissolve blood clots in blocked coronary arteries. Blood clots that develop in major arm or neck veins usually develop after a venous access device (VAD) or catheter has been placed in the vein. The clot often causes arm, shoulder or neck swelling and pressure or discomfort. Current treatments include removing the VAD, using blood thinners such as heparin and warfarin, or using rtPA to dissolve the clot. All these options have disadvantages, however, including the risk of abnormal bleeding. This study will evaluate whether lower doses of rtPA can effectively dissolve clots without requiring an extended hospital stay, as is needed with the current higher-dose regimen. Patients 18 years of age and older who are enrolled in or are being evaluated for a Clinical Center study and who have a blocked jugular, axillary, subclavian, or brachiocephalic vein may be eligible for this study. The blockage may or may not be associated with use of a VAD. Participants will have one or two treatments with a low dose of rtPA, followed by a blood thinner taken by mouth or by injection for 5 to 7 weeks. On the first treatment day, the patient has a venogram, in which a catheter is placed in an arm vein and passed up to and through the blood clot that is blocking the blood flow in the vein. This is done under an x-ray machine so the radiologist can see exactly where the tube is going. Then, rtPA is injected into the clot about every 30 seconds for 15 to 30 minutes. The catheter is kept in place to maintain access to the vein for additional treatment the next day, if needed. The patient then begins treatment with heparin, either as an outpatient or an inpatient. A second venogram is done the next day. If the venogram shows that the vein is open, anti-clotting treatment with heparin or warfarin continues. If the venogram shows that the vein is still blocked, the rtPA treatment is repeated while the blood thinner treatment continues. The patient has a third venogram the following day. If the vein has opened, heparin and warfarin treatment continues. If the vein is still blocked, the patient's participation in the study ends. Although the patient is no longer formally in the study, he or she may choose to receive additional treatments with rtPA in higher doses at NIH or to continue using blood thinners under the direction of the primary physician. Blood tests are done during blood thinning therapy to monitor and adjust the dosage. Additional blood samples are taken before and at timed intervals after each rtPA treatment to measure the response to therapy. Patients who benefit from rtPA treatment remain on blood thinners for 5 to 7 weeks and then return to NIH for a follow-up venogram to see if the vein is still open. During warfarin therapy, blood tests are done every few days during the first week or two and every 2 weeks thereafter to ensure the optimal drug dose is being administered. If the repeat venogram at 5 to 7 weeks shows that the vein has closed, the blood thinners (warfarin or heparin) will be stopped and the patient's participation in this study will end. If the vein has remained open, the patient's doctor will decide whether or not to continue anti-clotting therapy. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00055159
62
•
Blood Clots
Risk Factors for Venous Thromboembolism Condition(s): Deep Venous Thrombosis; Pulmonary Embolism Study Status: This study is currently recruiting patients. Sponsor(s): Department of Veterans Affairs Medical Research Service Purpose - Excerpt: Deep venous thrombosis is the presence of blood clots, usually in the legs that lead to either local problems or breathing problems if the clot moves to the lungs. This study is designed to assess both clinical conditions as well as common genetic factors that lead to more risk of deep venous thrombosis. Clinical conditions of venous thrombosis include: stroke, malignancy, and situations such as surgery, pregnancy, trauma, or travel. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00018772
•
Study of Abnormal Blood Clotting in Children with Stroke Condition(s): Abnormalities; Blood Coagulation Cerebrovascular Accident; Vascular Disease
Disorder;
Brain
Disease;
Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: A stroke is a sudden neurological condition caused by an abnormality in blood flow to the brain. Studies on strokes in children estimate that 2.5 out of 100,000 children will suffer a stroke. Pediatric strokes occur more frequently in children less than 2 years old. The causes of strokes in children are often undetermined. Effective treatment and prevention plans for childhood strokes can only be developed once the causes are understood. There is increasing evidence that blood-clotting abnormalities alone or in combination with environmental factors may be responsible for blood clots in arteries and veins. There are many compounds that play a role in the normal pathway of blood clotting in the body. Abnormalities in any one of these compounds can account for the development of stroke-causing blood clots. Presently, there is very little information on these abnormalities in children. This study is designed to measure the frequency of several specific blood-clotting abnormalities in children with a history of stroke and porencephaly (pockets/cavities within the brain). Data collected from this study will be compared to statistics of these conditions in the rest of the population. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00001927 •
Treatment for Blood Clots in the Veins of the Legs Condition(s): Embolism; Thrombophlebitis Study Status: This study is currently recruiting patients. Sponsor(s): Warren G Magnuson Clinical Center (CC) Purpose - Excerpt: Acute deep venous thrombosis (ADVT) of the lower extremity is a common disorder. Traditional treatment with anticoagulation therapy is effective in reducing the associated risk of pulmonary embolism, but is ineffective in restoring
Clinical Trials 63
patency of the venous system of the lower extremity. While systemic thrombolytic therapy has been shown to be more effective than anticoagulation, catheter directed local thrombolytic therapy is the most effective treatment in restoring venous patency. Current treatment regimens are based on use of urokinase, infused continuously through catheters imbedded into the thrombus. These treatment regimens require doses on the order of 10,000,000 units of urokinase, resulting in significant bleeding complications and prohibitive costs. Experience at NIH with pulse-spray treatment of axillary subclavian venous thrombosis with rtPA indicates that this is a highly effective and safe alternative thrombolytic regimen. The proposed protocol is designed to evaluate the efficiency, safety, and doses of rtPA associated with pulse spray directed rtPA treatment of the more extensive venous thrombosis encountered in the lower extremity. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00001713 •
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters Condition(s): Thromboembolism Study Status: This study is currently recruiting patients. Sponsor(s): Cancer Research Campaign Clinical Trials Centre Purpose - Excerpt: RATIONALE: Warfarin may be effective in preventing the formation of blood clots in patients with central venous catheters. PURPOSE: Randomized clinical trial to study the effectiveness of warfarin in preventing blood clots in cancer patients who have central venous catheters. Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00024297
•
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Condition(s): stage III prostate cancer; stage IV prostate cancer; Thromboembolism; recurrent prostate cancer Study Status: This study is no longer recruiting patients. Sponsor(s): National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center Purpose - Excerpt: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Anticoagulant drugs such as warfarin may reduce the risk of blood clots. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus warfarin in treating patients who have prostate cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00014352
64
•
Blood Clots
ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) Condition(s): Thromboembolism; Deep Vein Thrombosis; Venous Thromboembolism; Pulmonary Embolism Study Status: This study is no longer recruiting patients. Sponsor(s): (Sponsor Name Pending) Purpose - Excerpt: The purpose of this study is to gain additional safety information as well as to determine after the study drug has been given to patients who have undergone total hip replacement surgery, whether the study drug is effective in preventing late deep vein thrombosis (blood clots in legs) or pulmonary embolism (blood clots in lungs). Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00041509
•
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIVPositive Males with Hemophilia Condition(s): HIV Infections; Hemophilia A Study Status: This study is completed. Sponsor(s): Merck Research Laboratories Purpose - Excerpt: The purpose of this study is to see if indinavir plus two other antiHIV drugs affect blood clotting in HIV-positive patients with hemophilia. Phase(s): Phase IV Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00002386
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “blood clots” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials:
Clinical Trials 65
•
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
67
CHAPTER 5. PATENTS ON BLOOD CLOTS Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “blood clots” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on blood clots, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Blood Clots By performing a patent search focusing on blood clots, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
68
Blood Clots
example of the type of information that you can expect to obtain from a patent search on blood clots: •
Aneurysm embolization device Inventor(s): Jones; Donald K. (Lauderhill, FL), Mitelberg; Vladimir (Aventura, FL) Assignee(s): Cordis Corporation (Miami Lakes, FL) Patent Number: 6,428,558 Date filed: February 16, 2000 Abstract: An aneurysm embolization device which may be used to occlude a blood vessel or aneurysm. The device has a plurality of support struts which form a substantially ellipsoidal shape. The support struts are preferably formed from a nickeltitanium alloy, such as nitinol, which has superelastic characteristics. A mesh sleeve is disposed over the support struts. The mesh sleeve is preferably formed of a thrombogenic material, such as polyurethane, so as to encourage the formation of blood clots and scar tissue to permanently occlude the vessel. Excerpt(s): This invention relates generally to vascular occlusion devices and particularly to a vascular occlusion device which self-expands to occlude a blood vessel or an aneurysm. Medical devices adapted for implantation in the vasculature of the human body are well known and commercially available. Such devices are typically used to permanently occlude blood flow in a blood vessel or seal an aneurysm to prevent the catastrophic results of it rupturing. A variety of occlusion devices are known to the art. U.S. Pat. No. 4,517,979 to Pecenka discloses a detachable balloon catheter. The balloon catheter is inserted into a blood vessel and inflated with a fluid. When the catheter is withdrawn, the balloon section detaches and an internal mechanism seals the balloon to prevent the outflow of fluid. The balloon is typically fabricated from either latex or silicone rubber. Web site: http://www.delphion.com/details?pn=US06428558__
•
Antibodies that bind to.alpha.2-antiplasmin crosslinked to fibrin which do not inhibit plasma.alpha.2-antiplasmin Inventor(s): Haber; Edgar (Salisbury, NH), Matsueda; Gary R. (Princeton, NJ), Reed; Guy L. (Winchester, MA) Assignee(s): The General Hospital Corporation (Boston, MA) Patent Number: 6,280,730 Date filed: November 24, 1997 Excerpt(s): The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to.alpha.2-antiplasmin crosslinked to fibrin (.alpha.2AP-Fx) which does not inhibit plasma.alpha.2-antiplasmin (.alpha.2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward.alpha.2-antiplasmin crosslinked to fibrin which does not inhibit plasma.alpha.2AP together with a thrombolytic agent. The initiating event of many myocardial infarctions (heart attacks) is the hemorrhage into atherosclerotic plaque. Such hemorrhage often results in the formation of a thrombus (or blood clot) in the coronary artery which supplies the infarct zone (i.e., an
Patents 69
area of coagulation necrosis which results from an obstruction of blood circulation). This thrombus is composed of a combination of fibrin and blood platelets. The formation of a fibrin-platelet clot has serious clinical ramifications. The degree and duration of the occlusion caused by the fibrin-platelet clot determines the mass of the infarct zone and the extent of damage. The primary goal of current treatment for myocardial infarction involves the rapid dissolution of the occluding thrombus and the restoration of blood flow ("reperfusion"). An agent which is capable of selectively binding to and affecting may enhance thrombolysis and may decrease the risk of general hemorrhage to the patient. A successful therapy must be capable of sustained effect so that reformation of the clot does not occur after the cessation of therapy. If the fibrin-platelet clot is able to reform, then the affected artery may become reoccluded. Web site: http://www.delphion.com/details?pn=US06280730__ •
Bacterial fibrin-dependent plasminogen activator Inventor(s): Reed; Guy L. (Winchester, MA) Assignee(s): The President and Fellows of Harvard College (Cambridge, MA) Patent Number: 6,210,667 Date filed: December 15, 1998 Abstract: A pharmaceutical composition in a preferred embodiment comprises an isolated bacterial protein that induces fibrin-dependent plasminogen activation, and methods for dissolving blood clots in a subject use such a composition. Embodiments also include a nucleic acid encoding such a bacterial protein, a nucleic acid encoding such a bacterial protein as a fusion to another protein, an expression vector with the nucleic acid, and a host cell transformed with the expression vector. Excerpt(s): The present invention relates to modifications of streptokinase and other microbial enzymes for use to activate plasminogen in the presence of fibrin, to efficiently dissolve an unwanted blood clot in a subject. Clinical studies of acute coronary thrombosis have established that administration of plasminogen (Pg) activators such as recombinant tissue plasminogen activator (t-PA) and streptokinase (SK) saves lives and reduces morbidity. Comparison of the efficacy of SK (administered according to a 30 year old dosing regimen) and t-PA (administered by a variety of different protocols), in the presence and absence of heparin, showed that SK is markedly cheaper and can cause less cerebral bleeding than t-PA, whereas t-PA appears to be slightly better at reducing mortality than SK, at least as it is currently administered (e.g. GUSTO, New Engl. J. Med. 329:1615-1622, 1993). However, problems with administration of these thrombolytic agents remain. For example, acute myocardial infarction patients receiving early administration of either t-PA or SK failed to show reperfusion within 90 min, and reperfusion was not observed in 45-67% of patients (Karagounis L., Amer. Coll. Cardiol. 19:1-10 (1992), Lincoff A., et al. Am J Cardio; 75(14):871-766 (1995); Simes R., et al. Circulation 91(7):1905-1907 (1995)). Failed reperfusion is associated with an approximately double mortality rate from myocardial infarction compared to successful reperfusion, and significantly increases morbidity in surviving patients. The results of thrombolytic therapy as a treatment for venous thromboembolism are also relatively disappointing. Further, the mortality rate for pulmonary embolism appears not to have changed in.about.30 years, and no Pg activator has been shown to change the death rate in these patients (Goldhaber S., Chest 107:45S-51S (1995)). When administered to patients with pulmonary embolism, t-PA restores blood flow to only.about.33% of occluded lung segments within 24 hours (Goldhaber S., Lancet 2:886-889 (1986)). Similar
70
Blood Clots
results have been described with other agents (UPET, Circulation 47:1-108, 1973). In cases of deep venous thrombosis, about two-thirds of patients treated with SK or t-PA have minimal or no lysis of the clot on repeat venography after 24 hours (Salzman E., et al. Basic Principles and Clinical Practice; 3rd Ed. Uppincott, Philadelphia (1994); Goldhaber S. Am J Med 88:235-240 (1990)), thus neither SK nor t-PA treatments are optimal for thrombotic disease in patients. Web site: http://www.delphion.com/details?pn=US06210667__ •
Bag for use in the intravascular treatment of saccular aneurysms Inventor(s): Greenhalgh; E. Skott (Wyndmoor, PA) Assignee(s): Prodesco, Inc. (Perkasie, PA) Patent Number: 6,346,117 Date filed: March 2, 2000 Abstract: A bag for use in the intravascular treatment of saccular aneurysms and a method of forming the bag are disclosed. The bag is formed from a plurality of flexible, resilient filamentary members braided into a tubular sleeve and biased into a first shape having an expanded first diameter sized to substantially fill the aneurysm. The bag is resiliently deformable into a second shape having a diameter smaller than the first and sized to slidingly interfit within the lumen of a catheter. An opening is provided in the bag to receive a clotting medium, such as a platinum wire, on which blood clots can be induced to form by mechanical or electrolytic means. A closure is provided by biasing the filamentary members to form a constriction around the opening. In use the, bag is inserted into a saccular aneurysm via the catheter and expands to its first diameter upon release therefrom. Interstices between the interbraided filamentary members provide pores allowing blood from the aneurysm to enter the bag when the bag is positioned within the aneurysm. The clotting medium wire is packed into the bag, blood clots on the wire and occludes the aneurysm, sealing it off from the blood stream and preventing rupture. The wire is released from the catheter and is contained within the bag in the aneurysm. Excerpt(s): This invention relates to an intravascular device used in the treatment of aneurysms, and especially in the occlusion of cerebrovascular saccular aneurysms. Saccular aneurysms occur at the branching of arteries in the body and comprise a sacklike formation of the artery wall which extends outwardly from the bifurcation point between the arterial branches. The aneurysm has a neck forming the juncture with the artery and is capped by a dome. During formation of the aneurysm, the arterial internal elastic lamina disappears at the base of the neck, the sack wall thins and weakens and connective tissue replaces smooth-muscle cells. The aneurysm tends to rupture at the dome and bleeding ensues. Rupture of a cerebrovascular saccular aneurysm is especially serious due to the associated high mortality rate (10% within the first day of rupture, 25% within three months) and the major neurological deficits experienced by those who survive the initial hemorrhage. Naturally, therapeutic treatment of cerebrovascular aneurysms emphasizes preventing the initial rupture. Web site: http://www.delphion.com/details?pn=US06346117__
Patents 71
•
Blood filtering device having improved permeability Inventor(s): Chevillon; Gerard (Montrouge, FR), Nadal; Guy (Poitiers, FR) Assignee(s): B. Braun Celsa (FR) Patent Number: 5,968,071 Date filed: December 22, 1997 Abstract: The invention relates to a blood filter that is to be positioned within a blood vessel to trap blood clots. The filter includes a head to which there are attached and from which there extend several legs comprising at least one elongated element having two opposite ends. The legs are radially movable and the elongated element of at least some of these legs has a shape folded back upon itself, substantially in the form of a loop. According to the invention, one of the ends of at least some of these elongated elements is disposed at a distance from the inside of the head of the filter. Excerpt(s): The invention relates to a blood filter that is to be positioned within a blood vessel to trap blood clots carried along by the flow of blood. It should be noted at this point that the filter according to the invention can be both a "definitive" (or permanent) filter and a "temporary" filter, that is a filter which can be implanted in a vessel and which can be left there permanently, or removed after a given period of implantation (nowadays typically of the order of a fortnight). Conventionally, a filter known as a "definitive" implantation filter is provided with means for fastening or attachment to the wall of the vessel in which it is implanted. Some examples of such filters are described in U.S. Pat. No. 5,059,205, U.S. Pat. No. 5,133,733 or U.S. Pat. No. 5,344,427. However, some such blood filters are also known which have hooks for attachment to the wall of the vessel and which are nevertheless defined as being removable or repositionable, as long as the period for which they have been positioned in a specific location within a vessel has not been too long and cellular development does not in practice prevent them from being moved. U.S. Pat. No. 5,324,304 describes such a filter whose head has a hook enabling the filter to be caught. Web site: http://www.delphion.com/details?pn=US05968071__
•
Continuous autotransfusion filtration system Inventor(s): Swisher; David Rork (St. Charles, MO) Assignee(s): Sherwood Services, AG (LU) Patent Number: 6,099,493 Date filed: May 6, 1997 Abstract: A progressive filtration system for a chest drainage unit during continuous autrotransfusion comprising a gross filter for filtering incoming blood at the inlet portion of a collection chamber of a chest drainage unit and a conventional fine micron filter assembly located at the bottom portion of the collection chamber for refiltering collected blood prior to reinfusion of that blood back to the patient. The micron filter assembly includes a valve cap at the top portion of the assembly that functions as a plug to seal the top portion of the assembly and as a one way valve that permits reflux of later developing blood clots that might clog the tubing once the blood has already passed through the assembly.The valve cap is also adapted for sealing engagement with a drop tube that places the filter assembly in fluid flow communication with an outlet of the collection chamber located at the top portion of the chamber.
72
Blood Clots
Excerpt(s): The present invention relates to a system for draining shed blood from the body cavity of a patient and reinfusing clean, filtered blood back to the patient, and more specifically to a chest drainage unit (CDU) that includes a progressive filtration system for filtering out blood clots and other contaminants at both the inlet and outlet ports inside the CDU's collection chamber. More particularly, this invention relates to a high flow, micron filter assembly that refilters blood that collects at the bottom portion of the collection chamber prior to reinfusion to the patient with the assembly further including a drop tube that permits the refiltered blood to exit at an outlet port located at the top portion of the CDU. A CDU is an apparatus for suctioning gases and liquids from the pleural cavity of patients. The pleural cavity lies within the rib cage above the diaphragm and is surrounded by the pleural membrane. The pleural cavity contains both lungs, which in their normal expanded state fill the pleural cavity. Several conditions and diseases such as interventional surgery, trauma, emphysema and various infections can cause a build up of liquid and gases around the lungs in the intrapleural space. When this happens, it causes the lungs to collapse to a volume much less than that of the pleural cavity, thereby severely impairing breathing functions of the patient. The lungs can be re-expanded to their normal state to fill the pleural cavity by draining the liquid and gases from the intrapleural space using a CDU. Various devices have been developed to drain and collect fluids such as blood from the intrapleural space for subsequent autotransfusion. U.S. Pat. No. 4,114,416 to Karwoski et al. illustrates the prior art development of autotransfusion CDUs. The device includes a collection chamber for the collection of fluid from the pleural cavity, a water seal chamber for preventing passage of gas from the atmosphere into the patient's pleural and mediastinal cavities, and a manometer chamber for regulating the degree of vacuum in the system. An inlet port of the collection chamber is connected to the patient's pleural cavity via a thoracotomy tube that deposits shed blood and gases into the collection chamber. As the shed blood enters the inlet portion of the collection chamber, a large area gross filter, such as a fabric or an open-pore sponge filter, is used to remove blood clots and gross particles from incoming fluids. Once filtered, the blood collects at the bottom portion of the collection chamber until reinfusion is effected and the blood is drained through an outlet port located at the bottom portion of the collection chamber. The Karwoski et al. device is also placed in fluid flow communication with a blood compatible pump set through tubing that connects the pump to the outlet port and permits the collected blood to drain therethrough for reinfusion to the patient. Web site: http://www.delphion.com/details?pn=US06099493__ •
Crustacean and fish derived multifunctional enzyMen Inventor(s): de Faire; Johan R. (Vattholma, SE), Franklin; Richard L. (London, GB), Kay; John (Cardiff, GB), Lindblom; Ragnvald (Muang Rayong, TH) Assignee(s): Phairson Medical Inc. (London, GB) Patent Number: 5,945,102 Date filed: February 8, 1995 Abstract: The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral
Patents 73
infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme. Excerpt(s): The present invention relates to the discovery that there exists a family of crustacean and fish derived enzymes having substantial structural similarity to an enzyme derived from antarctic krill. The krill enzyme is the subject of U.S. patent application Ser. No. 08/338,501, filed Nov. 22, 1994, which is the national-stage application for PCT/SE93/00455, filed May 21, 1993, which claims the priority Swedish Application No. 9201628-6, filed May 22, 1992. The entire disclosure of U.S. patent application Ser. No. 08/338,501, is incorporated herein by reference. These related enzymes are believed to have the same utility as the krill enzyme. In particular, these enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme. U.S. Pat. Nos. 4,801,451 and 4,963,491 disclose a mixture of exo- and endopeptidases isolated from antarctic krill (Euphasia superba) and the use of the mixture as cleaning solutions. U.S. Pat. No. 4,801,451 discloses the use of such enzymes to remove foreign matter and dead tissue from wounds. Patent Application WO 85/04809 discloses the use of krill enzymes as a digestion promotor. European Application EP-A1-0170115 discloses the use of krill enzymes to dissolve blood clots. Web site: http://www.delphion.com/details?pn=US05945102__ •
Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas Inventor(s): Guglielmi; Guido (Santa Monica, CA), Sepetka; Ivan (Redwood City, CA) Assignee(s): The Regents of the University of California (Oakland, CA) Patent Number: 5,925,037 Date filed: October 6, 1997 Abstract: An artery, vein, aneurysm, vascular malformation or arterial fistula is occluded through endovascular occlusion by the endovascular insertion of a platinum wire and/or tip into the vascular cavity. The vascular cavity is packed with the tip to obstruct blood flow or access of blood in the cavity such that the blood clots in the cavity and an occlusion if formed. The tip may be elongate and flexible so that it packs the cavity by being folded upon itself a multiple number of times, or may pack the cavity by virtue of a filamentary or fuzzy structure of the tip. The tip is then separated from the wire mechanically or by electrolytic separation of the tip from the wire. The wire and the microcatheter are thereafter removed leaving the tip embedded in the thrombus formed within the vascular cavity. Movement of wire in the microcatheter is more easily tracked by providing a radioopaque proximal marker on the microcatheter and a corresponding indicator marker on the wire. Electrothrombosis is facilitate by placing the ground electrode on the distal end of the microcatheter and flowing current between the microcatheter electrode and the tip.
74
Blood Clots
Excerpt(s): The invention relates to a method and apparatus for endovascular electrothrombic formation of thrombi in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas. Approximately 25,000 intracranial aneurysms rupture every year in North America The primary purpose of treatment for ruptured intracranial aneurysm is to prevent rebleeding. At the present time, three general methods of treatment exist, namely an extravascular, endovascular and extraendovascular approach. The extravascular approach is comprised of surgery or microsurgery of the aneurysm or treatment site for the purpose of preserving the parent artery. This treatment is common with intracranial berry aneurysms. The methodology comprises the step of clipping the neck of the aneurysm, performing a suture-ligation of the neck, or wrapping the entire aneurysm. Each of these surgical procedures is performed by intrusive invasion into the body and performed from outside the aneurysm or target site. General anesthesia, craniotomy, brain retraction and arachnoid dissection around the neck of the aneurysm and placement of a clip are typically required in these surgical procedures. Surgical treatment of vascular intracranial aneurysm can expect a mortality rate of 4-8% with a morbidity rate of 18-20%. Because of the mortality and morbidity rate expected, the surgical procedure is often delayed while waiting for the best surgical time with the result that an additional percentage of patients will die from the underlying disease or defect prior to surgery. For this reason the prior art has sought alternative means of treatment. Web site: http://www.delphion.com/details?pn=US05925037__ •
Filter system and methods for removing blood clots and biological material Inventor(s): Tu; Hosheng (2151 Palermo, Tustin, CA 92782) Assignee(s): none reported Patent Number: 6,068,645 Date filed: June 7, 1999 Abstract: A filter system and methods for removing blood clots and/or emboli by collecting them in a filtering element and thermally treating same by delivering therapeutic energy through a bipolar electrode members to the collected blood clots and emboli. Other alternate energy may also be applied to the collected blood clots and emboli for treating them in situ. Excerpt(s): The present invention generally relates to improved medical system and methods for treating blood vessels, and more particularly, to such a filter system and methods for removing blood clots and emboli by collecting them in a filtering element and thermally treat same by delivering therapeutic RF energy through a bipolar electrode means to the collected blood clots and emboli. Other alternate energy may also be applied to the collected blood clots, emboli or biological debris for treating them in situ. Blood vessel embolism is referred to hereby as an obstruction of a blood vessel by blood clots, emboli, or other foreign substances. This is a major cause of mortality and morbidity in the United States, particularly when blood vessel embolism occurs in a pulmonary vein or a coronary artery. To prevent embolism from occurring, patients are commonly treated with anticoagulants or with thrombolytic agents. In some situations, reliance on drugs may be inappropriate where a patient has high risk of internal bleeding or sensitive to a particular drug. A blood filtration device has been widely used to collect and remove the blood clots, emboli and foreign substance from a blood vessel. Nadal in U.S. Pat. No. 5,725,550 discloses a blood filtration unit that is to be implanted in a vessel of a patient's body, especially for the purposes of retaining blood clots. The
Patents 75
implanted filtration unit, either permanently or temporarily, continues to collect blood clots or emboli. The collected junk, including blood emboli, blood clots, debris and any foreign substance, should be removed and disposed of out of the body. Alternately, the junk should be treated in situ so that the treated blood emboli or clots are so small that they do not pose any harm to the blood vessel or to the patient. A permanently implanted filter system may need frequent junk removal when the accumulation of clots or emboli is excessive. Web site: http://www.delphion.com/details?pn=US06068645__ •
Gross filter for a drainage device Inventor(s): Lewis; Anthony K. (St. Charles, MO), Swisher; David Rork (St. Charles, MO), Weilbacher; Eugene E. (Ellisville, MO), Yam; Jacky S. (St. Louis, MO) Assignee(s): Sherwood Services AG (Schaffhausen, CH) Patent Number: 6,280,429 Date filed: December 4, 1998 Abstract: A gross filter in a drainage device for filtering fluids drained from the pleural cavity of a patient comprising a filter body having a first side panel, second side panel, back panel and bottom panel that assemble to form a generally box-shape filter with open front and top portions. The gross filter is located in the first of two subchambers that comprise the collection chamber. The filter body further comprises a filter screen sized for filtering gross particulates, such as blood clots, that may become entrained in fluid drained from a patient. The gross body is configured so as to permit the further filtering of fluids when blood clots have formed and blocked the filter screen of the filter's bottom panel from fluid flow therethrough, thereby allowing uninterrupted filtering of blood into the collection chamber through the first and second side panels instead. To further facilitate the filtering of blood through the filter body when a blocked state exists at the bottom panel portion thereof, the first and second side panels are angled toward each other at their bottom ends and gradually spaced apart from the collection chamber walls in order to permit unimpeded filtering of fluid through the side panels. The open front portion of the gross filter permits clear viewing by medical personnel of the amount of blood clots being retained inside the filter body so that measuring indicia may be provided on the drainage unit's front panel as an indication of the amount and rate of blood clot retention inside the filter. An overflow filter portion is also provided at the top portion of one of the side panels for filtering fluid when the rest of the filter body is clogged and blocked by blood clots or when the first subchamber is filled to capacity. Excerpt(s): Gross filters for use in filtering out large particulate matter entrained in body fluids drained from a patient during convalescence or post-operative recovery are well known in the art. Typically, gross filters of this kind are incorporated in a drainage device, for example a Chest Drainage Unit (CDU), for filtering blood clots and other gross contaminates from body fluids before reinfusing such fluids back to the patient. A CDU is an apparatus for suctioning gases and liquids from the pleural cavity of a patient in order to re-expand the patient's lungs. The pleural cavity lies within the rib cage above the diaphragm and is surrounded by the pleural membrane. The pleural cavity contains both lungs, which in their normal expanded state fill the pleural cavity. Several conditions and diseases such as interventional surgery, trauma, emphysema and various infections can cause a build up of liquid and gases around the lungs in the intrapleural space. When this happens, it causes the lungs to collapse to a volume much less than
76
Blood Clots
that of the pleural cavity, thereby severely impairing breathing functions of the patient. The lungs can be re-expanded to their normal state to fill the pleural cavity by draining the liquid and gases from the intrapleural space using the CDU. A typical CDU and its operation is disclosed in U.S. patent application Ser. No. 08/810,056 to Swisher et al. entitled "Chest Drainage Unit with Controlled Automatic Excess Negativity Relief Feature", assigned to the assignee, and is herein incorporated by reference in its entirety. During the draining of fluid from a patient's pleural cavity blood clots may develop and become entrained in the fluid as it enters the collection chamber of the CDU for eventual reinfusion to the patient. During reinfusion of blood, it is desirable that the collected blood be free of any large particulate matter or other kinds of gross contaminants before entering and collecting at the bottom portion of the collection chamber. In order to screen out these undesirable contaminants a gross filter is provided near the inlet to the collection chamber for filtering out large particulate matter as fluid enters the CDU. The Swisher et al. device referenced above is generally exemplary of medical drainage devices that incorporate a gross filter for filtering out blood clots and other large particulate matter from fluid drained from a patient's pleural cavity. The gross filter used in the Swisher et al. device comprises a porous filtering material placed near the inlet of the collection chamber in a horizontal orientation so that all incoming fluid must pass through the gross filter before collecting in a pooling area located at the bottom portion of the collection chamber. In this manner, incoming fluid is filtered prior to entering the pooling area so that blood clots and other large particulate matter are retained on top of the filter. Web site: http://www.delphion.com/details?pn=US06280429__ •
Method and apparatus for determining anticoagulant therapy factors Inventor(s): Carroll; Wallace E. (1556 San Leandro La., Santa Barbara, CA 93108), Jackson; R. David (1556 San Leandro La., Santa Barbara, CA 93108) Assignee(s): none reported Patent Number: 5,981,285 Date filed: July 31, 1998 Abstract: A method and apparatuses are disclosed for determining an anticoagulant therapy factor (ATF), a corrected anticoagulant therapy factor (CATF), and a modified anticoagulant therapy factor (MATF), all selectively used for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The anticoagulant therapy factor (ATF), the corrected anticoagulant therapy factor (CATF), and a modified anticoagulant therapy factor (MATF) are based upon disclosed methods for determining the fibrinogen transformation rate (FTR) which, in turn, is dependent on a maximum acceleration point for fibrinogen (FBG) conversion. The ATF, CATF, and MATF quantities are also based upon the prothrombin time (PT), but have no need for the difficulty to obtain prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters. The International Normalized Ratio (INR) was created to relate all species' clotting material to human clotting material. The AFT, CATF, and MATF quantities embody only human clotting material. The ATF, CATF, and MATF quantities and International Normalized Ratio (INR) are, hereby, species specific and provide the same results. Excerpt(s): This invention relates to a relatively simple, yet accurate method and apparatus for monitoring oral anticoagulant therapy that takes into account varying
Patents 77
prothrombin times caused by different sensitivities of various thromboplastin formed from rabbit brain, bovine brain, or other sources all used for oral anticoagulant therapy. To prevent excessive bleeding or deleterious blood clots, a patient may receive oral anticoagulant therapy before, during and after surgery. To assure that the oral anticoagulant therapy is properly administered, strict monitoring is accomplished and is more fully described in various medical technical literature, such as the articles entitled "PTs, PR, ISIs and INRs: A Primer on Prothrombin Time Reporting Parts I and II" respectively published November, 1993 and December, 1993 issues of Clinical Hemostasis Review, and herein incorporated by reference. These technical articles disclose anticoagulant therapy monitoring that takes into account three parameters which are: International Normalized Ratio (INR), International Sensitivity Index (ISI) and prothrombin time (PT), reported in seconds. The prothrombin time (PT) indicates the level of prothrombin in a plasma sample and is a measure of the coagulation response of a patient. The INR and ISI parameters are needed so as to take into account various differences in instrumentation, methodologies and in thromboplastins' (Tps) sensitivities used in anticoagulant therapy. In general, thromboplastins (Tps) used in North America are derived from rabbit brain, those previously used in Great Britain from human brain, and those used in Europe from either rabbit brain or bovine brain. The INR and ISI parameters take into account all of these various different factors, such as the differences in thromboplastins (Tps), to provide a standardized system for monitoring oral anticoagulant therapy to reduce serious problems related to prior, during and after surgery, such as excessive bleeding or the formation of blood clots. Web site: http://www.delphion.com/details?pn=US05981285__ •
Method and apparatus for removing blood clots and other objects Inventor(s): Samuels; Shaun Lawrence Wilkie (1055 Sonoma Ave., Menlo Park, CA 94025) Assignee(s): none reported Patent Number: 5,947,995 Date filed: August 6, 1998 Abstract: A catheter has a central lumen so that it may be positioned by a guidewire within a tubular structure of the human body. The catheter has attached to its distal end an inflatable cuff featuring an inflation space with a ring-like cross section. A pouch is circumferentially attached to the cuff The catheter features an inflation lumen that is in communication with the inflatable cuff. The proximal port of the inflation lumen receives a syringe so that the cuff may be inflated when the cuff and pouch are positioned within a tubular structure. A filament passes through the inflation space of the cuff and the inflation lumen and exits the proximal port of the inflation lumen. As a result, the cuff may be cinched so that the pouch is closed in a purse-string fashion to capture an object in the tubular structure. The object may then be removed from the patient's body. Excerpt(s): Many medical procedures involve the removal of undesirable material from various tubular structures within the human body. Such materials may be of the body's origin or man-made. Examples include, but are not limited to, blood clots in the arteries and veins, foreign bodies introduced by surgery that have migrated or become dysfunctional and stones in the biliary or urinary systems. While these unwanted objects may be removed by surgical procedures, interventional radiological techniques have been developed to provide a less-invasive alternative. One type of interventional
78
Blood Clots
radiological technique involves the use of a snaring device that is introduced into the tubular structure by a catheter or sheath and positioned by a guidewire with endoscopic or fluoroscopic guidance. The snaring devices commonly feature a wire cage-like structure positioned upon their distal end portions that may be flexed to receive the target object. Once the snaring device is in position, it is operated remotely by the physician to capture, and in some instances crush, the target object. The object may then be withdrawn from the body through the catheter or sheath insertion site or left to be ultimately washed out of the body by normal body fluids. Examples of such devices are presented in U.S. Pat. No. 4,198,960 to Utsugi, U.S. Pat. No. 4,927,426 to Dretler and U.S. Pat. No. 5,496,330 to Bates et al. While such devices are effective, they do not feature a means for affirmatively trapping an object. As a result, there is always a danger that an object will become unintentionally dislodged from the snare prior to its removal. The object would then be free to migrate through the tubular structure which could cause severe medical complications. Web site: http://www.delphion.com/details?pn=US05947995__ •
Method of making a blood-compatible antimicrobial surface Inventor(s): Anders; Christine (Haltern, DE), Hoecker; Hartwig (Aachen, DE), Lorenz; Guenter (Marl, DE) Assignee(s): Huels Aktiengesellschaft (Marl, DE) Patent Number: 6,022,553 Date filed: April 21, 1998 Abstract: A method for making antimicrobial, blood-compatible surfaces is provided, articles having surfaces made by this method, and the use of these articles in fields where controlling the spread of microbes and blood-compatibility are important. Such fields include the medical field, where it is critical to eliminate infection causing microbes and reduce the number of dangerous blood clots in patients. Excerpt(s): The present invention relates to a method of making blood-compatible, antimicrobial surfaces. Microbial growth can pose serious threats to human health. Microbes able to grow on the surfaces of medical articles can put patients at risk for developing uncontrollable infections. Increasing numbers of antibiotic resistant microbes are creating an urgent need to develop methods of inhibiting microbial growth on surfaces. The rapidly growing biotechnology industry is especially sensitive to the dangers of microbial contamination and growth. In the laboratory, uncontrolled microbial growth can contaminate experiments and ruin their results. In a pharmaceutical plant, unwanted microbial growth in a reactor can taint drugs and disrupt production. Web site: http://www.delphion.com/details?pn=US06022553__
Patents 79
•
Multifunctional protein and DNA sequence encoding saMen Inventor(s): Kay; John (1 Sycamore Tree Close, Radyr, Cardiff CF4 8RT, GB), Kille; Peter (9 Lisvane Street, Cathays, Cardiff CF2 4LH, GB) Assignee(s): none reported Patent Number: 6,040,155 Date filed: August 28, 1996 Abstract: The present invention provides nucleic acid and corresponding amino acid sequences of a multifunctional protein that has been found to be useful in numerous medical and cosmetic contexts. A protein having "multifunctional activity," is defined herein as including at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity or asialo GM.sub.1 ceramide binding activity. These proteins are useful for multiple purposes, including treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Excerpt(s): The present invention relates to purified nucleic acids encoding a krillderived multifunctional protein and to purified polypeptides having multifunctional activity. A protein having "multifunctional activity," is defined herein as including at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity, or asialo GM.sub.1 ceramide binding activity. Multifunctional proteins are useful for multiple purposes, including treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease, such as lupus erythematosus and multiple sclerosis, and cancer. Purified polypeptides having multifunctional activity and purified nucleic acids encoding such polypeptides are desirable to provide pharmaceutically useful products. One preferred embodiment of the present invention is a substantially pure nucleic acid comprising a nucleic acid encoding a polypeptide having at least about 70% homology to a krill-derived multifunctional protein, such as the polypeptide of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, and especially SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:10, and more preferably, at least about 80% homology, and most preferably, at least about 90% homology. Even more preferably, the nucleic acid comprises a nucleic acid encoding a polypeptide sharing at least about 70% amino acid identity with a krillderived multifunctional protein, and yet more preferably, at least about 80% identity, and most preferably, at least about 90% identity. Web site: http://www.delphion.com/details?pn=US06040155__
80
•
Blood Clots
Perfusion-isolation catheter apparatus and method Inventor(s): Ashby; Mark (10 Bellcrest, Laguna Niguel, CA 92677), Brustad; John R. (34056 Formosa Dr., Dana Point, CA 92629), Hansen; Paul D. (2226 SE. 55th Ave., Portland, OR 97215), Hart; Charles C. (8252 Mandeville, Huntington Beach, CA 92646), Hilal; Said (25291 Spindlewood, Laguna Niguel, CA 92677), Pravongviengkham; Bounsavanh (450 Wilson Cir., Corona, CA 91719), Swanstrom; Lee L. (1405 NW. 24th Ave., Portland, OR 97227) Assignee(s): none reported Patent Number: 6,183,492 Date filed: August 27, 1998 Abstract: A catheter includes an introducer and a flow isolator adapted for disposition in a primary conduit to facilitate flow in the primary conduit while inhibiting flow and intersecting secondary conduits. The flow isolator may include a tubular mesh and surrounding balloon structure. Alternatively, a sleeve can be provided with a primary opening and a secondary opening which are sized to inflate the sleeve with the body fluid. Structures for deploying the sleeve between a low-profile state and high-profile state may include expandable fingers, or pneumatic chambers inflatable from an external source. In operation the sleeve can be forced by the body fluid against the intersection with the secondary conduits to achieve isolation. Alternatively, the pneumatic chambers can be inflated to form seals with the primary conduit. A blood filter or snare is contemplated to filter any blood clots which may develop around the flow isolator. Excerpt(s): This invention relates generally to devices for controlling the flow of body fluids in body conduits and more specifically to such devices which can be remotely controlled in a less-invasive procedure. The human body is composed of a labyrinth of body conduits generally organized into various systems of the body. By way of example, a labyrinth of body conduits including the urethra, form the urinary system of the body. Various blood vessels, including the inferior vena cava, are interconnected to form the vascular system of the body. Regardless of the system involved or the particular conduits forming that system, there are many surgical procedures which can benefit from a flow isolator to control flow of a body fluid within the particular system. In general, the flow isolator might function to facilitate the flow of the body fluid in a primary conduit, while inhibiting the flow of that fluid into a secondary conduit. By way of example, hepatic surgery generally requires that the portal vein and hepatic veins be occluded. In the past, this occlusion has been accomplished with cross-clamps which stop the back-flow of blood into the hepatic veins after the portal vein has been clamped. Unfortunately, there is a significant risk involved in total occlusion of the inferior vena cava. For this reason, this surgery in the past has required that the vena cava be dissected above and below the liver, with the placement of clamps on both sides of the dissection. This has been a time-consuming and a technically challenging part of the procedure. Shunts have also been used to isolate the hepatic veins in similar procedures involving hepatic resection or liver trauma, for example. This procedure is merely representative of many surgical procedures where it is desirable to maintain flow within one body conduit while inhibiting flow in an intersecting conduit. Web site: http://www.delphion.com/details?pn=US06183492__
Patents 81
•
Photoacoustic removal of occlusions from blood vessels Inventor(s): Celliers; Peter M. (Berkeley, CA), Da Silva; Luiz B. (Danville, CA), Esch; Victor C. (San Francisco, CA), London; Richard A. (Orinda, CA), Maitland, IV; Duncan J. (Lafayette, CA), Visuri; Steven R. (Livermore, CA) Assignee(s): Endovasix, Inc. (Belmont, CA), The Regents of the University of California (Oakland, CA) Patent Number: 6,428,531 Date filed: June 27, 2000 Abstract: Partial or total occlusions of fluid passages within the human body are removed by positioning an array of optical fibers in the passage and directing treatment radiation pulses along the fibers, one at a time, to generate a shock wave and hydrodynamics flows that strike and emulsify the occlusions. A preferred application is the removal of blood clots (thrombin and embolic) from small cerebral vessels to reverse the effects of an ischemic stroke. The operating parameters and techniques are chosen to minimize the amount of heating of the fragile cerebral vessel walls occurring during this photo acoustic treatment. One such technique is the optical monitoring of the existence of hydrodynamics flow generating vapor bubbles when they are expected to occur and stopping the heat generating pulses propagated along an optical fiber that is not generating such bubbles. Excerpt(s): This invention relates generally to the removal of a partial or total occlusion from a blood vessel by generating pressure waves within the vessel through optical fiber media, and, more specifically, to the removal of a blood clot from a vessel within the human brain. The term "clot" is used herein to refer to a thrombus, embolus or some other total occlusion of a vessel. Medical procedures to open a partially or totally blocked blood vessel are available. Angioplasty has long been used to restore full blood flow in a coronary artery by mechanically deforming deposits on the arterial walls but has been less successful to open a totally occluded vessel. Laser techniques have been proposed to directly ablate obstructing material from arteries, such as plaque and certain types of clots, by inserting optical fibers into the artery to the point of the obstructing material but these techniques have enjoyed only limited success in practice. Various uses of ultrasonic energy to generate acoustic waves directed against plaque or a clot within an artery to mechanically break up the obstructing material have also been proposed but medical procedures utilizing these techniques have not enjoyed widespread acceptance. Photo acoustic techniques have been proposed for vasodilation and the break-up of plaque and clots in arteries, wherein one or more optical fibers are inserted into the vessel and pulses of radiation delivered to the vessel through the fibers generate a pressure or acoustic wave directed against the obstruction. Major blood vessels within the brain are very small, generally not exceeding three millimeters in diameter and being much smaller than that in most places. Most cerebral blood vessels decrease in diameter along their lengths until becoming capillaries. Besides being small, the walls of cerebral vessels are more fragile than those of vessels in other parts of the body and are more loosely connected to surrounding tissue. Web site: http://www.delphion.com/details?pn=US06428531__
82
•
Blood Clots
Plasminogen activator from saliva of the vampire bat Inventor(s): Alagon; Alejandro (Mor., MX), Baldus; Berthold (Berlin, DE), Boidol; Werner (Berlin, DE), Donner; Peter (Berlin, DE), Haendler; Bernard Jacques (Berlin, DE), Kratzschmar; Jorn Reiner (Berlin, DE), Langer; Gernot (Berlin, DE), Schleuning; WolfDieter (Berlin, DE) Assignee(s): Schering Aktiengesellschaft (Berlin, DE) Patent Number: 6,008,019 Date filed: June 1, 1995 Abstract: The present invention relates to novel thrombolitic v-PA's which dissolve blood clots in the human body and thus are suitable for the treatment of cardial infarction, for example. Excerpt(s): The present invention relates to a novel thrombolytic, processes for its isolation, and its pharmaceutical usage. Thromboses are produced by the formation of a blood clot in blood vessels. One distinguishes between venous thromboses including pulmonary embolisms and arterial thromboses including acute myocardial infarction. Pulmonary embolism and cardiac infarction are life-threatening events requiring immediate medical intervention. Web site: http://www.delphion.com/details?pn=US06008019__
•
Retrievable umbrella sieve and method of use Inventor(s): Lowery; Samuel R. (400 N. Main St. Apt. 7, Fostoria, OH 44830) Assignee(s): none reported Patent Number: 6,245,088 Date filed: August 14, 1999 Abstract: The present invention is a retrievable umbrella sieve for removing blood clots and other debris in blood vessels. The umbrella sieve also functions to prevent blood clots and other derbies from reaching the heart of a human or animal. One of the main uses of the umbrella sieve is for the insertion of the Inferior Vena Cava to prevent and remove blot clots before the clots reach the heart. There are two embodiments of the umbrella sieve. The umbrella sieve provides a method and apparatus for used during the medical surgical treatment phase of thrombophlebitis and venous thrombosos in the precautionary prevention of pulmonary emboli. The umbrella sieve provides a method and apparatus for routinely placing a preventive device in lower extremity fractures, especially that of the hip, in anticipation of preventing pulmonary emboli. The umbrella sieve provides a method and apparatus that is retrievable. Excerpt(s): The medical community is in constant search for new ways to prevent blood clots from reaching the heart of humans and animals, as well as other objects or debris in the blood flow which may cause health problems. It is an object of the present invention to provide a method and apparatus for catching any blood clots, or other debris, that might dislodge from their origin of the veins in the pelvic or femoral systems. Another object of the present invention is to provide a method and apparatus for used during the medical surgical treatment phase of thrombophlebitis and venous thrombosos in the precautionary prevention of pulmonary emboli. Another object of the present invention is to provide a method and apparatus for routinely placing a preventive device in lower extremity fractures, especially that of the hip, in anticipation
Patents 83
of preventing pulmonary emboli. Another object of the present invention is to provide a method and apparatus for a non-permanent manner of accomplishing the foregoing, whereby the apparatus is retrievable. The present invention is an umbrella sieve for capturing objects in a blood vessel which includes an inserter tube having a top; an umbrella cap having a lower peripheral circumference edge and an ability to fold like a rain umbrella; the umbrella cap having a perforated surface to allow the passage of fluids of the blood vessel; the umbrella cap being attached to the top of the inserter tube; an inflatable circumfrential balloon attached to the lower peripheral circumference edge for extending the umbrella cap when inflated; a first inflation line connected to the circumfrential balloon for inflating the circumfrential balloon. The umbrella sieve also includes an occlusive membrane attached to the inserter tube and below the umbrella cap; and wherein the membrane is extendible around the inserter tube to form a treatment compartment. The method of using the umbrella sieve includes inserting the umbrella sieve into the blood vessel; inflating the circumfrential balloon to extend the umbrella cap; capturing objects in flow of the blood vessel; removing any objects captured; deflating the circumfrential balloon; and removing the umbrella sieve. The method also includes extending the membrane around the inserter tube to form a treatment compartment by inflating the occlusive balloon attached to the membrane from a second inflation line after capturing of the objects to form a treatment compartment and further including before removal of the umbrella sieve, the deflation of the occlusive balloon to retract the occlusive membrane. After treatment, the occlusive balloon 20 is deflated to resume normal blood flow through the Vena Cava 26. Upon decision that the umbrella sieve 10 is no longer required, the circumfrential balloon 14 is deflated and the entire umbrella sieve 10 is retrieved from the Vena Cava 26. The umbrella cap 12 is flexible enough so that the as the umbrella sieve 10 is retrieved, the cap 12 inverts and folds down like a reversed rain umbrella in the wind, as shown in FIGS. 6 and 7. Web site: http://www.delphion.com/details?pn=US06245088__ •
Self-centering, self-expanding and retrievable vena cava filter Inventor(s): Kim; Hannah S. (Stow, MA), Nott; Sepideh H. (Melrose, MA), Sandock; David Lee (late of Littleton, MA), Suon; Naroun (Lawrence, MA), Thistle; Robert (Brockton, MA), Yampolsky; Iiya (West Roxbury, MA) Assignee(s): Boston Scientific Corporation (Natick, MA) Patent Number: 6,214,025 Date filed: October 27, 1999 Abstract: A self-centering blood clot filter is provided. The filter includes an anchoring portion including a generally cylindrical radially expandable body including an axial lumen extending therethrough. The filter further includes a filtering portion including a conical body concentrically aligned within the axial lumen of the anchoring portion. The conical body of the filtering portion is tapered to form a distal tip. As such, the blood clot filter can be properly centered within the lumen of a vessel for effective lysing of blood clots. Excerpt(s): This invention relates to blood clot filtering. Blood clots that form in the lower part of the body may migrate to the heart and may be subsequently pumped to the lungs. Small clots can be absorbed by the body without adverse effect. However, larger clots (e.g., on the order of 3 mm in diameter and 10-30 cm in length) can interfere with the oxygenation of blood and can possibly cause shock or sudden death. Many
84
Blood Clots
transvenous filtering devices have been developed for installation in the vena cava to prevent especially large clots from reaching the lungs. These filters have fine wires positioned in the blood flow to catch and hold clots for effective lysing in the blood stream. Some of these devices are inserted into the vena cava by dissecting the internal jugular vein in the neck or the femoral vein in the groin, inserting a metallic capsule containing a filtering device to the proper position in the vena cava, and releasing the filtering device into the vena cava. More recently, filters have been designed for percutaneous introduction into the vasculature. Web site: http://www.delphion.com/details?pn=US06214025__ •
Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging Inventor(s): Stein; Stanley (East Brunswick, NJ) Assignee(s): University of Medicine & Dentistry of NJ (Newark, NJ) Patent Number: 6,210,655 Date filed: June 18, 1997 Abstract: The present invention relates to site-specific.sup.13 C-enriched reagents for diagnostic medicine for magnetic resonance imaging. The site-specific.sup.13 C-enriched reagents may be represented by the formula: T-L-R. T is a site-specific targeting group which selectively binds to a disease-related target in an animal or human, R is an inert polymer containing repeating.sup.13 C reporting groups which provide a magnetic resonance imaging signal, and L is a linker group which connects the site-specific targeting group to the inert polymer. The site-specific.sup.13 C-enriched reagents are targeted to and capable of identifying, quantifying, and localizing disease-specific loci, such as blood clots,.beta.-amyloid plaques of Alzheimer's disease, and tumors through the use of magnetic resonance imaging. The present invention also pertains to a method for employing the site-specific.sup.13 C-enriched reagents in a living mammal. Excerpt(s): Many diagnostic and therapeutic medical procedures for visualizing internal organs for the early detection and treatment of many diseases require the administration of contrast enhancing agents to improve the quality of the procedure. Contrastenhancing agents are used in Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), and X-ray procedures. Computerized Tomography provides a more sophisticated visualization of tissues and organs than does conventional X-ray techniques. Magnetic Resonance Imaging provides a superior soft tissue differentiation than does Computerized Tomography. Magnetic Resonance Imaging procedures generally employ the nuclear magnetic resonance of hydrogen (.sup.1 H) or fluorine (.sup.19 F). The nuclear magnetic resonance sensitivity of.sup.19 F is nearly equivalent to that of.sup.1 H but the biological background of.sup.19 F is negligible. The usefulness of a contrast enhancing agent depends upon the ease of the synthesis of the agent, the site-specificity of the agent, the resistance to in vivo hydrolysis of the agent, and a sufficient amount of signal from the agent along with a high signal-to-noise ratio. In radioscintigraphy, a radioactive monoclonal antibody is typically injected into a patient for identifying and localizing a tumor, (reviewed in Bischof Delaloye, A. and Delaloye, B.: Tumor imaging with monoclonal antibodies. Seminars in Nuclear Medicine 25(2):144-164, 1995). Web site: http://www.delphion.com/details?pn=US06210655__
Patents 85
•
Thermodilution catheter method using a safe, flexible heating element Inventor(s): Quinn; Michael D. (Plano, TX), Yelderman; Mark L. (Plano, TX) Assignee(s): Edwards Lifesciences Corporation (Irvine, CA) Patent Number: 6,355,001 Date filed: May 13, 1996 Abstract: A thermodilution catheter having a heating filament which is fabricated so as to be thin and flexible enough to avoid contact with the patient's blood. The heating filament is either inserted in a preformed catheter lumen, incorporated into a wall of the catheter body itself, or wrapped around the catheter body wall and surrounded by an external sheath. Generally, the covering of the heating filament is minimally thin so as to allow the heat from the heating filament to be transferred to the surrounding blood and to minimally increase the overall cross-sectional area. Since the heating filament does not directly touch the patient's blood, the outer surface may be made smooth so as to prevent inducement of blood clots. In addition, the heating filament may be maintained at a safe temperature by forming the heating element of a flexible material having a high temperature coefficient of resistance, low thermal capacitance and high thermal conductivity. Preferably, the temperature coefficient of resistance of the material forming the heater filament is greater than 0.001.OMEGA./.OMEGA.-.degree. C. and the resistance of the heating filament is proportional or inversely proportional to its temperature. By monitoring this resistance, the application of power to the heating filament may be regulated to prevent overheating of the heating filament. Calibration techniques are also disclosed whereby a memory containing encoded calibration information is disposed within or connected to a connector of the catheter. This memory may also include a program segment used by a cardiac output computer having a cardiac output calculation program, whereby the portion of code stored in the memory must be input into the cardiac output computer before the determination of the cardiac output can be performed. As a result of these improvements, the invention enables the thermodilution cardiac output calculation to be performed quite safely and accurately in a clinical setting. Excerpt(s): The present invention relates to a thermodilution catheter, and more particularly, to a thermodilution catheter having a flexible heating filament disposed therein for applying heat to the patient's blood for purposes of measuring cardiac output, volumetric blood flow, blood pressure, blood volume, blood components and the like. As is well known, catheters have been developed for purposes of applying physiologic preparations directly into the blood streams of animals or humans or for measuring cardiovascular parameters such as cardiac output, blood pressure, blood volume, blood components and the like. Conventional catheters are made from various materials including plastics and are typically inserted into various body compartments, cavities and vessels to either deliver therapeutic agents, diagnostic agents, or to measure directly various physiologic parameters. Numerous techniques have been disclosed in the prior art for measuring blood flow using catheters. For example, in U.S. Pat. No. 4,507,974, Yelderman describes a technique for measuring blood flow by applying a stochastic excitation signal to a system inlet and measuring the output signal at a downstream system outlet. The blood flow rate is then extracted by cross-correlating the excitation signal and the measured output signal. The problem addressed by systems of this type is particularly difficult since the physiologic blood vessels are elastic, thereby making classic fluid measuring techniques unacceptably inaccurate. In fact, because the blood vessels are elastic, blood flow cannot be measured unless (1) the physical heart dimensions are measured simultaneously with the blood velocity, (2) a technique is
86
Blood Clots
used which is independent of the vessel geometry or (3) a blood velocity technique is used which is calibrated by some other technique. Examples of each of these techniques may be found in the prior art. Web site: http://www.delphion.com/details?pn=US06355001__ •
Thrombolytic agents with antithrombotic activity Inventor(s): Bush; Larry R. (Exeter, NH), Markland, Jr.; Francis S. (Manhattan Beach, CA), Sanchez; Eladio Flores (Belo Horizonte-ma, BR), Swenson; Stephen (Arcadia, CA) Assignee(s): Diatide, Inc. (Londonderry, NH) Patent Number: 5,951,981 Date filed: December 2, 1996 Abstract: This invention provides thrombolytic agents and methods for making and using thrombolytic agents. Specifically, the invention provides thrombolytic agents comprising a thrombolytic proteinase and a specific binding peptide that specifically binds at the site of blood clots and thrombi in vivo. The invention particularly provides chemically crosslinked conjugates of a thrombolytic proteinase and a plurality of specific binding peptide. Methods for producing such chemically crosslinked conjugates and methods for using such conjugates for eliminating thrombi in vivo to alleviate pathological conditions caused thereby are also provided. The preferred thrombolytic proteinase in the conjugate is fibrolase obtainable from Agkistrodon contortrix confortrix venom. Excerpt(s): This invention relates to thrombolytic agents and methods for making and using thrombolytic agents. Specifically, the invention relates to thrombolytic agents comprising a thrombolytic proteinase and a specific binding peptide that specifically binds at the site of blood clots and thrombi in vivo. The invention particularly provides chemically crosslinked conjugates of a thrombolytic proteinase and a plurality of specific binding peptides. Methods for producing such chemically crosslinked conjugates and methods for using such conjugates for eliminating thrombi in vivo to alleviate pathological conditions caused thereby are also provided by the invention. Thrombosis and thromboembolism, the occurrence of occlusive thrombi in the vasculature of human patients, poses a significant clinical problem and is a significant cause of morbidity and mortality. Arterial thrombi are responsible for myocardial infarction (MI) and ischemia (stroke), while venous thrombi cause deep vein thrombosis (DVT) and pulmonary embolism (PE). The magnitude of the clinical challenge created by thrombi is reflected in morbidity and mortality statistics. One of the leading causes of death in men over the age of 50 is acute MI, and stroke remains a debilitating and unpredictable disease. It has been estimated that in the U.S. approximately 5 million patients experience one or more episodes of DVT per year and that over 500,000 cases of PE occur, resulting in 100,000 deaths (Seabold, Society of Nuclear Medicine Annual Meeting 1990). Anticoagulant therapy can effectively treat these conditions in many cases, if applied early enough. However, such treatment is associated with risks (e.g. internal bleeding) that preclude unnecessary prophylactic application. More advanced techniques of thrombolytic intervention (such as the administration of recombinant tissue plasminogen activator or streptokinase) can be used in acute cases, but these techniques carry even greater risks, due in large part to systemic side effects. In addition, particularly in arterial thrombi, rethrombosis and reocclusion of blood vessels at the thrombus site is a significant (10-30%) clinical outcome. Even using these
Patents 87
advanced methodologies, 25-30% of acute MI patients fail to restore perfusion to the thrombus-occluded coronary artery that are the proximal cause of the heart attack. Web site: http://www.delphion.com/details?pn=US05951981__ •
Two-planar vena cava filter with self-centering capabilities Inventor(s): Suon; Naroun (Lawrence, MA), Weldon; James (Roslindale, MA) Assignee(s): SciMed Life Systems, Inc. (Maple Grove, MN) Patent Number: 6,468,290 Date filed: June 5, 2000 Abstract: A self-centering filter is useful for trapping blood clots, reducing their size and arresting their further migration from the vena cava into pulmonary circulation. The two-planar filter design is formed from a conical array of filter wires wherein two sets of filter wires are included, each set differing in length from the other. The filter wires diverge from a common apex at one end and extend radially outwardly therefrom to an attachment end attachable to the wall of a blood vessel such that the attachment ends of the first set of wires are anchored at a location spaced apart from the location of anchoring of the attachment ends of the second set, effecting a two-planar filter design. This establishes a single filtering element having two planes of contact with the vein wall which also provides for centering of the filtering element. At least one of the sets of wires contains barbs, e.g. hooks, for anchoring the filter to the inner venal wall. Excerpt(s): This invention relates generally to filter devices useful for trapping blood clots and controlling embolization and thrombosis in blood vessels. More specifically, the present invention is directed to a blood clot filter, which has improved self-centering capabilities. Blood clots (emboli) which are carried in the blood stream often pose serious threats to a person's health and may lead to death. For that reason, the reduction of such clots and their stabilization and arrest against further migration from the vena cava into the pulmonary circulation are necessary. A number of types of permanent filters have been designed for this purpose. Generally, these filters are in the form of a frustoconical basket which is attached to the interior of a vein downstream of the area sought to be filtered. One type includes a plurality of wire legs of the same length extending in a generally conical array from a common apex to their free ends which attach to the wall of the vessel, thus forming a cone of revolution with a single plane of contact with the vessel wall. A filter of this type is described in U.S. Pat. No. 3,952,747. The filter shown therein includes sharpened hooks at the free wire ends to permanently anchor the filter by impaling the hooks in the blood vessel. If the hooks engage the cava in a plane perfectly perpendicular to the vena cava, the filter, in theory, would be centered. In reality such perfect deployments rarely occur and so the filter is often deployed in a tipped position, with its apex not coincident with the apex of the vessel. Web site: http://www.delphion.com/details?pn=US06468290__
88
•
Blood Clots
Vascular filtering device Inventor(s): Kanesaka; Nozomu (81 Greenwoods Rd., Old Tappan, NJ 07675) Assignee(s): none reported Patent Number: 6,340,364 Date filed: January 26, 2001 Abstract: A vascular filtering device is formed of a flexible shaft having a passageway extending inside the shaft, an inflatable member communicating with the passageway and having a spiral form, and a filter member fixed to the distal end portion of the shaft. The inflatable member is attached at an inner side thereof to a distal end portion of the shaft. The filter member is attached to the shaft and fixed onto the outer side surface of the inflatable member along the entire length thereof. When the inflatable member is inflated, the filter member is enlarged to allow a blood containing debris or blood clots to flow through the filter member. Thus, the debris or blood clots are captured by the filter member. When the inflatable member is deflated, the filter member is disposed close to the side surface of the shaft. Thus, the filter member with the debris or clots can be easily removed from the blood vessel. Excerpt(s): The present invention relates to a device for capturing a debris or blood clots in a blood vessel, and more particularly, it relates to a vascular filtering device for capturing and removing the debris or blood clots used in, e.g. percutaneous transluminal coronary angioplasty (PTCA) procedure. In recent years, an inter-vascular treatment, such as PTCA, has been widely practiced for a treatment of stenosis in the artery. In the PTCA procedure, a catheter which is provided with a balloon at a distal end thereof is inserted into a blood vessel which has a stenosis, and the balloon is inflated to enlarge the stenosis. Also, after enlarging the stenosis, a stent may be provided for preventing re-stenosis. In performing the PTCA procedure, however, it may cause other problems. Namely, debris or blood clots formed at the stenosis may be separated from the portion at the stenosis and migrate to other critical area, such as brain and pulmonary arteries, while the PTCA procedure is being performed. Web site: http://www.delphion.com/details?pn=US06340364__
Patent Applications on Blood Clots As of December 2000, U.S. patent applications are open to public viewing.10 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to blood clots:
10
This has been a common practice outside the United States prior to December 2000.
Patents 89
•
Antibodies that bind to alpha2-antiplasmin crosslinked to fibrin which do not inhibit plasma alpha2-antiplasmin Inventor(s): Haber, Edgar; (Salisbury, NH), Matsueda, Gary R.; (Princeton, NJ), Reed, Guy L.; (Winchester, MA) Correspondence: Sterne, Kessler, Goldstein & Fox Pllc; 1100 New York Avenue, N.W., Suite 600; Washington; DC; 20005-3934; US Patent Application Number: 20020086025 Date filed: August 16, 2001 Excerpt(s): This application is a Continuation-In-Part of U.S. application Ser. No. 07/589,003 filed Sep. 27, 1990 which is a Continuation-In-Part of U.S. application Ser. No. 07/177,222 filed Apr. 4, 1988, now abandoned, the contents of both of which are incorporated herein by reference. The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to.alpha.2-antiplasmin crosslinked to fibrin (.alpha.2AP-FX) which does not inhibit plasma.alpha.2-antiplasmin (.alpha.2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward.alpha.2-antiplasmin crosslinked to fibrin which does not inhibit plasma.alpha.2AP together with a thrombolytic agent. The initiating event of many myocardial infarctions (heart attacks) is the hemorrhage into atherosclerotic plaque. Such hemorrhage often results in the formation of a thrombus (or blood clot) in the coronary artery which supplies the infarct zone (i.e., an area of coagulation necrosis which results from an obstruction of blood circulation). This thrombus is composed of a combination of fibrin and blood platelets. The formation of a fibrin-platelet clot has serious clinical ramifications. The degree and duration of the occlusion caused by the fibrin-platelet clot determines the mass of the infarct zone and the extent of damage. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Apparatus and methods for aspirating emboli Inventor(s): Krolik, Jeffrey; (Campbell, CA), Salahieh, Amr; (Saratoga, CA) Correspondence: Glenn M. Seager; Crompton, Seager & Tufte, Llc; Suite 895; 331 Second Avenue South; Minneapolis; MN; 55401-2246; US Patent Application Number: 20030023263 Date filed: July 24, 2001 Abstract: Apparatus and methods for aspirating emboli from a vascular filter or stent within a patient's circulatory system are provided. A filter sac of the vascular filter permits blood flow and captures emboli from the flow. The aspiration device removes emboli from within or proximal to the vascular filter or stent to reduce the risk to the ischemia during retrieval of the vascular filter and during a treatment procedure. Retrieval of the vascular filter may be accomplished using either the aspiration catheter or a separate retrieval catheter. Excerpt(s): The present invention relates to apparatus and methods for aspirating emboli. More particularly, the present invention provides apparatus useful for aspirating emboli from a vascular device such as a vascular filter used to prevent embolization associated with diagnostic or therapeutic interventional procedures,
90
Blood Clots
thrombectomy and embolectomy. Percutaneous interventional procedures to treat occlusive vascular disease, such as angioplasty, atherectomy, and stenting, often dislodge material from the vessel walls. This dislodged material, known as emboli, enters the bloodstream and may be large enough to occlude smaller downstream vessels, potentially blocking blood flow to tissue. The resulting ischemia poses a serious threat to the health or life of a patient if the blockage occurs in critical tissue, such as the heart, lungs, or brain. The deployment of stents and stent-grafts to treat vascular disease, such as aneurysms, involves the introduction of foreign objects into the bloodstream, and also may result in the formation of clots or release of emboli. Such particulate matter, if released into the bloodstream, also may cause infarction or stroke. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Apparatus and methods for removing emboli during a surgical procedure Inventor(s): Hogendijk, Michael; (Palo Alto, CA), Parodi, Juan Carlos; (Buenos Aires, AR) Correspondence: Fish & Neave; 1251 Avenue OF The Americas; 50th Floor; New York; NY; 10020-1105; US Patent Application Number: 20020151922 Date filed: March 14, 2002 Abstract: Methods and apparatus for removing emboli during an endarterectomy procedure are provided. The present invention provides a proximal catheter disposed proximal to a stenosis and a distal catheter disposed distal to the stenosis. Each catheter may selectively communicate with a venous return catheter via a manifold having a setting controlled by a physician. Blood flows into an aspiration lumen of the distal catheter and is reperfused into a remote vein via the venous return catheter. Additionally, emboli generated during the procedure are removed via an aspiration lumen of the proximal catheter, and filtered blood then is reperfused into the remote vein. Excerpt(s): The present application is a continuation-in-part of U.S. patent application Ser. No. 09/418,727, filed Oct. 15, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 09/333,074, filed Jun. 14, 1999, now U.S. Pat. No. 6,206,868, which is a continuation-in-part of International Application PCT/US99/05469, filed Mar. 12, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 09/078,263, filed Mar. 5, 1998. This invention relates to apparatus and methods to protect against embolization during vascular interventions, such as endarterectomy. More particularly, the present invention reperfuses blood into a patient's venous vasculature and removes emboli using natural aspirational techniques. Carotid artery stenoses typically manifest in the common carotid artery, internal carotid artery or external carotid artery as a pathologic narrowing of the vascular wall, for example, caused by the deposition of plaque, that inhibits normal blood flow. Endarterectomy, an open surgical procedure, traditionally has been used to treat such stenosis of the carotid artery. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 91
•
Barrier device for ostium of left atrial appendage Inventor(s): Hauser, Robert G.; (Long Lake, MN), Van Tassel, Robert A.; (Excelsior, MN) Correspondence: Fish & Neave; 1251 Avenue OF The Americas; 50th Floor; New York; NY; 10020-1105; US Patent Application Number: 20030120337 Date filed: December 3, 2002 Abstract: A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage. The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient. Excerpt(s): The invention relates to a membrane or plug structure applied to the ostium of an atrial appendage for preventing blood flow and physical connection between an atrium of the heart and the associated atrial appendage or appendages to isolate an atrial appendage and prevent thrombus leaving therefrom. There are a number of heart diseases (e.g. coronary artery disease, mitral valve disease) that have various adverse effects on the heart. An adverse effect of certain cardiac diseases, such as mitral valve disease, is atrial (or auricular) fibrillation. Atrial fibrillation may result in pooling of blood in the left atrial appendage. Blood pooling may also be spontaneous. When blood pools in the atrial appendage, blood clots can form and accumulate therein, build upon themselves, and propagate out from the atrial appendage into the atrium. These blood clots can then enter the systemic or pulmonary circulations and cause serious problems if they migrate from the atrial appendage and become free in the blood stream and embolize distally into the arterial system. Similar problems also occur when a blood clot extending from an atrial appendage into an atrium breaks off and enters the blood supply. Since blood from the left atrium and ventricle supply the heart and brain, blood clots from the atrial appendages can obstruct blood flow therein causing heart attacks, strokes or other organ ischemia. It is therefore necessary to find a means of preventing blood clots from forming in the atrial appendages and to prevent these blood clots, once formed, from leaving the atrial appendages to the heart, lungs, brain or other circulations of the patient which can cause heart attacks or strokes or other organ ischemia. U.S. Pat. No. 5,865,791 relates to the reduction of regions of blood stasis and ultimately thrombus formation in such regions, particularly in the atrial appendages of patients with atrial fibrillation. More specifically, the invention relates to procedures and devices for affixing the atrial appendages in an orientation that prevents subsequent formation of thrombus. The invention removes the appendage from the atrium by
92
Blood Clots
pulling on it and putting a loop around it to form a sack of the atrial appendage and then cut off from the rest of the heart. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Bladder dialysis urinary catheter Inventor(s): McGuckin, James F. JR.; (Radnor, PA) Correspondence: Rex Medical, L.P.; 585 County Line Road; Radnor; PA; 19087; US Patent Application Number: 20020029057 Date filed: August 1, 2001 Abstract: An irrigating bladder dethrombulator for removing blood clots in the urine. The device includes a housing having an outflow conduit insertable into the bladder through the urethra for transporting bodily fluid from the bladder and a bladder pressurization conduit for transporting fluid into the bladder to increase the internal pressure of the bladder. Connected to the housing is a structure for mechanically reducing the size of the blood clots in the urine. The mechanism for driving the reducing structure can be a magnetic drive or a fluid drive. Excerpt(s): This patent application is based on and claims the benefit of the filing date of U.S. provisional patent application 60/053,557 filed Jul. 24, 1997 by James F. McGuckin, Jr., M.D. and entitled "Method and Apparatus for Bladder Irrigation Mechanical Thrombolysis". One of the side effects of many urological procedures is formation of blood clots in the urine within the bladder. Typically after urological procedures the patient will be fitted with a catheter to facilitate bladder drainage. Clots forming in the urine within the bladder tend to clog the inlet orifice for a catheter thereby preventing effective voiding of the bladder. This is a particular problem subsequent to urological procedures such as transectional prostatectomies, radial prostatectomies and nephrolithotomies. Magnetic coupling in surgical devices is known, being disclosed in U.S. Pat. No. 5,609,602. However, '602 is concerned with a magnetic couple which limits rotation of one element when driven by a second element, incorporating a mechanical stop for the first element allegedly to produce high frequency oscillations in one of the magnetically coupled pair of elements. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Blood clot filtering system Inventor(s): Goldberg, Mark; (Sharon, MA), Mallick, Ron; (Wilmette, IL), Melinyshyn, Lev; (Buffalo Grove, IL) Correspondence: Laff, Whitesel & Saret, LTD.; 401 North Michigan Avenue; Chicago; IL; 60611; US Patent Application Number: 20020116024 Date filed: February 20, 2001 Abstract: A blood clot filtering system including an anchor which is permanently affixed in a blood vessel, and a filter which is removably attached to the anchor. Excerpt(s): This invention relates generally to devices and methods for trapping blood clots and controlling embolization and some of the complications of thrombosis in blood
Patents 93
vessels. More particularly, this invention relates to a blood filtering system that comprises two separable independent parts: a permanent anchor, and a filter removably attached to the anchor. The two parts of the system are attached in such a way that, once emplaced, the filter is continuously maintained along the central axis of the blood vessel to ensure that the filter operates at optimal efficiency. If and when it is necessary or desirable to remove the filter, it may readily be separated from the anchor and withdrawn, leaving a permanently attached anchor that does not interfere with blood flow within the blood vessel. The presence of thrombus within the body's circulatory system presents significant health hazards, as manifested by potential acute venous thrombosis and chronic deep vein thrombosis. Acute venous thrombosis can lead to pulmonary emboli, a potentially lethal condition when an embolus travels into the pulmonary arteries. Currently, the most widespread treatment is the administration of systemic and oral anticoagulants such as heparin and coumadin, and thrombolytic agents such as TPA, urokinase and streptokinase. Unfortunately, conventional drug therapy is ineffective or inappropriate for controlling emboli within the circulatory system of some patients. In particular, since most pulmonary emboli originate in veins of the lower limbs, pelvis or inferior vena cava, it has been recognized that lifethreatening pulmonary emboli can be prevented from reaching the lungs by mechanically interrupting the inferior vena cava to filter out emboli. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Blood pump Inventor(s): Palmer, Arthur; (Chicago, IL) Correspondence: Greer, Burns & Crain, LTD.; Suite 2500; 300 South Wacker Drive; Chicago; IL; 60606; US Patent Application Number: 20030032854 Date filed: August 13, 2001 Abstract: A pump especially designed for pumping blood comprises a bladder, the interior surface area and volume of which is changeable, i.e., it stretches and expands during the filling phase, and elastically contracts to its normal relaxed size during the ejection phase. The bladder has a fluid inlet and a fluid outlet. A device, such as a vacuum pump, alternately expands and contracts the interior surface area and volume of the bladder. Most of the interior surface area of the bladder expands and contracts in each cycle. One or more check valves or other means for causing substantially one-way fluid flow through the bladder are also provided. The pump of the invention decreases the likelihood of blood clots forming in the pump, decreases the risk of damage to blood cells, improves the pumping characteristics of the device, and decreases or eliminates the chance of foreign fluids passing into the blood stream should a tear or break occur in the bladder. Excerpt(s): The present invention relates to pumps and more specifically to blood pumps, ventricular assist devices, and artificial hearts. The natural heart functions in a fashion similar to a positive displacement pump. Each of the two pumping chambers in the natural heart has two check valves (an inlet and an outlet valve). The walls of the natural heart are made of contractile muscle that provide the power to pump the blood. Each pumping cycle consists of a filling or diastolic phase of the pumping cycle and an ejection or systolic phase of the pumping cycle. During the filling phase, the muscle fibers making up the walls of the heart relax allowing the chamber they surround to fill with blood. During the ejection phase of the cycle the muscle making up the walls of the
94
Blood Clots
heart contracts ejecting a portion of the blood from the chamber. The check valves assure one-way flow. Mechanical blood pumps have been developed for use as artificial hearts to replace or assist the natural heart. Present blood pumps which are available to assist or replace the heart fall into two general categories. One category uses a rotary impeller and includes centrifugal pumps and axial flow pumps. The other category is pulsatile pumps, the diaphragm type pump being the most common. Blood pumps may also be classified as internal (intracorporeal) or external (extracorporeal) to the body. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Blood purifier featuring micro-euthanasia of undesirable blood organisms Inventor(s): Kling, Carl C.; (Cos Cob, CT) Correspondence: Carl C. Kling; PO Box 305; Hawthorne; NY; 10532-0305; US Patent Application Number: 20020120223 Date filed: February 20, 2001 Abstract: A blood purifying system, in which a patient is connected to a blood centrifuge, and certain components of the patient's blood are forwarded and further treated at a purifying station by a microscopic automatic review to identify undesirable organisms, and with a controlled laser blast focused on such identified undesirable organisms to destroy them as they pass through the purifying station. A patient having a suspected condition involving blood clots or undesirable organisms in the patient's bloodstream is connected so that the blood flows slowly through a purifying station where the stream is spread across a significant area in a very smooth layer enabling inspection by a laser scanner and pattern recognition system. When an undesired particle is detected, there is a double check of the pattern recognition, and, assuming recognition as undesirable, the organism is destroyed by a focused laser blast. Wherever the destruction particulates are expected to be appropriately heavier or lighter, the bloodstream portion is diverted to another centrifuge to remove the resulting particles before returning the blood to the patient. Excerpt(s): This invention relates to a blood purifying system, and particularly relates to a blood purifying system in which a patient is connected to a blood centrifuge, and certain components of the patient's blood are forwarded and further treated by a microscopic automatic review to identify undesirable organisms, with a controlled laser blast focused on such identified undesirable organisms to destroy them as they pass through the purifying station. Dialysis is the most common procedure in which a patient is connected to a blood system for a period of time while the blood itself is purified, essentially by differential osmotic pressure across a semi-permeable membrane. Dialysis mimics the purifying technique of the human kidneys, by a sort of mechanical kidney. Another blood purifying procedure is the multiple-transfusion procedure used in treating the "blue-baby" syndrome in which maternal antibodies have improperly passed through a wound in the placenta and are attacking the bay's blood. The baby's blood is replaced by progressively greater dispersion of new blood into the baby's circulatory system--until the antibodies are so diminished in number that they no longer present a risk to the baby. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 95
•
CARDIAC STIMULATING APPARATUS HAVING A BLOOD CLOT FILTER AND ATRIAL PACER Inventor(s): Pappu, Ramesh; (Cherry Hill, NJ) Correspondence: Dann Dorfman Herrell & Skillman; Suite 720; 1601 Market Street; Philadelphia; PA; 19103-2307; US Patent Application Number: 20020183823 Date filed: June 4, 2002 Abstract: An apparatus is provided for reducing the formation and migration of blood clots from an atrial appendage, such as the left atrial appendage, to the blood vessel system of a patient. The apparatus comprises an atrial pacer to treat non-rheumatic atrial fibrillation (NRAF) of an atrial appendage so that the formation blood clots within the atrial appendage is decreased or eliminated. In addition, the apparatus includes a blood clot filter supported by the atrial pacer proximate the atrial appendage and the atrium to reduce the migration of blood clots from the atrial appendage into the blood vessel system of a patient. Excerpt(s): The present invention relates generally to a device that deters migration of emboli from an atrial appendage into the vascular system of a patient, and more particularly to a device that includes a filter to deter such migration and a pacer to deter the formation of emboli such as blood clots within the atrial appendage. Non-rheumatic atrial fibrillation (NRAF) is associated with thromboembolic complications such as strokes. For example, when a thrombus or embolus occludes a vessel supplying blood to the brain, a stroke may result causing temporary or lasting paralysis of a part of the body or, in severe cases, death. Blockage of other blood vessels can occur as well causing attendant health concerns, including heart attack or gangrene. Presently, a five percent risk of stroke per year in a largely aging population causes NRAF to be a significant health concern. Given the potentially irreversible and destructive nature of such blood vessel occlusion, safe and effective methods are needed to eliminate embolic material like blood clots from the vascular system, some of which may be formed within an atrial appendage of the heart. The left atrial appendage forms a small protrusion which is attached to the lateral wall of the left atrium between the mitral valve and the root of the left pulmonary vein and normally contracts along with the left atrium. Atrial fibrillation is a cardiac condition wherein the atria beat faster than the ventricles, causing the ventricles to contract irregularly and consequently eject less blood into the vascular system. A major problem associated with atrial fibrillation is pooling of blood in the left atrial appendage. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Catheter composition and uses thereof Inventor(s): Semba, Charles P.; (Palo Alto, CA) Correspondence: Genentech, INC.; 1 Dna Way; South San Francisco; CA; 94080; US Patent Application Number: 20030206906 Date filed: November 25, 2002 Abstract: A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a
96
Blood Clots
preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent. Excerpt(s): This application is a non-provisional application filed under 37 CFR 1.53(b)(1), claiming priority under 35 USC 119(e) to provisional application No. 60.backslash.333,369 filed Nov. 26, 2001, the contents of which are incorporated herein by reference. The present invention relates to the field of indwelling medical devices, in particular catheters, as well as to the field of methods and compositions for flushing, locking, priming, and coating these medical devices. The invention also relates to pharmaceutical preparations useful in increasing catheter flow and preventing infection in catheters with the potential for fibrin deposition or with preexisting fibrin-bound clots. Delivery systems are widely used in medicine as a means for introducing liquid material that might include medicaments, nutrition, or other active agents to a particular locus in a patient. Such systems frequently involve the use of catheters, which, for many applications, are surgically or intravenously located and stitched into place for longterm administration of the desired material. Typical systems include central catheters such as may be used for total parenteral nutrition (TPN) used in, e.g., short bowel syndrome (for the duration of life), with the risk of sepsis or endocarditis. Such systems also include catheters and drains that are involved in peritoneal dialysis for those with terminal kidney failure, which, if infected, can lead to peritonitis with serious consequences. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Catheter for removing emboli from saphenous vein grafts and native coronary arteries Inventor(s): Bates, Mark C.; (Charleston, WV), Boucher, Ryan P.; (San Francisco, CA), Hogendijk, Michael; (Palo Alto, CA) Correspondence: Fish & Neave; 1251 Avenue OF The Americas; 50th Floor; New York; NY; 10020-1105; US Patent Application Number: 20020107479 Date filed: July 19, 2001 Abstract: Methods and apparatus are provided for removing emboli generated during a surgical procedure comprising a catheter having proximal and distal ends, a lumen extending therethrough, an occlusive member affixed to the distal end, and at least one blood intake port disposed in a lateral surface of the catheter. The occlusive member preferably is disposed in a treatment vessel, and the blood intake port, when uncovered, permits a portion of the antegrade flow from a host vessel to be diverted into the lumen of the catheter. A pressure differential caused by the blood intake from the host vessel establishes a venturi-effect suitable for manipulating flow in the treatment vessel. The flow characteristics may be manipulated via the intake port to direct emboli into the lumen of the catheter for subsequent removal. Excerpt(s): The present application is a continuation-in-part of U.S. patent application Ser. No. 09/418,727, filed Oct. 15, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 09/333,074, filed Jun. 14, 1999, which claims the benefit of priority of International Application PCT/US99/05469, filed Mar. 12, 1999. The present invention relates to apparatus and methods for removal of emboli from within a vascular system. More particularly, the present invention provides a catheter having at least one blood intake port and an occlusive member through which venturi flow may
Patents 97
be induced to remove emboli generated during an interventional procedure. Today there is a growing realization that steps must be taken to reduce the release of emboli during interventional procedures such as stenting, atherectomy and angioplasty. These procedures generally present a high risk for the release of embolic material that may occlude downstream portions of the vascular bed and cause ischemia. The resulting ischemia may pose a serious threat to the health or life of a patient if the blockage forms in a critical area, such as the heart, lungs, or brain. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
CATHETER SYSTEM FOR EMBOLI CONTAINMENT Inventor(s): BAGAOISAN, CELSO J.; (UNION CITY, CA), MUNI, KETAN P.; (SAN JOSE, CA), ZADNO-AZIZI, GHOLAM-REZA; (NEWARK, CA) Correspondence: Knobbe Martens Olson & Bear Llp; 620 Newport Center Drive; Sixteenth Floor; Newport Beach; CA; 92660; US Patent Application Number: 20020016565 Date filed: May 18, 1999 Abstract: A multi-catheter emboli containment system is disclosed which is adapted to provide at least one pair of optimized paths for irrigation and aspiration fluid flow. Through careful design of the cross-sectional area of these paths, the present system is able to be compactly utilized in even the smaller size blood vessels. The catheter system itself is provided with occlusive devices to form an emboli containment chamber in which irrigation and aspiration occur. The catheter system of the present invention provides an improved emboli containment and removal system which can be utilized in a wide range of vessel diameters. The system is easy to use and can quickly and efficiently evacuate the containment chamber. Excerpt(s): This application is a continuation-in-part of U.S. patent application Ser. No. 08/650,464 filed May 30, 1996, the entirety of which is hereby incorporated by reference. The present invention relates generally to medical devices, and, in particular, to a system of improved irrigation and aspiration catheters used in the containment and removal of emboli resulting from therapeutic treatment of occlusions within blood vessels. Human blood vessels often become occluded or blocked by plaque, thrombi, other deposits, or emboli which reduce the blood carrying capacity of the vessel. Should the blockage occur at a critical place in the circulatory system, serious and permanent injury, and even death, can occur. To prevent this, some form of medical intervention is usually performed when significant occlusion is detected. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Convertible blood clot filter Inventor(s): Appling, William M.; (Hartford, NY), Moresco, Kenneth P.; (Alexandria, VA), Patel, Nilesh H.; (Fishers, IN) Correspondence: Daniel P. Lent; Reed Smith Llp; 29th Floor; 599 Lexington Avenue; New York; NY; 10022; US Patent Application Number: 20030139765 Date filed: February 7, 2003
98
Blood Clots
Abstract: A vena cava blood clot filter is described that is attached to the walls of the vena cava by barbed anchors. In its filtering state, the filter is cone shaped which causes the blood to be filtered. The cone shape is formed by an appropriate restraining mechanism. When it is desired to stop filtering, the restraining mechanism is released and the filter takes a cylindrical shape. The cylindrical shaped filter will then line the vena cava wall and cease filtration of the blood. Excerpt(s): The following invention relates to a clot filter and more specifically to a convertible vena cava blood clot filter. Vena cava blood clot filters are generally placed in the inferior vena cava, introduced either through the femoral or jugular vein. These filters trap blood clots that have arisen from the peripheral veins and that travel through the vena cava. By trapping the blood clots, the filter prevents the clots from lodging in the pulmonary bed, which can lead to a condition known as pulmonary embolus. Pulmonary embolus (PE) has long been recognized as a major health care concern. Untreated PE is associated with a high mortality rate, widely held to be approximately 30%, although the exact rate is unknown. Symptomatic PE, however, represents only one manifestation of a more protean disorder, venous thromboembolic disease (VTD), which includes both deep venous thrombosis (DVT) and PE. Understanding of the interrelationship of these disorders has increased in recent years, as has the extent to which VTD contributes to patient mortality. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Doppler ultrasound method and apparatus for monitoring blood flow and detecting emboli Inventor(s): Moehring, Mark A.; (Seattle, WA), Myers, Timothy R.; (Snohomish, WA) Correspondence: Kimton N. Eng, ESQ.; Dorsey & Whitney Llp; Suite 3400; 1420 Fifth Avenue; Seattle; WA; 98101; US Patent Application Number: 20020091319 Date filed: December 6, 2000 Abstract: A pulse Doppler ultrasound system and associated methods are described for monitoring blood flow and detecting emboli. A graphical information display includes simultaneously displayed depth-mode and spectrogram displays. The depth-mode display indicates the various positions along the ultrasound beam axis at which blood flow is detected. These positions are indicated as one or more colored regions, with the color indicating direction of blood flow and varying in intensity as a function of detected Doppler ultrasound signal amplitude or detected blood flow velocity. The depth-mode display also includes a pointer whose position may be selected by a user. The spectrogram displayed corresponds to the location identified by the pointer. Embolus detection is also provided. Excerpt(s): This application is a continuation-in-part of U.S. patent application Ser. No. 09/190,402, filed Nov. 11, 1998, now pending. The invention relates generally to medical monitoring and diagnostic procedures and devices, and more particularly to a Doppler ultrasound method and apparatus for monitoring blood flow. Doppler ultrasound has been used to measure blood flow velocity for many years. The well-known Doppler shift phenomenon provides that ultrasonic signals reflected from moving targets will have a shift in frequency directly proportional to the target velocity component parallel to the direction of the ultrasound beam. The frequency shift is the same for any object moving at a given velocity, whereas the amplitude of the detected signal is a function of the
Patents 99
acoustic reflectivity of the moving object reflecting the ultrasound. Pulse Doppler ultrasound systems commonly produce a spectrogram of the detected return signal frequency (i.e., velocity) as a function of time in a particular sample volume, with the spectrogram being used by a physician to determine blood flow characteristics of a patient. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Electrical stimulation device and methods of treatment of various body conditions Inventor(s): Mellen, Craig R.; (Salt Lake City, UT) Correspondence: Mallinckrodt & Mallinckrodt; 10 Exchange Place, Suite 510; Salt Lake City; UT; 84111; US Patent Application Number: 20030114900 Date filed: December 14, 2002 Abstract: An electrical stimulation device for applying electrical stimulus to a living body includes a pair of applicators adapted to each contact the living body. The applicators each include electrically conductive material covered by electrically insulating material whereby the electrically conductive material is separated from the living body by the electrically insulating material when the applicators contact the living body. A preferred applicator is formed of flat cable having a plurality of conductors therein that form a plurality of antennas for transmitting electrical signals to the body. A signal generator generates a series of positive electrical pulses to be applied to the living body through the applicators. The applicators of the invention allow much more power to be applied to the body than is possible with prior art devices and the signal generator allows a user a wide range of power adjustment so that the intensity of the signal applied to the body can adjusted over a wide range to obtain desired intensity effects. The device can be used for treating and creating a wide range of body conditions such as treating pain and related stress and bleeding and blood clots, stimulating muscles, finding microorganisms, and treating UV skin damage. Excerpt(s): The invention is in the field of devices for applying electrical signals to a living body and to methods of treating body conditions and producing reactions and conditions in living bodies by means of applying electrical signals to such bodies. There are currently various kinds of electric stimulators and methods of applying electrical signals to a body available for the purpose of managing pain and its associated stress, stimulating muscle function, and for treating various medical and other body conditions and/or the symptoms thereof. The stimulators and methods of the prior art are usually referred to in catagories recognized by the acronyms: TENS (Transcutaneous Electrical Nerve Stimulation), MENS (Microvolt Electrical Nerve Stimulation), and EMS (Electric Muscle Stimulation). When the application of electrical signals are directed to the treatment of pain, the equipment and methods used are usually referred to as TENS (Transcutaneous Electrical Nerve Stimulation) systems. It is claimed that such systems are able to stimulate specific nerves to ease pain at a specific point in a body. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
100
•
Blood Clots
Emboli capturing device Inventor(s): Fisher, John S.; (Belleair, FL) Correspondence: Smith & Hopen PA; 15950 Bay Vista Drive; Suite 220; Clearwater; FL; 33760 Patent Application Number: 20020156456 Date filed: April 18, 2001 Abstract: An apparatus used in balloon angioplasty and/or stenting in a first embodiment includes a guide wire, a balloon catheter that ensleeves the guide wire, and a guide catheter that ensleeves the balloon catheter. The balloon catheter has a plurality of longitudinally-extending, circumferentially spaced apart slots formed in it to define a plurality of elongate members between the slots. A joint is formed at the proximal, distal, and mid-point of each elongate member. Displacing the respective proximal and distal joints toward one another causes the respective middle joints to displace radially outwardly, and radial inward travel of the middle joints is caused by increasing the distance between the proximal and distal joints. A bead is formed in the distal end of the guide wire and retraction of the guide wire causes the bead to abut the distal end of the balloon catheter and displace it in a distal-to-proximal direction, opening the elongate, jointed members. A mesh that captures emboli while allowing blood perfusion partially overlies the jointed members and is opened when the jointed members are opened and closed when they are closed. The guide catheter is used to close the jointed members and the emboli-capturing mesh at the conclusion of the angioplasty procedure. In a second embodiment, the jointed members are formed in an inner lumen received within a delivery catheter. In a variation of the second embodiment, a predetermined extent of the inner lumen is enlarged to facilitate the formation of the jointed members. In a third embodiment, a guide wire having an outer coil and an inner rod that is slideably received within it is modified so that the jointed members are formed in the outer coil and the mesh is opened and closed by axially retracting and advancing the inner rod with respect to the outer coil, respectively. Excerpt(s): This invention relates, generally, to endovascular surgical tools. More particularly, it relates to a tool used in balloon angioplasty and stenting of blood vessel narrowings (stenoses). Percutaneous angioplasty is an efficacious treatment for improving the blood carrying capacity of an artery that has become occluded by plaque, calcification, and other deposits. There are several ways of performing the procedure and the type and number of catheters and other tools used may vary between differing procedures. Typically, a needle puncture is made into an artery and an elongate guide wire is fed through the puncture site until it has traversed the stenotic lesion (the area where the plaque has built up). A guide catheter having a relatively large diameter is then introduced into the artery, using the guide wire to guide it. A balloon-carrying catheter is then fed through the guide catheter, also using the guide wire as a guide. The guide catheter is then advanced to a preselected point so that its distal end is downstream of the stenotic lesion, and the balloon catheter is positioned so that the balloon is in registration with said lesion, also known as a stenosis. The guide catheter is withdrawn a relatively short distance to expose the balloon catheter. The balloon is then inflated to permanently dilate and tear the two inner layers of the artery, thereby enlarging its diameter, breaking up the stenosis, thereby increasing the blood-carrying capacity of the artery. An expandable stent may be carried on the outer surface of the balloon and left in place after the balloon is deflated and withdrawn. Alternatively, a self-expanding stent may be deployed over the treated lesion using a different delivery catheter. The stent holds the arterial walls in their expanded condition. After the balloon
Patents 101
is deflated, the balloon catheter is withdrawn into the guide catheter, and both of said catheters and the guide wire are withdrawn to conclude the procedure. The primary drawback to balloon angioplasty or stenting is the creation of debris and thrombus that can clog blood vessels downstream of the treatment site. The stretching of the two inner arterial walls breaks up the stenotic lesion and creates debris known as emboli. Accordingly, when the balloon is deflated, the emboli flow downstream with the blood. If the stenotic lesion is in the iliac or femoral arteries, the emboli may flow to the feet; this may or may not be problematic. However, if the stenotic lesion is in the carotid artery, the emboli can flow into various brain vessels and cause permanent brain damage. Similarly, kidney damage can ensue from dilating a lesion in the main renal artery. For this reason, balloon angioplasty carries a higher risk of embolic complications for stenotic lesions in the carotid, renal, and coronary arteries unless means are provided for preventing the flow of emboli to the blood vessels of the brain, kidney, or heart, respectively. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Emboli extraction catheter and vascular filter system Inventor(s): Johnson, Kirk; (Weston, FL), O'Neill, Patrick; (Doylestown, PA) Correspondence: Audley A. Ciamporcero JR.; Johnson & Johnson; One Johnson & Johnson Plaza; New Brunswick; NJ; 08933-7003; US Patent Application Number: 20020188313 Date filed: June 12, 2001 Abstract: An emboli extraction catheter and vascular filter system comprising a guidewire, a vascular filter attached near the distal end of the guidewire, and an emboli extraction catheter. The vascular filter has a smaller first diameter for insertion into the lumen of a vessel, and a second larger diameter for expanding to substantially equal the diameter of the lumen and to be placed in generally sealing relationship with the lumen. The emboli extraction catheter is a flexible catheter comprising a hub attached to the proximal end of the catheter. The hub further comprises a sideport and means for maintaining a seal on the guidewire. The emboli extraction catheter can be used to aspirate embolic particulates, so as to avoid their accidental release after they are captured in a vascular filter, and can also be used to empty full vascular filters of embolic particulates which may block distal flow. Excerpt(s): The present invention relates to the treatment of vascular disease, and more particularly to an emboli extraction catheter and vascular filter system for use during medical procedures. Percutaneous transluminal coronary angioplasty (PTCA), stenting and atherectomy are therapeutic medical procedures used to increase blood flow through the coronary arteries. These procedures can often be performed as alternatives to coronary bypass surgery. Percutaneous transluminal angioplasty (PTA) and stenting can often be performed as alternatives to carotid endarterectomy, and femoral-popliteal bypass procedures. In PTCA or PTA procedures, the angioplasty balloon is inflated within the stenosed vessel, at the location of an occlusion, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen. In stenting, an endoluminal prosthesis is implanted in the vessel to maintain patency following the procedure. In atherectomy, a rotating blade is used to shear plaque from the arterial wall. One of the complications associated with all these techniques is the accidental dislodgment of plaque, thrombus or other embolic particulates generated during manipulation of the vessel, thereby causing occlusion of the narrower vessels
102
Blood Clots
downstream and ischemia or infarct of the organ which the vessel supplies. Such emboli may be extremely dangerous to the patient, and may result in myocardial infarction, stroke or limb ischemia. In 1995, Waksman et al. disclosed that distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. See Waksman et al., American Heart Journal 129(3): 430-5 (1995). This study found that distal embolization occurs in 28% (31 out of 111) of the patients undergoing atherectomy. In January 1999, Jordan, Jr. et al. disclosed that treatment of carotid stenosis using percutaneous angioplasty with stenting procedure is associated with more than eight times the rate of microemboli seen using carotid endarterectomy. See Jordan, Jr. et al. Cardiovascular Surgery 7(1): 33-8 (1999). Microemboli, as detected by transcranial Doppler monitoring in this study, have been shown to be a potential cause of stroke. The embolic materials include calcium, intimal debris, atheromatous plaque, and thrombi. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Emboli filter Inventor(s): Blackledge, Victor R.; (Cologne, MN), Hall, Todd A.; (Goshen, KY), Morris, Benjamin E.; (Louisville, KY), Reuss, William A. JR.; (Louisville, KY), Whatley, Charles H. JR.; (Louisville, KY) Correspondence: Merchant & Gould PC; P.O. Box 2903; Minneapolis; MN; 55402-0903; US Patent Application Number: 20030125765 Date filed: January 2, 2003 Abstract: An emboli filter for deployment in a body lumen to capture emboli entrained in a fluid flowing through the lumen includes a flexible elongated member sized to be passed through the lumen. A filter media is carried on and substantially surrounding the elongated member. The filter media has a first end secured to the elongated member adjacent the distal end. A second end of the filter media has a periphery movable toward and away from the elongated member. Opposing internal surfaces of the filter media define a volume into which emboli may flow through the second end when the periphery is moved away from the elongated member. The emboli are trapped within the volume when the periphery is moved toward the elongated member. An actuator moves the periphery toward and way from the elongated member. The actuator includes a plurality of elastic loops. The loops are biased to an open loop configuration with the loops urging the periphery away from the elongated member. The actuator is adapted to be manipulated by an operator to urge the loops against the bias to a closed position permitting movement of the periphery toward the elongated member without interference from the loops. Excerpt(s): This invention pertains to a medical apparatus for passage into a body lumen of a patient. More particularly, this invention pertains to an emboli filter for deployment in a patient's body lumen to capture emboli entrained in fluid flowing through the lumen. There are numerous medical procedures for introducing tools into a patient's body lumen. For example, occlusion treatment tools (such as angioplasty balloon-tipped catheters, stents or ablation catheters) may be admitted into a lumen of an artery to treat an occluded site within the artery. A balloon tipped catheter may be expanded at the site to urge the occlusion against the walls of the artery to improve patency of the arterial lumen. A stent may be expanded at the site to maintain lumen patency. Alternatively, or in combination with other procedures, an ablation tool may be used to mechanical
Patents 103
remove the occluding material. The manipulation and use of tools within a lumen of a body passage may cause the release of emboli in the lumen. In arteries, such emboli become entrained within blood flow within the artery. Such emboli can contribute to morbidity. For example, emboli can be transported to the brain and contribute to cranial ischemia (stroke). In treating occlusions in coronary arteries, emboli may flow to occlude distal, micro-vessels contributing to myocardial ischemia. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Emboli filtration system and methods of use Inventor(s): Bates, Mark C.; (Charleston, WV), Hogendijk, Michael; (Palo Alto, CA) Correspondence: Fish & Neave; 1251 Avenue OF The Americas; 50th Floor; New York; NY; 10020-1105; US Patent Application Number: 20030150821 Date filed: October 21, 2002 Abstract: An emboli filtration apparatus is provided comprising a guide wire having a filter element captured thereon, so that the guide wire is free to rotate and translate while the filter element remains stationary. The apparatus allows for movement and rotation of the guide wire as devices are advanced over it to treat occlusive disease, substantially without dislodging the filter element. In a preferred embodiment, the guide wire comprises a proximal stop configured to reposition the filter element during a medical procedure without having to remove or insert additional interventional devices. Excerpt(s): The present application is a continuation-in-part of U.S. patent application Ser. No. 09/774,197, filed Jan. 29, 2001, which is a continuation-in-part of U.S. patent application Ser. No. 09/354,897, filed Jul. 16, 1999, now U.S. Pat. No. 6,179,859. The present invention relates to apparatus and methods for removing emboli from the blood stream that are generated during treatment of vascular disease, such as angioplasty, atherectomy or stenting. More particularly, an emboli filtration device and methods are provided having a captured filter that enables movement of a guide wire associated with the filter without displacing the filter. Atherosclerosis and other vascular occlusive diseases are becoming prevalent today in many developed countries. In such diseases, the flow areas of blood vessels become narrowed or occluded by the buildup of plaque on the walls of the vessels, leading to ischemia, and depending upon the location of the vessel, damage to the organ or limb. A number of surgical and percutaneous procedures have been developed for treating stenosis in the coronary arteries and carotid arteries, including endarterectomy, angioplasty, atherectomy and stenting. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Exchange method for emboli containment Inventor(s): Zadno-Azizi, Gholam-Reza; (Newark, CA) Correspondence: Knobbe Martens Olson & Bear Llp; 620 Newport Center Drive; Sixteenth Floor; Newport Beach; CA; 92660; US Patent Application Number: 20020065507 Date filed: January 22, 2001
104
Blood Clots
Abstract: The present invention provides a method for exchanging catheters while containing emboli within a blood vessel such as a saphenous vein graft, coronary artery, carotid artery, or other similar vessels. A guidewire is inserted through the vasculature of a patient until it reaches a desired treatment site. A therapy catheter is then inserted over the guidewire until the distal end of the therapy catheter reaches the treatment site. The guidewire has a distally mounted balloon which is inflated to occlude the blood vessel. Then, the therapy catheter provides means for treating the vessel at the treatment site. After treatment, the therapy catheter is removed from the guidewire and exchanged with an aspiration catheter which rides over the guidewire until the distal end of the aspiration catheter reaches the treatment site. The aspiration catheter applies negative pressure to remove any emboli formed by the treatment procedure. Excerpt(s): This application is a continuation-in-part of application Ser. No. ______, entitled LOW PROFILE CATHETER VALVE AND INFLATION ADAPTOR, filed Nov. 20, 1997 (Attorney Docket No. PERCUS.006CP1), the entirety of which is hereby incorporated by reference. The present invention relates to medical catheters used in treating saphenous vein grafts, coronary arteries, and other blood vessels, and more particularly, to a method for exchanging catheters during emboli containment in such vessels. Guidewires are conventionally used to guide the insertion of various medical instruments, such as catheters, to a desired treatment location within a patient's vasculature. In a typical procedure, the clinician forms an access point for the guidewire by creating an opening in a peripheral blood vessel, such as the femoral artery. The highly flexible guidewire is then introduced through the opening into the peripheral blood vessel, and is then advanced by the clinician through the patient's blood vessels until the guidewire extends across the vessel segment to be treated. Various treatment catheters, such as a balloon dilatation catheter for a percutaneous transluminal coronary angioplasty, may then be inserted over the guidewire and similarly advanced through vasculature until they reach the treatment site. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Low profile emboli capture device Inventor(s): Chin, Yem; (Burlington, MA), Griego, John; (Blackstone, MA), Stanford, Ulf Harry; (Incline Village, NV), Zhong, Sheng-Ping; (Northborough, MA) Correspondence: Bruce H. Johnsonbaugh; Eckhoff, Hoppe, Slick, Mitchell & Anderson; Suite 3125; 333 Market Street; San Francisco; CA; 94105; US Patent Application Number: 20020115942 Date filed: February 20, 2001 Abstract: A low profile emboli capture device is provided for use in angioplasty and other intravascular procedures. A standard guidewire is utilized having a reduced cross-sectional area formed near its distal end. A filter and self-expanding stent are packaged on the reduced cross-sectional area of the guidewire. A movable sleeve extends over the guidewire and holds the self-expanding stent and filter in their retracted positions while the device is being positioned in the artery. The sheath is moved relative to the self-expanding stent and filter, whereupon the self-expanding stent and filter become deployed. Excerpt(s): The present invention relates generally to an emboli capture device for use in conjunction with angioplasty and other intravascular surgeries. More particularly, the present invention provides a low profile emboli capture device (i.e. approximately 0.020
Patents 105
inch diameter or less in its retracted position) capable of being used in smaller diameter blood vessels than prior art emboli capture devices, as well as reducing the risk of dislodging plaque in larger vessels. The present invention provides an emboli capture device carried by a standard guidewire; a catheter is not required to insert and deploy the emboli capture device. The invention is capable of use in carotid angioplasty without occluding blood flow to the brain, and can be used in saphenous vein grafts, native coronary arteries and arteries as small as 1 mm. diameter. As angioplasty and other intravascular surgical procedures progress, it becomes increasingly important to be able to use an emboli capture device in smaller and smaller arteries, requiring the use of lower profile devices. In accordance with the present invention, an emboli capture device is provided which in its preferred form includes three main components that cooperate with a standard guidewire; a self-expanding stent (or other expansion means), a filter and a sleeve. The filter and self-expanding stent in the preferred embodiment are carried directly on a reduced cross-sectional mounting region of the guidewire so that those components of the device in their retracted form have essentially the same crosssectional profile as the guidewire, itself. The present invention also provides a thin sleeve which holds the filter and self-expanding stent against the guidewire. The thin sleeve is then retracted proximally relative to the guidewire, allowing the filter and selfexpanding stent (or other expansion means) of the present invention to expand. The same guidewire which is used to place the emboli capture device of the present invention is used to guide the surgical catheter into place for performing the angioplasty or other intravascular surgery. The catheter, itself, is utilized to retract and retrieve the emboli capture device at the conclusion of the procedure. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method and apparatus for emboli containment Inventor(s): Bagaoisan, Celso J.; (Union City, CA), Ha, Hung V.; (San Jose, CA), Patel, Mukund R.; (San Jose, CA), Zadno-Azizi, Gholam-Reza; (Newark, CA) Correspondence: Knobbe Martens Olson & Bear Llp; 620 Newport Center Drive; Sixteenth Floor; Newport Beach; CA; 92660; US Patent Application Number: 20020026145 Date filed: November 30, 2000 Abstract: Disclosed herein is a catheter for use in an emboli containment system. In one embodiment, the catheter has a tubular body with a metallic braid construction. Two lumens extend through the tubular body, the lumen being in a side-by-side configuration. One of the lumens functions as an inflation lumen, and is in fluid communication with an inflatable balloon mounted on the distal end of the catheter. The second lumen is adapted to receive other therapeutic catheters which comprise the emboli containment system. In another embodiment, apparatus is provided for treatment of a stenosis in a lumen in a blood-carrying vessel comprising a main catheter and a therapeutic catheter. The main catheter comprises a first flexible elongate tubular member having proximal and distal extremities. A sealing element is carried on the distal extremity of the first flexible elongate tubular member. The first flexible elongate tubular member has a main lumen therein extending from the proximal extremity to the distal extremity and exits through the distal extremity. An adapter is mounted on the proximal extremity of the first flexible elongate tubular member. The therapeutic catheter comprises a second flexible elongate tubular member having proximal and distal extremities. An element for performing work is mounted on the distal extremity
106
Blood Clots
of the second flexible elongate tubular member. An adapter is mounted on the proximal extremity of the second flexible elongate tubular member. The second flexible elongate tubular member is slidably mounted in the main lumen of the first elongate tubular member. A mechanism is carried by the first flexible elongate tubular member for causing the sealing element to form an occlusion in the vessel proximal of the stenosis to provide a working space distal of the sealing element. A mechanism is coupled to the attachment of the therapeutic catheter for causing operation of the element for performing work in the working space adjacent the stenosis. Excerpt(s): This application is a continuation of application Ser. No. 08/813,023, filed on Mar. 6, 1997, which is a continuation-in-part of application Ser. No. 08/650,464 filed on May 20, 1996, the entirety of which is incorporated herein by reference, which is a continuation-in-part of application Ser. No. 08/464,579, filed Jun. 5, 1995, now U.S. Pat. No. 5,833,650. The present invention generally relates to medical devices, and in particular, to catheters which can be used in an emboli containment system. This invention also relates to an apparatus and method for treating occluded vessels in living bodies and more particularly balloon catheters and balloon guide wires for treating occlusions in vessels in human bodies, as for example carotid arteries. Balloon angioplasty, and other transluminal medical treatments, are well-known, and have been proven efficacious in the treatment of stenotic lesions in blood vessels. The application of such medical procedures to certain blood vessels, however, has been limited, due to the risks associated with creation of emboli during the procedure. For example, angioplasty is not the currently preferred treatment for lesions in the carotid artery, because of the possibility of dislodging plaque from the lesion, which can enter the various arterial vessels of the brain and cause permanent brain damage. Instead, surgical procedures are currently used, but these procedures present substantial risks. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method and apparatus for medical device for aspiration of thromboembolic debris Inventor(s): Wholey, Mark H.; (Oakmont, PA), Wholey, Michael; (San Antonio, TX), Wholey, Petra; (San Antonio, TX) Correspondence: Pietragallo, Bosick & Gordon; One Oxford Centre, 38th Floor; 301 Grant Street; Pittsburgh; PA; 15219-6404; US Patent Application Number: 20020026212 Date filed: March 15, 2001 Abstract: An apparatus for collecting blood clots, plaque, and other debris in arteries or veins, said apparatus comprising: a filter assembly having a chamber with a paddle assembly and a porous floor disposed therein; and tubes for coupling said filter assembly to an artery and to a vein. Excerpt(s): This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/190,513, filed Mar. 15, 2000. This invention relates to an apparatus and method for collecting blood clots, pieces of plaque and other material that may be accidentally dislodged during interventional procedures in the human vasculature such as arterial and venous angioplasty and stent placement. The invention utilizes a chamber that collects the blood from one sheath or catheter through an aspirating force where the blood can be filtered with removal of thromboembolic debris. The blood can then be recirculated back into the bloodstream through a second access. It is common practice today to open occluded (i.e. blocked) or stenotic (i.e. narrowed) blood vessels by
Patents 107
inserting a guidewire and then a catheter carrying a balloon shaped distal end and inflating the balloon, which exerts radial force, to press the stenosis outward against the wall of the vessel. This procedure is called balloon angioplasty. Frequently, an implantable metallic stent will be used additionally to provide greater radial strength and longer-term patency. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method and compositions for inhibiting thrombin-induced coagulation Inventor(s): Davis, Stacey; (College Station, TX), Hook, Magnus A.O.; (Houston, TX) Correspondence: Larson & Taylor, Plc; 1199 North Fairfax Street; Suite 900; Alexandria; VA; 22314; US Patent Application Number: 20030044418 Date filed: May 13, 2002 Abstract: A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal B.beta. chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogenbinding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin. Excerpt(s): This application claims the benefit of U.S. Provisional Patent Application No. 60/290,072, filed May 11, 2001. The present invention relates in general to SdrG, a fibrinogen-binding bacterial adhesin, and in particular to the use of SdrG or its binding region as an anti-coagulation agent by virtue of its ability to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B. In addition, the invention relates to methods and compositions utilizing SdrG or its binding region for treating or preventing thrombin-induced coagulation and co